Visit IMLYGIC.com to learn more

IMLYGIC™
(talimogene laherparepvec)
SUSPENSION FOR INJECTION
10^7 PFU/mL and 10^8 PFU/mL single-use vials

NOW APPROVED

SOCIETY OF SURGICAL ONCOLOGY

69th SSO Annual Cancer Symposium
BOSTON, MA

SEE INSIDE FOR OUR SCHEDULE-AT-A-GLANCE!

TOMORROW’S TREATMENTS FOR TODAY’S PATIENTS

The Exceptional Surgical Oncology Experience

© 2016 Amgen Inc. All rights reserved.
01/16 USA-678-122464

Visit IMLYGIC.com to learn more

IMLYGIC™
(talimogene laherparepvec)
SUSPENSION FOR INJECTION
10^7 PFU/mL and 10^8 PFU/mL single-use vials

NOW APPROVED

SOCIETY OF SURGICAL ONCOLOGY

69th SSO Annual Cancer Symposium
BOSTON, MA

SEE INSIDE FOR OUR SCHEDULE-AT-A-GLANCE!

TOMORROW’S TREATMENTS FOR TODAY’S PATIENTS

The Exceptional Surgical Oncology Experience

© 2016 Amgen Inc. All rights reserved.
01/16 USA-678-122464
## SCHEDULE-AT-A-GLANCE
### THURSDAY, MARCH 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45-7:45 am</td>
<td>Industry Forum: Preparative Multidisciplinary Considerations for HER2+ Breast Cancer (Room 206)</td>
</tr>
<tr>
<td>8-9:30 am</td>
<td>International Perspectives on Gastric Cancer (MOC) (Auditorium A)</td>
</tr>
<tr>
<td>8-9:30 am</td>
<td>Surgical Management of Soft Tissue Sarcomas: An Update on Current and Future Approaches (MOC) (Ballroom B)</td>
</tr>
<tr>
<td>8-9:30 am</td>
<td>Case Presentations with Professors and Fellows (Room 303/304)</td>
</tr>
<tr>
<td>9:30-9:45 am</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>9:45-10:45 am</td>
<td>Hepatobiliary Parallel Session* (Ballroom A)</td>
</tr>
<tr>
<td>9:45-11:45 am</td>
<td>Breast Parallel Session* (Ballroom B)</td>
</tr>
<tr>
<td>9:45-11:45 am</td>
<td>Colorectal Parallel Session* (Room 303/304)</td>
</tr>
<tr>
<td>11:45 am-1 pm</td>
<td>Exhibit Hall Opening Lunch; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge (Room 303/304)</td>
</tr>
<tr>
<td>1:15-2 pm</td>
<td>John Wayne Clinical Research Lecture (Auditorium)</td>
</tr>
<tr>
<td>2:45-3:45 pm</td>
<td>Exhibit Hall Refreshment Break; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge (Room 303/304)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Contemporary Management of Adrenal Neoplasms (MOC) (Ballroom A)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Susan G. Komen® Symposium: Selective Management of ECs (MOC) (Ballroom B)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Immunotherapy: New Paradigms in the Treatment of Solid Tumors (MOC) (Room 302/304)</td>
</tr>
</tbody>
</table>

### FRIDAY, MARCH 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-8 pm</td>
<td>Welcome Reception; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge (Exhibit Halls C &amp; D)</td>
</tr>
<tr>
<td>8-8:45 am</td>
<td>Meet the Professor Breakfasts ∆</td>
</tr>
<tr>
<td>8:45-9 am</td>
<td>Distinguished Service Award &amp; James Ewing Layperson’s Award (Auditorium)</td>
</tr>
<tr>
<td>9-9:45 am</td>
<td>SO Presidential Address (Auditorium)</td>
</tr>
<tr>
<td>9:45-10:15 am</td>
<td>Exhibit Hall Refreshment Break; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge (Exhibit Halls C &amp; D)</td>
</tr>
<tr>
<td>10:15 am-12:15 pm</td>
<td>Upper Gastrointestinal Parallel Session* (Ballroom A)</td>
</tr>
<tr>
<td>10:15 am-12:15 pm</td>
<td>Breast Parallel Session* (Ballroom B)</td>
</tr>
<tr>
<td>10:15 am-12:15 pm</td>
<td>Melanoma Parallel Session* (Room 302/304)</td>
</tr>
<tr>
<td>12:15-1:15 pm</td>
<td>Exhibit Hall Lunch; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge (Exhibit Halls C &amp; D)</td>
</tr>
<tr>
<td>1:15-2 pm</td>
<td>The Great Debates I (Auditorium)</td>
</tr>
<tr>
<td>2-3 pm</td>
<td>The Great Debates I (Auditorium)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Exhibit Hall Ice Cream Break (Exhibit Halls C &amp; D)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Making Treatment Choices in Colorectal Cancer Patients with Synchronous Hepatic Metastases (MOC) (Ballroom A)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Joint SSO/ESSO Symposium: Cytoadhesive Surgery for Malignancy: When Does It Make Sense? (MOC) (Ballroom B)</td>
</tr>
</tbody>
</table>

### SATURDAY, MARCH 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45-5:45 pm</td>
<td>Melanoma Multidisciplinary Tumor Board (Room 302/304)</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Endocrine Parallel Session* (Ballroom A)</td>
</tr>
<tr>
<td>4-5 pm</td>
<td>2nd Annual Presidential Address (Auditorium)</td>
</tr>
<tr>
<td>4:45-5:45 pm</td>
<td>Break (Ballroom B)</td>
</tr>
<tr>
<td>5-6 pm</td>
<td>Town Hall and Annual Business Meeting (Room 103)</td>
</tr>
</tbody>
</table>

### SUNDAY, MARCH 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-7:30 pm</td>
<td>President’s Reception (Grand Ballroom, Sheraton Boston Hotel)</td>
</tr>
</tbody>
</table>

### COMING SOON! SOSAP 2nd Edition

SOSAP, created by the Society of Surgical Oncology, is the premier case-based learning tool that helps surgical oncologists, general surgeons, Fellows and physician assistants:

- **Remain current in the latest advances in surgical oncology.**
- **Prepare for the ABS Certification Exam in Complex General Surgical Oncology.**
- **Fulfill Maintenance of Certification (MOC) Part 2 self-assessment requirements.**
- **Earn 60 AMA PRA Category 1 Credits™.**
- **Get real-time scoring and feedback.**

SOSAP was written by more than 50 experts, covers six major disease topic areas and is available online 24/7/365. TO LEARN MORE ABOUT SOSAP AND PURCHASE AT A DISCOUNT, VISIT SURGONC.ORG/SOSAP.

The SOSAP iPad App is available for FREE in the App Store to those who purchase SOSAP.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45-7:45 am</td>
<td>Welcome Reception; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge</td>
</tr>
<tr>
<td>8-8:45 am</td>
<td>Meet the Professor Breakfasts Δ</td>
</tr>
<tr>
<td>8-8:45 am</td>
<td>Exhibit Hall C</td>
</tr>
<tr>
<td>8:45-9:0 am</td>
<td>Distinguished Service Award &amp; James Ewing Layperson’s Award Auditorium</td>
</tr>
<tr>
<td>7:45-9:45 am</td>
<td>Hepatobiliary Parallel Session* Ballroom A</td>
</tr>
<tr>
<td>9:45-11:45 am</td>
<td>Breast Parallel Session 1* Ballroom B</td>
</tr>
<tr>
<td>9:45-11:45 am</td>
<td>Exhibit Hall Refreshment Break; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge</td>
</tr>
<tr>
<td>10:45-11:15 am</td>
<td>Upper Gastrointestinal Parallel Session* Ballroom A</td>
</tr>
<tr>
<td>10:15 am-12:15 pm</td>
<td>Breast Parallel Session 2* Ballroom B</td>
</tr>
<tr>
<td>10:15 am-12:15 pm</td>
<td>Melanoma Parallel Session* Room 302/304</td>
</tr>
<tr>
<td>12:15-1:15 pm</td>
<td>Exhibit Hall Lunch; Visit Exhibits, Posters*, Fellows &amp; Residents Lounge</td>
</tr>
<tr>
<td>1:15-2:0 pm</td>
<td>The Great Debates I Auditorium</td>
</tr>
<tr>
<td>2:45-3:45 pm</td>
<td>Exhibit Hall Ice Cream Break Exhibit Halls C &amp; D</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Making Treatment Choices in Colorectal Cancer Patients with Synchronous Hepatic Metastases (MOC) Room 302/304</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Joint SSO/ESSO Symposium: Cytoreductive Surgery for Malignancy: When Does It Make Sense?(MOC) Ballroom B</td>
</tr>
<tr>
<td>3:45-5:45 pm</td>
<td>Melanoma Multidisciplinary Tumor Board Room 302/304</td>
</tr>
<tr>
<td>5:15-6:15 pm</td>
<td>Town Hall and Annual Business Meeting Room 103</td>
</tr>
<tr>
<td>6:15-7:30 pm</td>
<td>President’s Reception Grand Ballroom, Sheraton Boston Hotel</td>
</tr>
</tbody>
</table>

**SOSAP**, created by the Society of Surgical Oncology, is the premier case-based learning tool that helps surgical oncologists, general surgeons, Fellows and physician assistants:

- Remain current in the latest advances in surgical oncology.
- Prepare for the ABS Certification Exam in Complex General Surgical Oncology.
- Fulfill Maintenance of Certification (MOC) Part 2 self-assessment requirements.
- Earn 60 AMA PRA Category 1 Credits™.
- Get real-time scoring and feedback.

**SOSAP** was written by more than 50 experts, covers six major disease topic areas and is available online 24/7/365.

**TO LEARN MORE ABOUT SOSAP AND PURCHASE AT A DISCOUNT, VISIT SURGONC.ORG/SOSAP.**

The SOSAP iPad App is available for FREE in the App Store to those who purchase SOSAP.
SSO is compliant with the rules and regulations of the Physician Payments Sunshine Act. As a result, there may be changes in the overall annual meeting structure. SSO’s corporate supporters and partners are responsible for reporting indirect payments and/or transfers of value to physicians. SSO does not collect data, NPI numbers or any other information on behalf of vendors as it is their sole responsibility to maintain compliance with the Physician Payments Sunshine Act.
The Society of Surgical Oncology and The SSO Foundation recognize the essential role that health care organizations play in furthering the mission of the Society. SSO and The SSO Foundation thank its partners for their generous support of the 69th SSO Annual Cancer Symposium and other important SSO and The SSO Foundation programs.

**HEALTHY LEGACY**
- Amgen, Inc.
- Ethicon Endo-Surgery, Inc.
- Genentech, Inc.

**FOUNDER**
- Faxitron Bioptics, LLC
- Genomic Health, Inc.
- Merck & Co., Inc.

**AMBASSADOR**
- Hologic, Inc.
- Medtronic
- Myriad Genetics, Inc.

**SUPPORTER**
- Celgene Corporation
- Hitachi-Aloka Medical America, Inc.
- iCAD, a subsidiary of Xoft
- John Wayne Cancer Foundation
- NeuWave Medical
- Pacira Pharmaceuticals, Inc.
- Susan G. Komen®
- The SSO Foundation

**FRIEND**
- American Cancer Society
- AngioDynamics, Inc.
- Belmont Instrument Corporation
- Colon Cancer Challenge Foundation
- Dune Medical Devices
- Navidea Biopharmaceuticals

*As of January 28, 2016*
2015-2016
SSO OFFICERS &
EXECUTIVE COUNCIL

Officers
President                Jeffrey A. Drebin, MD, PhD (2016)
President-Elect          Daniel G. Coit, MD (2016)
Vice President           Kelly M. McMasters, MD, PhD (2016)
Secretary                Armando E. Giuliano, MD (2016)
Treasurer                David L. Bartlett, MD (2017)

Executive Council Members
V. Suzanne Klimberg, MD   Past President (2016)
Ronald J. Weigel, MD, PhD Immediate Past President (2016)
Russell S. Berman, MD (2018)
Hong Jin Kim, MD (2016)
Robert C.G. Martin, II, MD, PhD (2017)
Hector Martinez-Said, MD (2018)
Nipun B. Merchant, MD (2016)
Christopher M. Pezzi, MD (2016)
Elin R. Sigurdson, MD, PhD (2018)
Sharon M. Weber, MD (2017)

Councilors-at-Large
Tari A. King, MD (2017)
Julie A. Margenthaler, MD (2018)
Kevin K. Roggin, MD (2016)

Ex Officio
Executive Director        M. Eileen Widmer, CAE, CFRM
The SSO Foundation         Mitchell C. Posner, MD
Editor,                   Charles M. Balch, MD
    Annals of Surgical Oncology
SSO STAFF

Executive Director  M. Eileen Widmer, CAE, CFRM
Associate Executive Director, Administration  Karen A. Hurley, MA, CAE
Associate Executive Director, Strategic Partnerships and Programs  Charmaine J. Cummings, PhD, RN
Director, Quality & Research  R. Dawn Brenneman, MPA
Director, Communications  Anne O’Day
Director, Education  Patti Stella, CHCP
Senior Accountant  William Rohe, MBA
Manager, Training Programs  Jenny Ramion
Manager, Scientific Programs  Becky Williams
Manager, Global Outreach & Special Programs  Ana Olivares
Manager, Communications & Membership  Tracy Hulett
Manager, Board Governance  Rochelle Jerry
Asst. Manager, IT Products  James Trigueros, MA
Education Coordinator  Julie Rossberger
Operations Coordinator  Kathy Sampson
Executive Assistant  Leslee Olson

HEADQUARTERS OFFICE
9525 W. Bryn Mawr Ave., Suite 870
Rosemont, IL 60018
847-427-1400 • info@surgonc.org • surgonc.org

ANNUAL MEETING & TRADESHOW TEAM

Senior Vice President, Healthcare Events  Sue Deveaux
Senior Director of Meeting Logistics  Tiffany Melton, CMP
Meetings Manager  Kayce Henderson
Exhibit Sales Associate, Healthcare Events  Darnella Bradley
Exhibit Operations Manager  Shirley Harris
Senior Registration Account Manager  Anna Roscigno
Housing Account Manager  Erin Davis
2015-2016
**SCIENTIFIC PROGRAM COMMITTEE**
Richard D. Schulick, MD, MBA — Chair (2016)
Peter J. Allen, MD — Vice Chair (2016)
Brian D. Badgwell, MD, MS (2016)
Carmen C. Solorzano, MD (2016)
David J. Winchester, MD (2016)
Adam C. Berger, MD (2017)
Kenneth Cardona, MD (2017)
Electron Kebebew, MD (2017)
Karl Y. Bilimoria, MD, MS (2018)
Robert J. Canter, MD (2018)
Brian J. Czerniecki, MD, PhD (2018)
Ryan C. Fields, MD (2018)
Robert E. Roses, MD (2018)
Randall P. Scheri, MD (2018)
Charles R. Scoggins, MD, MBA (2018)
Glenda G. Callender, MD - *Ex Officio* (CME) (2016)
Jeffrey E. Gershenwald, MD - *Ex Officio* (Educational Prod. Comm.) (2016)
James R. Howe, MD - *Ex Officio* (2016)

2015-2016
**LOCAL ARRANGEMENTS TEAM**
Kenneth K. Tanabe, MD – Chair (2016)
Richard B. Arenas, MD (2016)
Gerard M. Doherty, MD (2016)
Roger A. Graham, MD (2016)
Jennifer LaFemina, MD (2016)
Jennifer F. Tseng, MD, MPH (2016)
Giles F. Whalen, MD (2016)
M. Eileen Widmer, CAE, CFRM

2015-2016
**CONTINUING MEDICAL EDUCATION COMMITTEE**
Glenda G. Callender, MD – Chair (2016)
Brian J. Kaplan, MD – Vice Chair (2016)
Chandrakanth Are, MD, MBA (2018)
Abigail Caudle, MD, MS (2018)
Laura S. Dominici, MD (2018)
Declan Fleming, MD (2018)
Marissa Howard-McNatt, MD (2017)
John C. Mansour, MD (2016)
David McFadden, MD (2018)
Sarah A. McLaughlin, MD (2018)
Sanjay Reddy, MD (2018)
John H. Stewart, IV, MD, MBA (2016)
Jason Paul Wilson, MD (2018)
Richard D. Schulick, MD, MBA – *Ex Officio* (Scientific Program Committee) (2016)
# TABLE OF CONTENTS

**Schedule-at-a-Glance** ......................Inside front cover

**Daily Events**.................................................................7

**New and Exciting at SSO 2016**.................................12

**General Information** (listed alphabetically) ............14

**Mobile Access for SSO 2016**.................................20

**Social Events**...............................................................23

**Meeting Highlights**.................................................26

**International Career Development Award Recipients**..29

**SSO Committee Meetings**.......................................30

**Education Information**.............................................32

**SSO and The SSO Foundation Partners**
**and Supporters**.......................................................34

**ACGME Core Competencies**..................................36

**MOC Part 2 Self-Assessment Opportunities**.............37

**Wednesday Program**.............................................39

**Thursday Program**...................................................43

  - James Ewing Lecture..............................................53

  - John Wayne Clinical Research Lecture..................54

**Friday Program**.......................................................58

  - Distinguished Service Award..................................60

  - James Ewing Layperson’s Award............................61

  - SSO Presidential Address........................................62

  - The Great Debates I.................................................69

**Saturday Program**..................................................74

  - American Cancer Society/SSO
    Basic Science Lecture............................................78

  - Clinical Investigator Award Presentations...............79

  - The Great Debates II................................................80

  - Town Hall and Annual Business Meeting.................89

  - President’s Reception..............................................89

**Global Partner Posters**...........................................90

**Scientific Posters**.....................................................93

**Disclosure Information**..........................................132

**Industry Forum**.......................................................139

**Exhibit Hall Theater Presentations**......................140

**Exhibits**................................................................142

**Faculty Index**............................................................157

**Convention Center and Exhibit Hall Maps**.............160

**The SSO Foundation Information**.........................164
DAILY EVENTS

For complete Committee Meeting schedule and locations, please refer to pages 30-31. All locations are at the John B. Hynes Memorial Convention Center unless otherwise noted.

TUESDAY, MARCH 1
4-6 pm  Registration Open
         Level 2, outside Exhibit Hall C
4-6 pm  Speaker Ready Room Open
         Room 207

WEDNESDAY, MARCH 2
6 am-6 pm  Speaker Ready Room Open
           Room 207
6:30 am-6 pm  Registration Open
              Level 2, outside Exhibit Hall C
7 am-1:15 pm  Pre-Meeting Workshop
              (Ticket required)
              Fellows Institute II: Practical Aspects of Starting a Surgical Oncology Career
              Room 309
7:30 am-4:30 pm  Pre-Meeting Workshop
                   (Ticket required)
                   Ultrasound for the Surgical Oncologist
                   Room 202
1-6 pm  Pre-Meeting Workshop
         (Ticket required)
         Update Course in Surgical Oncology for the Practicing Surgeon
         Room 306
1:30-6 pm  Pre-Meeting Workshop
           (Ticket required)
           Effective Tools for Engaging in Research
           Room 309

THURSDAY, MARCH 3
6 am-6:30 pm  Registration Open
              Level 2, outside Exhibit Hall C
6 am-6:30 pm  Speaker Ready Room Open
              Room 207
6:45-7:45 am  Industry Forum: Preoperative Multidisciplinary Considerations for HER2+ Breast Cancer
              Room 206
8-9:30 am  International Perspectives on Gastric Cancer (MOC)
            Ballroom A
8-9:30 am  Surgical Management of Soft Tissue Sarcomas: An Update on Current and Future Approaches (MOC)  
   Ballroom B

8-9:30 am  Case Presentations with Professors and Fellows  
   Room 302/304

9:30-9:45 am  Refreshment Break  
   Ballroom Foyer

9:45-11:45 am  Hepatobiliary Parallel Session  
   Ballroom A

9:45-11:45 am  Breast Parallel Session 1  
   Ballroom B

9:45-11:45 am  Colorectal Parallel Session  
   Room 302/304

11:45 am-1 pm  Exhibit and Poster Hall Opening Lunch  
   (See details on page 19)  
   Exhibit Halls C & D

11:45 am-1 pm  SSO New Member Luncheon  
   (By invitation only)  
   Room 206

11:55 am-12:55 pm  Late Breaking Videos  
   Exhibit Hall Theater, Exhibit Hall D

12:15-12:45 pm  Poster Grand Rounds  
   (See details on page 21)  
   Exhibit Hall C

1-1:15 pm  Welcome and Announcements  
   Auditorium

1:15-2 pm  James Ewing Lecture  
   Auditorium

2-2:45 pm  John Wayne Clinical Research Lecture  
   Auditorium

2:45-3:45 pm  Refreshment Break in the Exhibit Hall  
   Exhibit Halls C & D

3-3:30 pm  Poster Grand Rounds  
   (See details on page 21)  
   Exhibit Hall C

3-3:45 pm  Exhibit Hall Theater Presentation: Effective Acute Postsurgical Pain Control: The Importance of a Multimodal and Opioid-Reducing Regimen  
   Exhibit Hall Theater, Exhibit Hall D

3:45-5:45 pm  Contemporary Management of Adrenal Neoplasms (MOC)  
   Ballroom A

3:45-5:45 pm  Susan G. Komen® Symposium: Selective Management of DCIS (MOC)  
   Ballroom B
3:45-5:45 pm  Immunotherapy: New Paradigms in the Treatment of Solid Tumors (MOC)  
Room 302/304
6-8 pm  Welcome Reception in the Exhibit Hall  
Exhibit Halls C & D

FRIDAY, MARCH 4
6 am-4 pm  Registration Open  
Level 2, outside Exhibit Hall C
6 am-6 pm  Speaker Ready Room Open  
Room 207
6:45-7:45 am  Meet the Professor Breakfasts  
(Ticket required) For full schedule and locations, see page 58
7-8 am  Breakfast in the Poster Hall  
Exhibit Hall C
7-7:55 am  Poster Grand Rounds  
(See details on page 21)  
Exhibit Hall Theater, Exhibit Hall D – Enter through Exhibit Hall C
8-8:45 am  Plenary I  
Auditorium
8:45-9 am  Distinguished Service Award & James Ewing Layperson's Award  
Auditorium
9-9:45 am  SSO Presidential Address  
Auditorium
9:45-10:15 am  Refreshment Break in the Exhibit Hall  
Exhibit Halls C & D
10:15 am-12:15 pm  Upper Gastrointestinal Parallel Session  
Ballroom A
10:15 am-12:15 pm  Breast Parallel Session 2  
Ballroom B
10:15 am-12:15 pm  Melanoma Parallel Session  
Room 302/304
12:15-1:15 pm  Lunch in the Exhibit and Poster Halls  
(See details on page 19)  
Exhibit Halls C & D
12:30-1 pm  Poster Grand Rounds  
(See details on page 21)  
Exhibit Hall C
12:30-1:15 pm  Exhibit Hall Theater Presentation: Oncolytic Viral Therapy and Intralesional Injection: A Surgeon’s Perspective  
Exhibit Hall Theater, Exhibit Hall D
1:15-2 pm  Plenary II  
Auditorium
2-3 pm  The Great Debates I  
Auditorium
3-3:45 pm  Ice Cream Break in the Exhibit and Poster Halls  
*Exhibit Halls C & D*

3:45-5:45 pm  Making Treatment Choices in Colorectal Cancer Patients with Synchronous Hepatic Metastases (MOC)  
*Ballroom A*

3:45-5:45 pm  Joint SSO/ESSO Symposium: Cytoreductive Surgery for Malignancy: When Does It Make Sense? (MOC)  
*Ballroom B*

3:45-5:45 pm  Melanoma Multidisciplinary Tumor Board  
*Room 302/304*

**SATURDAY, MARCH 5**

6 am-2 pm  Registration Open  
*Level 2, outside Exhibit Hall C*

6:45-7:45 am  Meet the Professor Breakfasts  
(Ticket required) For full schedule and locations, see page 74

7 am-3 pm  Speaker Ready Room Open  
*Room 207*

8-9:30 am  Update on Regional Therapy Options for Primary and Metastatic Liver Tumors (MOC)  
*Ballroom A*

8-9:30 am  Managing BRCA Mutation Carriers (MOC)  
*Ballroom B*

8-9:30 am  Gene Expression Profiling of Cancer: Implications for Clinical Management (MOC)  
*Room 302/304*

9:30-10 am  Refreshment Break  
*Ballroom Foyer*

10-10:45 am  American Cancer Society/SSO Basic Science Lecture  
*Ballroom B*

10:45-11:30 am  Clinical Investigator Award Presentations  
*Ballroom B*

11:30 am-12:30 pm  The Great Debates II  
*Ballroom B*

12:30-1:30 pm  Lunch on own

12:30-1:30 pm  Alliance for Clinical Trials in Oncology/American College of Surgeons Investigators Meeting  
*Room 107*

1:30-3 pm  Endocrine Parallel Session  
*Ballroom A*
1:30-3 pm  Quality Improvement/Clinical Outcomes Parallel Session  
*Ballroom B*

1:30-3 pm  Sarcoma and Thoracic/Eosophageal Parallel Session  
*Room 302/304*

3-3:15 pm  Refreshment Break  
*Ballroom Foyer*

3:15-4:45 pm  Neuroendocrine Tumors: Current Controversies (MOC)  
*Ballroom A*

3:15-4:45 pm  Managing Indolent Malignancies (MOC)  
*Ballroom B*

3:15-4:45 pm  Top Rated Videos  
*Room 302/304*

4:45-5 pm  Break

5-5:30 pm  Town Hall and Annual Business Meeting  
*Room 102 (Level 1)*

6-7:30 pm  President’s Reception  
*Grand Ballroom, Sheraton Boston Hotel (Level 2)*

**President’s Reception**

6-7:30 pm, Saturday, March 5  
(Ticket required)  
*Grand Ballroom, Sheraton Boston Hotel (Level 2)*

SSO President Dr. Jeffrey Drebin invites you to join him Saturday evening for cocktails and hors d’oeuvres. This event will provide an excellent opportunity for you to connect with friends and colleagues to discuss news from the meeting and make plans to reconnect next year in Seattle.
NEW AND EXCITING AT SSO 2016

Two Great Debates Sessions
Expanding our most popular offering, SSO 2016 will present two Great Debates sessions covering two controversial topics each. See pages 69 and 80 for full session information.

Global Partner Posters
As a result of SSO’s international program, SSO 2016 will feature the debut of the Global Partner Posters section in the hall, where top abstracts from four worldwide events over the past year will be highlighted. See page 90 for full information and poster listing.

SSO 2016 Mobile App
Reinvented at SSO 2015, this year’s mobile app is more robust than ever! Download the free application from your phone’s store to have access at your fingertips. Peruse the speaker and moderator listings for photos and biographies of our esteemed faculty and add sessions and abstracts to your personal itinerary. See page 20 for full details.

Disparities Abstracts Sub-category
Debuted at SSO 2015, abstracts reflecting this sub-category will be denoted with a symbol throughout the guide. See page 14-15 for full details.

International Perspectives on Gastric Cancer Symposium
Join your colleagues Thursday morning from 8-9:30 am in Ballroom A to hear first-hand updates on gastric cancer from surgeons around the world. Clinical trials from Korea, Japan and Europe as well as eastern versus western practices will be discussed. See page 43 for full details.

Exhibit Hall Passport to Prizes
Visit SSO exhibitors to earn a chance to win exciting prizes! As you make your way through the exhibit hall talking with the companies and visiting their booths, collect signatures on your Passport game card and enter to win. Participants must be present at the drawing to win. View full details on page 16.
Fellows & Residents Lounge
After a successful debut at SSO 2015, the Fellows & Residents Lounge is back for a second year. Dedicated for use by fellow and resident SSO members, the lounge is located in the Exhibit Hall and will be open during exhibit hours. This year’s lounge will feature informal discussions with prominent SSO leaders. The lounge can also be utilized as a space to network with other fellows and residents and relax during sessions. The lounge will provide internet access; snacks and refreshments will be provided throughout the day. Not an SSO member? Fellows and residents may complete an application for membership at the lounge. See page 17 for full details!
GENERAL INFORMATION
(Listed alphabetically)

Abstracts

Abstracts Available Electronically
This year, abstracts are available through the mobile.SSO2016.org website and through the SSO 2016 mobile app. Full app details can be found on page 20 of this guide. All abstracts are numbered to correspond with presentations listed in this Program Guide.

Abstract Contests

ANNUAL RESIDENT/FELLOW ESSAY AWARDS
Each year, the SSO offers two Resident/Fellow Essay Awards: one each for the best Clinical Research paper, and best Basic Science Research paper. Each award is $600, plus reimbursement of transportation expenses up to $600 (round trip coach airfare) for the recipient’s travel to the Annual Cancer Symposium. Winners will be announced during the Town Hall and Annual Business Meeting on Saturday, March 5 at 5 pm.

Supported by an independent grant from The SSO Foundation.

ABSTRACT POSTER CONTEST
The Society will present two Poster Awards of $500 each for Best Basic/Translational Research Poster and Best Clinical Research Poster. Please cast your votes by 4 pm on Friday, March 4. Poster Contest finalists are displayed outside Exhibit Hall C. Ballots were handed out with this Program Guide at Registration check-in. Winners will be announced at the beginning of The Great Debates II session on Saturday, March 5 at 11:30 am.

Disparities Abstracts Sub-category
This abstract sub-category, offered by SSO for the first time at SSO 2015, highlights abstracts and papers that span the complex nature of disparities as they relate to surgical oncology care and seek to understand the nature of disparities in surgical care and the factors that influence and mitigate them. Abstracts reflecting this sub-category will be denoted with a symbol throughout this guide.

Abstracts may cover:
• Constrained resources, systems of care, quality of surgical care and surgical safety
• The lack of access to surgical oncologists and cancer outcomes (both nationally and globally)
• The role of the surgical oncologist in reaching certain disparate communities and the impact of this on surgical oncology outcomes
• Evidence-based approaches to eliminate disparities and outcomes on screening, diagnosis, treatment, follow-up and survivorship
• Disparities in the elderly and issues that may impact surgical outcomes and survival
• Disparities on race/ethnicity/gender and surgical oncologic outcomes, and disparities and surgical oncologic outcomes addressing the global burden

Annals of Surgical Oncology
CME/MOC Opportunities
Earn AMA PRA Category 1 Credits™ and self-assessment credit that can be applied toward Part 2 of the ABS MOC Program by participating in educational activities offered by SSO through the Annals of Surgical Oncology!

NEW – Genomic Markers in the Multidisciplinary Treatment of Cancer CME/MOC Educational Review Series
Copies of this Educational Review Series are available at the SSO Membership Booth 1019 in the Exhibit Hall.

NEW – Manuscript Reviewer CME
Earn credit while learning about current issues, new research findings, multidisciplinary patient care and practice management in the field of surgical oncology.

Journal-Based CME/MOC
Earn credit by reading select articles from the Annals of Surgical Oncology. Two articles are available each month. For more information on any of the Annals CME/MOC educational opportunities, visit surgonc.org or moc.surgonc.org.

Committee Meetings
A list of SSO Committee Meetings scheduled this week is published on pages 30-31.
Exhibits Showcase New Products and Solutions

Exhibit Hall D
Over 60 technical and scientific exhibitors will display their latest products and services in the Exhibit Hall throughout SSO 2016. SSO appreciates the support of its exhibitors and strongly encourages all registrants to visit the displays.

Exhibit Hours
Thursday, March 3  11:45 am-8 pm
Friday, March 4  9:45 am-3:45 pm

Exhibit Hall Passport to Prizes
Visit SSO exhibitors to earn a chance to win exciting prizes!
As you make your way through the Exhibit Hall talking with exhibitors and visiting their booths, collect signatures on your Passport game card and enter to win.
1. Pick up your Passport game card at registration
2. Visit at least 8 exhibiting companies and ask them to sign your Passport game card
3. Drop your Passport game card in the entry box located at the SSO Membership Booth 1019
4. Attend the closing Exhibit Hall refreshment break scheduled from 3-3:45 pm on Friday, March 4 to see if your game card is selected as one of the winning cards.

The prize drawings will take place at 3:30 pm at the SSO Membership Booth 1019. Participants must be present to win.
Prizes include:
• iPad Air 2
• iPad Air Mini 4
• Amazon Fire HD 8

Exhibit Hall Theater Presentations
See page 140 for full details.

Exhibit Hall Theater Presentations offer you the opportunity to interact with select exhibitors and learn about their product and service innovations. See a listing of the featured exhibitors on signage at the back of Exhibit Hall D next to the Exhibit Hall Theater. These sessions occur during breaks on Thursday and Friday.
Fellows & Residents Lounge
After a successful debut at SSO 2015, the Fellows & Residents Lounge is back for a second year. Dedicated for use by fellow and resident SSO members* only, the lounge is located in Exhibit Hall D and will be open during exhibit hours:

**THURSDAY, MARCH 3**
11:45 am-8 pm

**FRIDAY, MARCH 4**
9:45 am-3:45 pm

This year’s lounge will feature informal discussions with prominent SSO leaders – schedule is below and in the SSO 2016 Mobile App. The lounge can also be utilized as a space to network with other fellows and residents and relax during sessions. The lounge will provide internet access; snacks and refreshments will be provided throughout the day. *Not an SSO member? Fellows and residents may complete an application for membership at the Fellow & Residents lounge.

**THURSDAY, MARCH 3**
12:15 pm-12:45 pm
Choosing Large Versus Small Institutions
Andrea V. Barrio, MD
Memorial Sloan Kettering Cancer Center
New York, NY

2:15-2:45 pm
Basic Science Research
Nancy DeMore, MD
Medical University of South Carolina
Charleston, SC

3-3:30 pm
Academic Pathways in HPB
Nipun B. Merchant, MD
University of Miami Medical Center
Miami, FL

3:45-4:15 pm
Teaching Surgical Trainees & Still Maintaining an Active Surgical Oncology Practice
Russell S. Berman, MD
New York University School of Medicine
New York, NY

4:30-5 pm
Considering Community Practice?
Joseph Guenther, MD
St. Elizabeth Physicians
Edgewood, KY
FRIDAY, MARCH 4

10-10:30 am
Using Cooperative Groups to Your Advantage to Get
Your Research Launched
Judy C. Boughey, MD
*Mayo Clinic*
Rochester, MN

10:45-11:15 am
How to Get Involved in the SSO
Kevin K. Roggin, MD
*University of Chicago Medicine*
Chicago, IL

11:30 am-12 pm
Program Director/Education as a Pathway
Jeffrey M. Farma, MD
*Fox Chase Cancer Center*
Philadelphia, PA

12:15-12:45 pm
Starting a Career in Health Services Research
Sandra L. Wong, MD, MS
*Dartmouth-Hitchcock Medical Center*
Lebanon, NH

1-1:30 pm
Chairman’s Perspective: What Are They Looking for in
a New Hire?
Michael Choti, MD, MBA
*University of Texas Southwestern Medical Center*
Dallas, TX

Industry Forums
(See page 139)
Industry Forums feature select exhibitors
addressing current issues in health care.
This year’s one hour non-CME breakfast session is from
6:45-7:45 am on Thursday. Check registration materials
for more information.

Internet Café
Visit the Internet Café to complete Maintenance of
Certification (MOC) self-assessment exams, claim your
CME credit, and send and retrieve email. The Café is
located on Level 2, outside Exhibit Hall C. This service is
complimentary to all SSO 2016 from Thursday, March 3
through Saturday, March 5.
**Lunch Options**

**Lunch vouchers** are provided to each meeting attendee for use at lunch on Thursday and Friday in the Exhibit and Poster Halls.

**Exhibit and Poster Hall Lunch Hours**

- Thursday, March 3  11:45 am-1 pm
- Friday, March 4  12:15-1:15 pm

**Manuscripts for Publication**

Authors of all clinical papers are encouraged, but not required, to submit their manuscripts for publication in the *Annals of Surgical Oncology* prior to their presentation.

To upload your manuscript, log into the Journal’s online submission site: [mc.manuscriptcentral.com/aso](http://mc.manuscriptcentral.com/aso)

Manuscripts must be prepared in accordance with the posted submission guidelines.

---

**MEMBERSHIP**

JOIN THE SSO TODAY!

Experience the value of SSO’s global community. Join SSO today and become a part of a worldwide community of surgeons and scientists dedicated to advancing surgical oncology and cancer care. Every surgeon should be a member of the SSO. Enjoy these benefits and much more:

- Online access to the world-renowned *Annals of Surgical Oncology*, SSO’s official journal
- Special savings and privileges on membership dues, the SSO Annual Cancer Symposium registration and access to valuable educational products and resources
- Listing in Find a Surgical Oncologist global database on [surgonc.org](http://surgonc.org)
- Stay current on multidisciplinary care with inclusion in SSO’s exclusive members-only website pages and social meeting groups on Twitter, Facebook and LinkedIn

For more information visit us online at [surgonc.org](http://surgonc.org).

**Annual Meeting Membership Special**

SSO will waive the application fee if you join the Society before Friday, April 29 — a savings of $150! Stop by the SSO Membership Booth 1019 in Exhibit Hall D.
MOBILE ACCESS FOR SSO 2016

Search “SSO 2016” in Google Play, App Store, BlackBerry World and Windows Phone Store to download the SSO 2016 mobile app!

The SSO 2016 mobile app allows you access to complete conference information at your fingertips. Be sure to download the app on your phone or tablet for one-touch access to the following:

- Poster, video and oral abstracts
- Interactive schedule
- Up-to-the-minute Symposium updates
- Speaker and moderator listings, photos and biographies
- Exhibitor listing and information
- Interactive maps
- Committee meeting schedule
- Audience response polling in select sessions

Enhance Your App Experience
Visit the app and enter your email address to log in and utilize additional features that allow you to:

- Create your own schedule
- Take notes during sessions
- Identify favorite exhibitors

SSO2016.org
Alternately, you can access the program schedule and all mobile app content at mobile.SSO2016.org. SSO is pleased to provide this enhanced mobile-friendly resource that allows you to view complete details about the Symposium’s education program, add sessions to your personal calendar and search by track, type, presenter or moderator.

The Society of Surgical Oncology gratefully acknowledges Amgen, Inc. for its support of the SSO 2016 app.
New Members of SSO

New members of SSO will be identified by a new member ribbon affixed to their name badge. We encourage you to introduce yourself so our new members feel welcome.

There is a special luncheon (by invitation only) for new members only from 11:45 am-1 pm on Thursday in Room 206.

Photographs and Recordings

By registering for this meeting, attendees acknowledge and agree that SSO or its agents may take photographs during events and may freely use those photographs in any media for SSO purposes including, but not limited to, news and promotional purposes.

The presentations, slides and handouts provided in this program are the property of SSO or used by permission. You may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from SSO. Any attendee believed to be violating this restriction will be removed from the session and may be prohibited from participating in further SSO meetings.

Poster Grand Rounds

During these interactive sessions, top scoring poster presentations will be highlighted by moderators in each disease site category. Discussion and comments will be encouraged in the Grand Rounds, taking place in Exhibit Hall C. Meet at the beginning of the topic section being discussed to participate. Posters of discussion will have this symbol starting on page 93.

**Poster Grand Rounds Schedule**

**THURSDAY, MARCH 3**

12:15-12:45 pm  
Colorectal  
Endocrine  
Quality Improvement/ Clinical Outcomes

3-3:30 pm  
Breast 1  
Sarcoma and Thoracic/ Esophageal  
Upper Gastrointestinal

**FRIDAY, MARCH 4**

7-7:25 am  
Clinical Poster Award Nominees*

7:30-7:55 am  
Research Poster Award Nominees*

12:30-1 pm  
Breast 2  
Hepatobiliary  
Melanoma

* Taking place in the Exhibit Hall Theater; enter through Exhibit Hall C
Poster Presentations
All Scientific Posters will be displayed from 11:45 am on Thursday to 3:45 pm on Friday in Exhibit Hall C. Authors are requested to be available during the times below, as their schedules permit, to answer questions about their presentations. Poster signage is color-coded by track. See full poster details starting on page 93.

THURSDAY, MARCH 3
11:45 am-1 pm
2:45-3:45 pm
6-8 pm

FRIDAY, MARCH 4
7-8 am
9:45-10:15 am
12:15-1:15 pm
3-3:45 pm

Global Partner Posters
As a result of SSO’s international program, SSO 2016 will feature the debut of the Global Partner Posters section in the hall, where top abstracts from five worldwide events over the past year will be highlighted. See pages 90-92 for full information and poster listing.

Registration Desk Hours
The registration desk is located on Level 2, outside Exhibit Hall C, and will be open during the following hours:

Tuesday, March 1 4-6 pm
Wednesday, March 2 6:30 am-6 pm
Thursday, March 3 6 am-6:30 pm
Friday, March 4 6 am-4 pm
Saturday, March 5 6 am-2 pm

SSO Badge Designation
Blue  SSO Member Physician, Scientist or Senior Member
Light Blue  SSO Associate Member (PA, NP, RN, LPN, LVN)
Teal  SSO Fellow/Resident/Medical Student
Gray  Non-Member Physician or Scientist
Green  Non-Member (Pharma or Other)
Lime  Non-Member Allied Health Provider (PA, NP, RN, LPN, LVN)
Purple  Non-Member Fellow/Resident/Medical Student
Yellow  Spouse/Guest
Red  Exhibitor
Orange  Press

Replacement badges are available at the Registration Desk for $10 each.
Schedule-at-a-Glance
Please refer to the Schedule-at-a-Glance that folds out from the front cover of this Program Guide to help you navigate SSO 2016. The Schedule is color coded into seven tracks including General Education, Breast, Colorectal, Gastrointestinal, Melanoma and Sarcoma, and Other Surgical Oncology.

SOCIAL EVENTS

Network with your colleagues in multidisciplinary surgical oncology care during these events:

Welcome Reception in the Exhibit Hall
6-8 pm, Thursday, March 3
Exhibit Halls C & D

Join us in the Exhibit Hall for hors d’oeuvres, refreshments, and networking as you visit the posters and exhibits. Participate in the Exhibit Hall Passport to Prizes game and win prizes by visiting with the exhibitors (see full details on page 16). Be sure to stop by the SSO Membership Booth 1019.

This complimentary event is open to all attendees. One drink ticket is located in your attendee registration materials. This event will have a cash bar.

President’s Reception
6-7:30 pm, Saturday, March 5
(Ticket required)
Grand Ballroom, Sheraton Boston Hotel (Level 2)

SSO President Dr. Jeffrey Drebin invites you to join him Saturday evening for cocktails and hors d’oeuvres. This event will provide an excellent opportunity for you to connect with friends and colleagues to discuss news from the meeting and make plans to reconnect next year in Seattle.
Speaker Ready Room
The Speaker Ready Room is located in Room 207 and is available to all program participants.

Tuesday, March 1          4-6 pm
Wednesday, March 2        6 am-6 pm
Thursday, March 3         6 am-6:30 pm
Friday, March 4           6 am-6 pm
Saturday, March 5         7 am-3 pm

All speakers should report to the Speaker Ready Room at least four (4) hours prior to the start of the session in which they are speaking.

Videos, Late Breaking
Due to the high quality of video abstracts submitted, a select number of additional high-ranked video abstracts will be shown in the Exhibit Hall Theater, Exhibit Hall D during Thursday’s lunch break. See page 52 for the full schedule.

SSO 2016 VIRTUAL MEETING
Miss a session here in Boston that you really hoped to see? Wondering how you can still get access to the cutting-edge material presented? As a registered conference attendee, you will have virtual access to SSO 2016 at no additional charge. You can begin viewing sessions from actual symposia presentations only hours after they occur.

To access the SSO 2016 Virtual Meeting, visit the SSO website at surgonc.org/vm and enter your email on file with SSO and your SSO password.
SSO provides exceptional continuing education opportunities for surgical oncologists, general surgeons and other health care professionals regardless of career level.

EDUCATION OFFERINGS INCLUDE:

Educational Webinars — Participate in live or archived webinars focusing on a variety of topics in surgical oncology. Earn CME and self-assessment credit for select activities.

Surgical Oncology Self-Assessment Program (SOSAP) — Gain 60 AMA PRA Category 1 Credits™ and fulfill three years’ worth of MOC Part 2 self-assessment requirements.

Annals of Surgical Oncology: CME/MOC Credit for Reading — Earn credit by reading select articles and/or educational review series and completing a self-assessment exam and evaluation online.

MOC Part 2 Online Modules — Participate in online modules and earn self-assessment credit.

Virtual Meeting — View sessions from SSO Annual Cancer Symposia, including SSO 2016.

Access these resources and learn more at surgonc.org/education.
MEETING HIGHLIGHTS

James Ewing Lecture: T Cells as a Drug for the Treatment of Human Cancer
1:15-2 pm, Thursday, March 3
Auditorium
Steven A. Rosenberg, MD, PhD

See page 53 for full details.
Supported by an independent grant from The SSO Foundation.

John Wayne Clinical Research Lecture: Bringing Precision Cancer Medicine Forward
2-2:45 pm, Thursday, March 3
Auditorium
José Baselga, MD, PhD

See page 54 for full details.
Supported by an independent grant from the John Wayne Cancer Foundation.

Harvey Baker Traveling Fellow Award
8 am, Friday, March 4
Auditorium, Plenary I Session
Lea Lowenfeld, MD

University of Pennsylvania
The Society congratulates Lea Lowenfeld, MD, who is attending SSO 2016 as the recipient of the 2016 Harvey Baker Traveling Fellow Award for the following abstract:

1: Combination Anti-Estrogen Therapy and Anti-HER2 Dendritic Cell Vaccination Improves Pathologic Complete Response in ER+/HER2+ DCIS Patients

Lea Lowenfeld, MD is a general surgery resident at the Hospital of the University of Pennsylvania where she also serves as the Chair of the Resident Executive Council in the Department of Surgery. Dr Lowenfeld received her BA in Philosophy from Cornell University where she graduated magna cum laude and received her medical degree from the School of Medicine at the University of Pennsylvania. After completing three years of general surgery clinical training, she was awarded the Henle Post-Doctoral Research Fellowship to study cancer immunotherapy. She plans to pursue a career in surgical oncology.

Supported by an independent grant from The SSO Foundation.
Distinguished Service Award
8:45-8:55 am, Friday, March 4
Auditorium
Mark S. Roh, MD
In recognition of his major contributions to the Society and the Annals of Surgical Oncology during his 22 years of service as the Journal’s Executive Editor.

See page 60 for full details.

James Ewing Layperson’s Award
8:55-9 am, Friday, March 4
Auditorium
Margaret Foti, PhD, MD (hc)
Supported by an independent grant from The SSO Foundation.

American Cancer Society/SSO Basic Science Lecture: Pancreatic Models and Medicine
10-10:45 am, Saturday, March 5
Ballroom B
David A. Tuveson, MD, PhD
Supported by an independent educational grant from the American Cancer Society.

Clinical Investigator Award Presentations
10:45-11:30 am, Saturday, March 5
Ballroom B
Be sure to attend this year’s presentation of CIA recipients Stephen R. Grobmyer, MD and Ryan C. Fields, MD to hear the results of their research efforts. The recipients of the 2016 Clinical Investigator Award will be announced at the conclusion of this year’s presentations. Recipients of the new SSOF Young Investigator Award will also be announced.

See page 79 for full details.
The Society congratulates David Y. Lee, MD, who is attending the 69th SSO Annual Cancer Symposium as the sixth annual recipient of the Colorectal Cancer Research Scholar Award. The goal of this award is to recognize excellence in transitional research focused on the molecular biology of colorectal cancer.

83: Race-Based Socioeconomic and Treatment Disparities in Adolescent and Young Adults with Stage II-III Rectal Cancer

D. Lee*, John Wayne Cancer Institute, Los Angeles, CA; A. Teng, Mount Sinai St. Lukes Roosevelt Hospital Center, New York, NY; R.C. Pedersen, F.R. Tavangari, V. Attaluri, M.C. Elisabeth, S.L. Stern, A.J. Bilchik, M. Goldfarb, Kaiser Permanente, Los Angeles, CA.

Dr. David Lee graduated from the University of Maryland at College Park Maryland with a degree in microbiology. He then obtained his medical degree from the Medical College of Virginia at Virginia Commonwealth University in Richmond Virginia. He then went on to complete his internship and residency at Mount Sinai St. Luke’s-Roosevelt hospital in New York and was awarded Charles McBurney award in surgery. He is currently completing his fellowship in Complex General Surgical Oncology at the John Wayne Cancer Institute in Santa Monica California as the Harold McAlister Charitable Foundation fellow.

Supported by an independent grant from the Colon Cancer Challenge Foundation.

Susan G. Komen® Breast Cancer Research Award

Please see the SSO 2016 Mobile App and Program Guide Addendum for full information.

Supported by an independent grant from Susan G. Komen®.
2016 marks the third year for the International Career Development Exchange Program. Participants have been selected by the Brazilian Society of Surgical Oncology, Chinese Society of Clinical Oncology, European Society of Surgical Oncology, Japanese Society of Gastroenterological Surgery, and the Sociedad Mexicana de Oncologia, AC based upon program criteria established by SSO. The participants are attending the Annual Conference followed by a visit to one to three academic institutions in their specialty areas to further their knowledge.

Please join the Society in congratulating and making them feel welcome at the 69th SSO Annual Cancer Symposium:

**Ranyell Matheus Spencer Sobreira Batista, MD, PhD**, was selected to participate in this program by the Brazilian Society of Surgical Oncology. Dr. Spencer is a surgeon of pelvic surgery at AC Camargo Cancer Center, Colorectal and Sarcomas Division.

**Fiore Marco, MD**, has been chosen for this program by the European Society of Surgical Oncology. Dr. Marco is an attending surgeon at the Fondazione Istituto Nazionale Tumori IRCCS.

**Yin Zi, MD**, joins us on behalf of the Chinese Society of Clinical Oncology. Dr. Zi is a surgical oncologist at the Guangdong General Hospital.

**Yoshikuni Kawaguchi, MD, PhD**, has been selected for this program by the Japanese Society of Gastroenterological Surgery. Dr. Kawaguchi is an assistant professor in the Hepato-Biliary-Pancreatic Surgery Division at the University of Tokyo, Graduate School of Medicine.

**Jorge Alberto Salazar Andrade, MD**, joins us on behalf of the Sociedad Mexicana de Oncologia, AC. Dr. Salazar Andrade is a surgical oncologist specializing in breast cancer at FUCAM Hospital.
SSO COMMITTEE MEETINGS

Changes to times or locations will be posted at the SSO Registration Desk or online at SSO2016.org. All locations are at the John B. Hynes Memorial Convention Center unless otherwise noted.

Wednesday, March 2

12-5 pm Executive Council Meeting
Commonwealth, Sheraton Boston Hotel

Thursday, March 3

7-8 am Colorectal/Gastrointestinal Disease Site Work Groups
Room 202

7-8 am Hepatobiliary Disease Site Work Group
Room 307

7-8 am Membership Committee
Room 203

8 am-12 pm Training Committee
Room 309

11:45 am-1 pm New Member Luncheon
Room 206 (By invitation only)

11:45 am-1 pm Surgical Oncology Program
Directors Subcommittee
Room 202

12-1 pm CME Committee
Room 203

2:45-3:45 pm Endocrine/Head and Neck Disease Site Work Group
Room 309

2:45-3:45 pm Web Site and Social Media Communications Committee Meeting
Room 202

2:45-4:15 pm International Committee
Room 204

3:30-6 pm The SSO Foundation Board of Directors Meeting
Room 203

4:30-5:30 pm Decker Section Editors
Room 309

4:30-6 pm Annals of Surgical Oncology Editors Meeting
Room 202
Friday, March 4
6:30-7:30 am  SOSAP Task Force
               Room 202
7-8 am         Research Committee
               Room 309
12:15-1:15 pm  SCORE Committee
               Room 202
3-4 pm         Breast Program Directors Subcommittee
               Room 204
3-4 pm         Disparities Committee
               Room 309
3-4 pm         Quality Committee
               Room 202

Saturday, March 5
7-8 am         Breast Disease Site Work Group
               Room 309
7-8 am         Decker Section Editors
               Room 101
9:30-10:30 am  Melanoma/Sarcoma Disease Site
               Work Group
               Room 309
12:30-1:30 pm  Scientific Program Committee
               Room 309
5-5:30 pm      Town Hall & Annual SSO
               Business Meeting
               Room 102 (Level 1)
Target Audience
This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with cancer.

Overall Educational Objectives
• Describe recent updates and current controversies in the multidisciplinary management of patients with breast cancer, melanoma, sarcoma, pancreas and hepatobiliary malignancies, esophageal cancer, thyroid and adrenal cancer, gastric cancer, colorectal cancer, neuroendocrine tumors and peritoneal surface malignancies.
• Discuss advances in basic and translational sciences, including demonstration of an understanding of prognostic and predictive assays as applicable to cancer care, through presentations of original research performed by members of the Society.
• Discuss the rationale for neoadjuvant therapy and/or genetic testing in the context of personalized cancer care.
• Discuss the goals of cost, value and quality as applied to cancer care.
• Describe novel techniques in cancer surgery.

Accreditation
The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The Society of Surgical Oncology (SSO) designates this live activity for a maximum of 31.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement
This activity is supported by independent educational grants from Amgen, Inc., Celgene Corporation, Ethicon Endo-Surgery, Inc., Genentech, Inc., Hitachi-Aloka Medical America, Inc., Hologic, Inc., Merck & Co., Inc. and Myriad Genetics, Inc.

In-kind support for the Pre-Meeting Workshop, Ultrasound for the Surgical Oncologist, from Cianna Medical, Hitachi-Aloka Medical America, Inc., Hologic, Inc. and SonoSite.

This activity is supported by independent educational grants from American Cancer Society, Colon Cancer Challenge Foundation, John Wayne Cancer Foundation, The SSO Foundation and Susan G. Komen®.
Complete information will be provided to participants prior to the start of the activity.

Disclaimer
The primary purpose of the SSO Annual Meeting is educational. Information, as well as technologies, products and/or services discussed, are intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the SSO disclaims any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.
SOCIETY OF SURGICAL ONCOLOGY AND THE SSO FOUNDATION PARTNERS AND SUPPORTERS

Our Partners
This activity is supported, in part, by independent educational grants. The Society of Surgical Oncology (SSO) and The SSO Foundation gratefully acknowledge the following organizations for their contributions:

American Cancer Society
Supporter of the American Cancer Society/SSO Basic Science Lecture, Pancreatic Models and Medicine

Amgen, Inc.
Partial supporter of the Melanoma/Sarcoma Track

Celgene Corporation
Partial supporter of the SSO Annual Cancer Symposium

Colon Cancer Challenge Foundation
Supporter of the Colorectal Cancer Research Scholar Award

Ethicon Endo-Surgery, Inc.
Partial supporter of the Colorectal and Gastrointestinal Tracks

Genentech, Inc.
Partial supporter of the Breast Track

Hitachi-Aloka Medical America, Inc.
Partial supporter of the Pre-Meeting Workshop, Ultrasound for the Surgical Oncologist

Hologic, Inc.
Partial supporter of the Breast Track

John Wayne Cancer Foundation
Supporter of the Thursday John Wayne Clinical Research Lecture, Bringing Precision Cancer Medicine Forward

Merck & Co., Inc.
Partial supporter of the Melanoma/Sarcoma Track

Myriad Genetics, Inc.
Partial supporter of the Breast Track.

The SSO Foundation
Supporter of the James Ewing Layperson’s Award, James Ewing Lecture, Harvey Baker Traveling Fellow Award, Annual Resident/Fellow Essay Awards, and the Clinical Investigator Awards Session

Susan G. Komen®
Supporter of the Susan G. Komen® Symposium, Management of DCIS, and the SSO/Susan G. Komen® Breast Cancer Research Award
Our Sponsors
SSO gratefully acknowledges the following organizations for their sponsorship commitments:

Amgen, Inc.
Sponsor of the Key Card, Mobile App, Program Guide Advertising, Registration Confirmations, Housing Confirmations, Table Clings, Premium SSO Program Guide Listing, Schedule-at-a-Glance, and the Friday Exhibit Hall Theater Presentation

AngioDynamics Inc.
Sponsor of Program Guide Advertising

Belmont Instrument Corporation
Sponsor of an Extended Directory Listing

Ethicon Endo-Surgery, Inc.
Sponsor of International Perspectives on Gastric Cancer Part II, two Daily Update Email Blasts, In-Room Table Tent, and a Charging Station

Genentech, Inc.
Sponsor of the Thursday Industry Forum

Navidea Biopharmaceuticals
Sponsor of the SSO Annual Cancer Symposium

Pacira Pharmaceuticals, Inc.
Sponsor of the Thursday Exhibit Hall Theater Presentation

Our In-kind Supporters of the Pre-Meeting Workshop
SSO and The SSO Foundation gratefully acknowledge the following organizations for their in-kind support for the Pre-Meeting Workshop, Ultrasound for the Surgical Oncologist:

Cianna Medical
Hitachi-Aloka Medical
America, Inc.

Hologic, Inc.
SonoSite

Our Supporters of Fellows Programming
SSO and The SSO Foundation gratefully acknowledge the following organizations for their support of the Pre-Meeting Workshop: Fellows Institute II, and the Fellows and Residents Lounge:

Amgen, Inc.
Ethicon-Endo Surgery
Faxitron Bioptics, LLC
Genentech, Inc.

Hitachi-Aloka Medical
America, Inc.
Hologic, Inc.
Medtronic

Our Clinical Investigator Award Supporters
SSO and The SSO Foundation gratefully acknowledge the following organizations for their research grant commitments:

Amgen, Inc.
Supporter of a 2016-2018 Melanoma Clinical Investigator Award

Genentech, Inc.
Supporter of a 2016-2018 Clinical Investigator Award
ACGME CORE COMPETENCIES

The 2016 scientific offerings assist the physician with the six core competencies first adopted by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Specialties (ABS). Attendees are encouraged to select areas of interest from the program which will enhance their knowledge and improve the quality of patient care.

Scientific session information pages within this Program Guide will include the number that corresponds with the core competency listed below, so that physicians can easily identify the competencies addressed during the session.

1. **Patient Care:** Provide care that is compassionate, appropriate, and effective treatment for health problems and to promote health.

2. **Medical Knowledge:** Demonstrate knowledge about established and evolving biomedical, clinical and cognate sciences and their application in patient care.

3. **Interpersonal and Communication Skills:** Demonstrate skills that result in effective information exchange and teaming with patients, their families, and professional associates (e.g., fostering a therapeutic relationship that is ethically sound, uses effective listening skills with non-verbal and verbal communication; working as both a team member and at times a leader).

4. **Professionalism:** Demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to diverse patient populations.

5. **Systems-Based Practice:** Demonstrate awareness of and responsibility to larger context and systems of health care. Be able to call on system resources to provide optimal care (e.g., coordinating care across sites or serving as the primary care manager when care involves multiple specialties, professions or sites).

6. **Practice-Based Learning and Improvement:** Able to investigate and evaluate their patient care practices, appraise, and assimilate scientific evidence and improve their practice of medicine.
MAINTENANCE OF CERTIFICATION (MOC) PART 2 SELF-ASSESSMENT OPPORTUNITIES

Self-assessment credit that may be applied towards Part 2 of the ABS MOC program will be offered for the sessions occurring within the educational tracks listed below.

Pre-Meeting
• Update Course in Surgical Oncology for the Practicing Surgeon

Breast
• Susan G. Komen® Symposium: Selective Management of DCIS
• Managing BRCA Mutation Carriers

Colorectal
• Making Treatment Choices in Colorectal Cancer Patients with Synchronous Hepatic Metastases

Gastrointestinal
• International Perspectives on Gastric Cancer
• Update on Regional Therapy Options for Primary and Metastatic Liver Tumors

Melanoma and Sarcoma
• Surgical Management of Soft Tissue Sarcomas: An Update on Current and Future Approaches

Other Surgical Oncology
• Contemporary Management of Adrenal Neoplasms
• Neuroendocrine Tumors: Current Controversies

General Education
• Immunotherapy: New Paradigms in the Treatment of Solid Tumors
• Joint SSO/ESSO Symposium: Cytoreductive Surgery for Malignancy: When Does It Make Sense?
• Gene Expression Profiling of Cancer: Implications for Clinical Management
• Managing Indolent Malignancies

For more information on each of the sessions listed above please utilize the SSO 2016 Mobile App or visit www.sso2016.org and select “MOC Information” listed under “Program” on the main menu.

Internet Café
To claim your self-assessment credit toward Part 2 of the American Board of Surgery (ABS) MOC program visit the SSO 2016 Internet Café from Thursday, March 3 through Saturday, March 5 to access a computer kiosk and complete the MOC self-assessment exam online. The Internet Café is located on Level 2, outside Exhibit Hall C.

MOC Online
To access the MOC modules online during or after SSO 2016, visit the SSO website at surgonc.org/moc.
SSO provides exceptional continuing education opportunities for surgical oncologists, general surgeons and other health care professionals regardless of career level.

**EDUCATION OFFERINGS INCLUDE:**

**Educational Webinars** — Participate in live or archived webinars focusing on a variety of topics in surgical oncology. Earn CME and self-assessment credit for select activities.

**Surgical Oncology Self-Assessment Program (SOSAP)** — Gain 60 AMA PRA Category 1 Credits™ and fulfill three years’ worth of MOC Part 2 self-assessment requirements.

**Annals of Surgical Oncology: CME/MOC Credit for Reading** — Earn credit by reading select articles and/or educational review series and completing a self-assessment exam and evaluation online.

**MOC Part 2 Online Modules** — Participate in online modules and earn self-assessment credit.

**Virtual Meeting** — View sessions from SSO Annual Cancer Symposia, including SSO 2016.

Access these resources and learn more at surgonc.org/education.
PRE-MEETING WORKSHOP

Fellows Institute II: Practical Aspects of Starting a Surgical Oncology Career
Separate Registration & Fee Required
4, 5, 6
(See page 36 for listing of ACGME Core Competencies)
7 am-1:15 pm, Wednesday, March 2
Room 309
Moderator: Keith A. Delman, MD

Faculty:

Benjamin O. Anderson, MD
Professor of Surgery and Global Health Medicine
University of Washington
Seattle, WA

Cletus A. Arciero, MD
Associate Professor of Surgery, Surgical Oncology
Emory University School of Medicine
Atlanta, GA

Steven L. Chen, MD, MBA
Director of Surgical Oncology
OasisMD
San Diego, CA

David P. Jaques, MD
Vice President, Surgical Services
Barnes-Jewish Hospital
St. Louis, MO

Troy F. Kimsey, MD
Surgical Oncologist
Premier Surgical Associates
Knoxville, TN

Timothy M. Pawlik, MD, MPH, PhD
Chief, Division of Surgical Oncology
The Johns Hopkins Hospital
Baltimore, MD

Charles R. Scoggins, MD, MBA
Professor and Vice-Chair, Department of Surgery
University of Louisville
Louisville, KY

Francis R. Spitz, MD
Vice Chief, Department of Surgery
Cooper University Hospital
Camden, NJ
PRE-MEETING WORKSHOP

Ultrasound for the Surgical Oncologist
Separate Registration & Fee Required
1, 2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
7:30 am-4:30 pm, Wednesday, March 2
Room 202

Moderators: Richard E. Fine, MD &
David J. Winchester, MD

Faculty:
Beth Boyd, RN
Consultant
Marietta, GA

Richard E. Fine, MD
Director of Education and Research
West Clinic Comprehensive Breast Center
Germantown, TN

Mark A. Gittleman, MD
Medical Director of Breast Cancer Services
Coordinated Health Breast Care Specialists
Allentown, PA

Carmen C. Solórzano, MD
Professor of Surgery
Vanderbilt University
Nashville, TN

Lorraine Tafra, MD
Medical Director of the Breast Center at Anne Arundel Medical Center
The Breast Center
Annapolis, MD

Shawna C. Willey, MD
Professor of Clinical Surgery
Medstar Georgetown University Hospital
Washington, DC

David J. Winchester, MD
Chief, Surgical Oncology
NorthShore University HealthSystem
Evanston, IL
PRE-MEETING WORKSHOP

Update Course in Surgical Oncology for the Practicing Surgeon
Separate Registration & Fee Required
1, 2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
1-6 pm, Wednesday, March 2
Room 306

Moderators: Ronda S. Henry-Tillman, MD, Augusto R. Leon, MD, T. Salewa Oseni, MD and Christopher M. Pezzi, MD

Faculty:

Ned Z. Carp, MD
Clinical Assistant Professor
Thomas Jefferson Medical College
Wynnewood, PA

Conor P. Delaney, MD, PhD
Chairman, Digestive Disease Institute
Cleveland Clinic
Cleveland, OH

Jeffrey A. Drebin, MD, PhD
The John Rhea Barton Professor and Chair,
Department of Surgery
University of Pennsylvania
Philadelphia, PA

Ronda S. Henry-Tillman, MD
Professor of Surgery
University of Arkansas for Medical Sciences
Little Rock, AR

Kevin S. Hughes, MD
Associate Professor of Surgery
Harvard Medical School
Boston, MA

V. Suzanne Klimberg, MD
Muriel Balsam Kohn Chair in Breast Surgical Oncology
Winthrop P. Rockefeller Cancer Institute
Little Rock, AR

Matthias F. Stopfkuchen-Evans, MD
Staff Anesthesiologist
Brigham and Women’s Hospital
Boston, MA

Linwah Yip, MD
Associate Professor
University of Pittsburgh
Pittsburgh, PA
PRE-MEETING WORKSHOP

Effective Tools for Engaging in Research
Separate Registration & Fee Required
4, 5, 6
(See page 36 for listing of ACGME Core Competencies)
1:30-6 pm, Wednesday, March 2
Room 309

Moderator: Keith A. Delman, MD

Faculty:

H. Richard Alexander, Jr. MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, MD

David L. Bartlett, MD
Bernard Fisher Professor of Surgery and Chief
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Michael I. D’Angelica, MD
Enid A. Haupt Chair in Surgery
Memorial Sloan Ketting Cancer Center
New York, NY

Shishir K. Maithel, MD
Associate Professor of Surgery
Winship Cancer Institute, Emory University
Atlanta, GA

Timothy M. Pawlik, MD, MPH, PhD
Chief, Division of Surgical Oncology
The Johns Hopkins Hospital
Baltimore, MD

Sandra L. Wong, MD, MS
Professor and Chair of Surgery
Dartmouth-Hitchcock Medical Center and Geisel School of Medicine at Dartmouth
Lebanon, NH
SYMPOSIUM
International Perspectives on Gastric Cancer (MOC)
1, 2
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Thursday, March 3
Ballroom A

Moderators: Brian D. Badgwell, MD, MS & Daniel G. Coit, MD

Introductions and Welcome
8 am Observed Differences in the Natural History of Eastern Versus Western Gastric Cancer: Lessons Learned from a Large International Gastric Cancer Database
Takeshi Sano, MD, PhD
Department Director of Gastroenterological Surgery
Cancer Institute Hospital of the Japanese Foundation for Cancer Research
Tokyo, Japan

8:18 am Minimally Invasive Surgery for Gastric Cancer: Lessons Learned from Prospective Randomized Clinical Trials of Laparoscopic and Robotic Gastrectomy
Hyung-Ho Kim, MD, PhD
Chairman, Department of Surgery
Seoul National University Bundang Hospital
Seoul, Korea

8:36 am Current Japanese Clinical Trials in Gastric Cancer
Mitsuru Sasako, MD, PhD
Professor, Chairman Upper Gastrointestinal Surgery
Hyogo College of Medicine
Nishinomiya, Japan

8:54 am Recent and Current European Clinical Trials in Gastric Cancer
Giovanni de Manzoni
Full Professor of Surgery
University of Verona
Verona, Italy

9:12 am Panel Discussion with Q&A

Refreshment Break
9:30-9:45 am, Thursday, March 3
Ballroom Foyer
SYMPOSIUM
Surgical Management of Soft Tissue Sarcomas: An Update on Current and Future Approaches (MOC) 1, 2, 6
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Thursday, March 3
Ballroom B
Moderators: Robert J. Canter, MD & Kenneth Cardona, MD

Introductions and Welcome
8 am  What is the Optimal Approach to Well-differentiated Liposarcoma/Atypical Lipomatous Tumor of the Extremity and Trunk?
Ricardo J. Gonzalez, MD
Chair, Sarcoma Department
Moffitt Cancer Center
Tampa, FL

8:15 am  What is the Optimal Approach for Locally Recurrent Extremity STS?
Francis J. Hornicek, Jr. MD, PhD
Professor of Orthopedic Surgery
Massachusetts General Hospital
Boston, MA

8:30 am  What is the Optimal Treatment Sequencing and Timing of Operation in Primary and Recurrent Retroperitoneal Sarcomas?
Alessandro Gronchi, MD
Chair, Sarcoma Service
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Italy

8:45 am  Multimodality Treatment Strategies for Oligometastatic Sarcoma
Chandrajit P. Raut, MD, MSc
Associate Professor of Surgery
Brigham and Women’s Hospital/Dana-Farber Cancer Institute
Boston, MA

9 am  Tumor Board with Case Discussion and ARS Questions

Refreshment Break
9:30-9:45 am, Thursday, March 3
Ballroom Foyer
SYMPOSIUM

Case Presentations with Professors and Fellows
1, 2, 3, 5, 6
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Thursday, March 3
Room 302/304

Moderators: Murray F. Brennan, MD & Kelly M. McMasters, MD, PhD
Session Coordinator: Aimee M. Crago, MD, PhD

40 y.o. with mass in pancreatic body
Heather Stuart, MD
Surgical Oncology Fellow
University of Miami/Jackson Memorial Hospital
Miami, FL

33 y.o. with breast mass during pregnancy
Surupa Sen Gupta, MD
Breast Surgical Oncology Fellow
MedStar Washington Hospital Center; MedStar Georgetown University Hospital
Washington, DC

25 y.o. with thigh mass on anticoagulation
Georgia Beasley, MD
Surgical Oncology Fellow
The Ohio State University Wexner Medical Center
Columbus, OH

63 y.o. with abdominal pain
Sean Ronnekleiv-Kelly, MD
Complex General Surgical Oncology Fellow
Johns Hopkins Hospital
Baltimore, MD

74 y.o. with ‘bruising’ of breast
Anne Mattingly, MD
Breast Surgical Oncology Fellow
H. Lee Moffitt Cancer Center
Tampa, FL

70 y.o. alcoholic with jaundice
Russell C. Langan, MD
Complex General Surgical Oncology Fellow
Memorial Sloan Kettering Cancer Center
New York, NY

41 y.o. with anemia and melana
Jessica A. Cintolo-Gonzalez, MD
Surgical Oncology Fellow
Partners Cancer Care/Dana-Farber Cancer Institute
Boston, MA
50 y.o. with right upper quadrant pain
Rebecca M. Dodson, MD
Complex General Surgical Oncology Fellow
Wake Forest Baptist Medical Center
Winston-Salem, NC

Refreshment Break
9:30-9:45 am, Thursday, March 3
Ballroom Foyer
PARALLEL SESSION
Hepatobiliary Parallel Session

9:45-11:45 am Thursday, March 3
Ballroom A

Moderators: Ho-Seong Han, MD, PhD, Nipun B. Merchant, MD and Sharon M. Weber, MD

9:45 am
Summary of Research
Ho-Seong Han, Korean Society of Surgical Oncology

9:50 am
PET-CT Compared to No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: The Cost Implications of a Randomized Controlled Trial
Pablo Serrano Aybar, McMaster University, Hamilton, ON, Canada

10:01 am
A Reappraisal of Staging Laparoscopy in Three Subtypes of Cholangiocarcinoma: A Multi-Institution Analysis from the U.S. Extrahepatic Biliary Malignancy Consortium
Jesse Davidson, Washington University in St. Louis School of Medicine, St. Louis, MO

10:12 am
Targeted Therapy in Pancreatic Cancer Utilizing the Novel Small Molecule Drug Conjugate SW V-49 in Combination with Standard Chemotherapy
Kerri Ohman, Washington University in St. Louis, St. Louis, MO

10:23 am
Improved Survival After Hepatectomy for Intrahepatic Cholangiocarcinoma at Academic Cancer Centers
Nicholas Berger, Medical College of Wisconsin, Milwaukee, WI

10:34 am
Hepatic Arterial Infusion with Modern Systemic Chemotherapy is Superior to Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastasis: A Retrospective Case Control Study
Mashaal Dhir, University of Pittsburgh Medical Center, Pittsburgh, PA

10:45 am
A Novel Pathology-Based Preoperative Risk Score to Predict Distant and Locoregional Residual Disease and Survival for Incidentally Discovered Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium
Cecilia Ethun, Emory University, Atlanta, GA
10:56 am
Pattern of CA19-9 Response to Neoadjuvant Chemotherapy in Locally Advanced, Borderline Resectable Pancreatic Cancer Predicts Progression
J. Bart Rose, Virginia Mason Medical Center, Seattle, WA

11:07 am
Optimal Prognostic Lymph Node Staging System for Gallbladder Adenocarcinoma: A Multi-Institutional Study
Neda Amini, The Johns Hopkins Hospital, Baltimore, MD

11:18 am
Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes Among Patients with Resected Gallbladder Cancer: A Multi-Institutional Analysis
Yuhree Kim, The Johns Hopkins Hospital, Baltimore, MD

11:29 am
Management of Neuroendocrine Tumor Liver Metastases: Long-term Outcomes and Prognostic Factors from a Large Prospective Database
Mark Fairweather, Brigham and Women’s Hospital/ Harvard Medical School, Boston, MA

PARALLEL SESSION
Breast Parallel Session 1

9:45-11:45 am Thursday, March 3
Ballroom B
Moderators: Julie A. Margenthaler, MD and Sarah A. McLaughlin, MD

9:45 am
Neoadjuvant Endocrine Therapy Use in the U.S. for Hormone Receptor Positive Breast Cancer: Results from the National Cancer Data Base
Akiko Chiba, Mayo Clinic, Rochester, MN

9:57 am
National Trends in the Use of Neoadjuvant Chemotherapy and Impact on Breast and Axillary Surgery in Hormone Receptor Negative Breast Cancer: A National Cancer Data Base Study
Carlos Puig, Mayo Clinic, Rochester, MN

10:09 am
Combining Clinical and Pathologic Staging Variables with Biologic Factors has Prognostic Value in Predicting Local-Regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer
Elizabeth Mittendorf, MD Anderson Cancer Center, Houston, TX
10:21 am .............................................................................22
Anti-HER2 Th1 Response is Superior to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy in Patients with HER2 Positive Breast Cancer
Lucy De La Cruz, University of Pennsylvania, Philadelphia, PA

10:33 am.............................................................................23
Circulating Tumor Cells After Neoadjuvant Therapy and Relapse in Stage I-III Breast Cancer
Anthony Lucci, The University of Texas MD Anderson Cancer Center, Houston, TX

10:45 am ........................................................................... 24
How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients with Histologically Confirmed Nodal Metastases? Results of a Prospective Study
Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, NY

10:57 am .............................................................................25
How Often is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?
Andrea Barrio, Memorial Sloan Kettering Cancer Center, New York, NY

11:09 am .............................................................................26
Correlation Between Preexisting Immunity and Clinical Response in a Phase II Trial Using HER2-Based Peptide Vaccines to Prevent Breast Cancer Recurrence
Doreen Jackson, San Antonio Military Medical Center, Converse, TX

11:21 am ..............................................................................27
Efficacy of Booster Inoculations in a Phase II Trial of GP2, a HER2-Derived Peptide Vaccine, for the Prevention of Breast Cancer Recurrence
Timothy Vreeland, Womack Army Medical Center, Fayetteville, NC

11:33 am ..............................................................................28
Impact of Boosting in the Phase II Trial of the AE37+GM-CSF Vaccine in High-risk Breast Cancer Patients to Prevent Recurrence
Mark Hardin, Madigan Army Medical Center, Tacoma, WA
9:45 am .................................................................29
Tumor-Targeting microRNA Delivery System in Colorectal Liver Metastases Model
Go Oshima, University of Chicago, Chicago, IL

9:57 am ................................................................. 30
Neutrophil-Lymphocyte Ratio Confers Prognostic Significance in MSI-high Colorectal Cancer
Callisia Clarke, MD Anderson Cancer Center, Houston, TX

10:09 am .................................................................31
Impact of Sentinel Lymph Node Mapping on Survival in Colon Cancer Compared to Conventional Surgery: A Prospective Study
Sukamal Saha, McLaren Flint, Flint, MI

10:21 am .................................................................32
KRAS Mutation in Locally Advanced Rectal Cancer is Independently Associated with a Lower Rate of Pathologic Complete Response Following Neoadjuvant Therapy
Oliver Chow, Beth Israel Deaconess Medical Center, Brookline, MA

10:33 am .................................................................33
Conventional Histological Analysis is Insufficient to Confirm Complete Pathological Response After Neoadjuvant Chemoradiation for Rectal Cancer
Ulysses Ribeiro, Sao Paulo Cancer Institute, University of Sao Paulo School of Medicine, Sao Paulo, Brazil

10:45 am .................................................................34
Development of a Prognostic Model for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC
Geert Simkens, Catharina Hospital Eindhoven, Eindhoven, Noord-Brabant, Netherlands

10:57 am .................................................................35
Predicting Incomplete Cytoreduction and Aborted Hyperthermic Intraperitoneal Chemotherapy in Patients with Mucinous Peritoneal Carcinomatosis of Appendiceal Origin
Vladimir Milovanov, Mercy Medical Center, Baltimore, MD
11:09 am .............................................................................36
Bridging Disparities in Colorectal Cancer Screening in the Indigent Population
Subhasis Misra, TTUHSC, Amarillo, TX

11:21 am ..............................................................................37
Impact of Insurance Expansion on Access to Colorectal Cancer Care
Andrew Loehrer, Massachusetts General Hospital, Boston, MA

11:33 am ..............................................................................38
Chasing the Proverbial Unicorn of Relative Value Units (RVU) and Block Time
Rahul Rajeev, Medical College of Wisconsin, Milwaukee, WI

EXHIBIT AND POSTER HALL OPENING LUNCH
(See page 19 for details.)
11:45 am-1 pm, Thursday, March 3
View Exhibits & Posters
Exhibit Halls C & D

NEW MEMBER LUNCHEON
(By invitation only)
11:45 am-1 pm, Thursday, March 3
Room 206

POSTER GRAND ROUNDS
12:15-12:45 pm, Thursday, March 3
(See page 21 for details)
Exhibit Hall C
VIDEO SESSION
Late Breaking Videos
11:55 am-12:55 pm, Thursday, March 3
Exhibit Hall Theater, Exhibit Hall D
Moderator: David C. Linehan, MD

11:55 am ................................................................. LBV1
Laparoscopic DP-2 Radical Pancreatobipancreaticoanastomosis with Left Adrenalectomy for a Primary Pancreatic Sarcoma
Stephen Jones, Valley Hospital, Ridgewood, NJ

12:05 pm ............................................................. LBV2
Lateral Laparoscopic Distal Pancreatectomy and Splenectomy for Pancreatic Cystic Neoplasm
Melanie Tsang, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada

12:15 pm ............................................................. LBV3
Laparoscopic, Spleen-Sparing, Distal Pancreatectomy for a Symptomatic Pro-Insulinoma
Carlo Contreras, University of Alabama at Birmingham, Birmingham, AL

12:25 pm ............................................................. LBV4
Total Laparoscopic Management of Multi-Stage Surgery for Stage IV Colorectal Cancer
Claudius Conrad, University of Texas MD Anderson Cancer Center, Houston, TX

12:35 pm ............................................................. LBV5
Feasibility of Robotic Hepatic Segmentectomy: Resection of Segment of 6 and 7
Federico Tozzi, City of Hope, Duarte, CA

12:45 pm ............................................................. LBV6
LigaSureTM-Assisted Laparoscopic Left Lateral Seionectomy for HCC
Federico Tozzi, City of Hope, Duarte, CA

Welcome and Announcements
1-1:15 pm, Thursday, March 3
Auditorium
Jeffrey A. Drebin, MD, PhD
SSO President
Richard D. Schulick, MD, MBA
SSO 2016 Scientific Program Committee Chair
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, DC. Dr. Rosenberg received his BA and MD degree at The Johns Hopkins University in Baltimore, Maryland and a PhD in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the National Cancer Institute, a position he has held to the present time.

Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. His studies of cell transfer immunotherapy have resulted in durable complete remissions in patients with metastatic melanoma. His recent studies have identified unique mutated antigens as the targets of immunotherapy. These findings are facilitating the application of immunotherapy to common epithelial cancers. He has pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His studies of the adoptive transfer of genetically modified lymphocytes resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. Dr. Rosenberg has published over 100 peer reviewed papers.

Dr. Rosenberg has been the recipient of numerous awards. He has received the Karnofsky Prize from the American Society of Clinical Oncology, the John Wayne Award for Clinical Research from the Society of Surgical Oncology, the Flance-Karl Award, from the American Surgical Association, the Richard V. Smalley, MD, Memorial Award from the International Society for Biological Therapy of Cancer, the Keio Medical Science Prize and the Massry Prize. In 2015 he received the Medal of Honor from the American Cancer Society.

Supported by an independent grant from The SSO Foundation.
JOHN WAYNE CLINICAL RESEARCH LECTURE

Bringing Precision Cancer Medicine Forward
2-2:45 pm, Thursday, March 3
Auditorium

José Baselga, MD, PhD
Physician-in-Chief and
Chief Medical Officer
Memorial Sloan Kettering
Cancer Center
New York, NY

José Baselga is the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weil Cornell Medical College. His long standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 350 peer-reviewed publications to date.

Prior to MSK, Dr. Baselga was the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He also was the Chairman of Medical Oncology and Founding Director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain.

Dr. Baselga is the President of the American Association of Cancer Research (AACR), a past President of the European Society for Medical Oncology, and a past member of the Board of Directors for the American Society of Clinical Oncology and AACR. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and a Fellow of the AACR Academy. He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal Cancer Discovery.

This lecture is supported by an independent grant from the John Wayne Cancer Foundation.

Refreshment Break
2:45-3:45 pm, Thursday, March 3
Exhibit Halls C & D

Poster Grand Rounds
3-3:30 pm, Thursday, March 3
(See page 21 for details)
Exhibit Hall C
SYMPOSIUM
Contemporary Management of Adrenal Neoplasms (MOC)

1, 2
(See page 36 for listing of ACGME Core Competencies)
3:45-5:45 pm, Thursday, March 3
Ballroom A

Moderators: Randall P. Scheri, MD & Carmen C. Solorzano, MD

Introduction and Welcome

3:45 pm Observation Versus Surgical Intervention in Non-Functioning Adrenal Incidentalomas
Allan E. Siperstein, MD
Chair, Center for Endocrine Surgery
Cleveland Clinic Foundation
Cleveland, OH

4:15 pm Optimal Surgical Approaches to Potentially Malignant Adrenocortical Tumors
Jeffrey E. Lee, MD
Professor and Chair, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

4:45 pm Informed Surgical Management of Pheochromocytoma/Paragangliomas
Electron Kebebew, MD
Chief, Endocrine Oncology Branch
National Cancer Institute, National Institutes of Health
Bethesda, MD

5:15 pm Management of Adrenal-Based Suclinical Cushings: When, Why or Why Not?
Rebecca S. Sippel, MD
Associate Professor
University of Wisconsin School of Medicine and Public Health
Madison, WI
SYMPOSIUM
Susan G. Komen® Symposium: Selective Management of DCIS (MOC)
1, 2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
3:45-5:45 pm, Thursday, March 3
Ballroom B
Moderators: Adam C. Berger, MD & Kandace P. McGuire, MD

Introduction and Welcome
3:45 pm What is the Appropriate Margin and When to Re-excise?
Monica Morrow, MD
Chief, Breast Service; Anne Burnett Windfohr Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

4:10 pm Radiation Therapy for DCIS: Can It be Used More Selectively?
Abram Recht, MD
Professor of Radiation Oncology
Harvard Medical School
Boston, MA

4:35 pm Adjuvant Endocrine Therapy for DCIS
Ann H. Partridge, MD, MPH
Associate Professor of Medicine
Harvard Medical School/Dana-Farber Cancer Institute
Boston, MA

5 pm Future Directions
Henry M. Kuerer, MD, PhD
Professor and Executive Director, Breast Programs, MD Anderson Cancer Network
The University of Texas MD Anderson Cancer Center
Houston, TX

5:25 pm Panel Discussion with Q&A
SYMPOSIUM

Immunotherapy: New Paradigms in the Treatment of Solid Tumors (MOC) 1, 2, 6
(See page 36 for listing of ACGME Core Competencies)
3:45-5:45 pm, Thursday, March 3
Room 302/304

Moderators: Robert J. Canter, MD & Ryan C. Fields, MD

Introduction and Welcome

3:45 pm  Rationale for Immunotherapy in Solid Tumors
Mark B. Faries, MD
Professor of Surgery
John Wayne Cancer Institute
Santa Monica, CA

4:15 pm  Checkpoint Blockade in Solid Tumors: Moving Beyond the Success in Melanoma
Luis Diaz, MD
Associate Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

4:40 pm  Vaccine Strategies in Solid Tumors
William E. Gillanders, MD
Professor of Surgery
Washington University School of Medicine
Saint Louis, MO

5:05 pm  Combining Immunotherapy with Other Treatment Modalities
Brian J. Czerniecki, MD, PhD
Rhodes-Harrington Professor in Surgical Oncology
University of Pennsylvania
Philadelphia, PA

5:30 pm  Panel Discussion with Q&A

WELCOME RECEPTION IN THE EXHIBIT HALL
6-8 pm, Thursday, March 3
Exhibit Halls C & D

Join us in the Exhibit Hall for hors d'oeuvres, refreshments and networking as you visit the posters and exhibits. Participate in the Exhibit Hall Passport to Prizes game and win prizes by visiting the exhibitors (see full details on page 16). Stop by the SSO Membership Booth 1019.

This complimentary event is open to all registrants. One drink ticket is located in your attendee registration materials. This event will have a cash bar.
MEET THE PROFESSOR BREAKFASTS
6:45-7:45 am, Friday, March 4
Separate registration and fee required.
Limit 30 per session. Breakfast is included.

The ABCs of Managing Retroperitoneal Sarcoma
Raphael E. Pollock, MD, PhD
The Ohio State University Wexner Medical Center
Room 110

Current Challenges in the Surgical Management of Pancreatic Cancer
Douglas B. Evans, MD
Medical College of Wisconsin
Susan Tsai, MD, MHS
Medical College of Wisconsin
Room 108

Current Management of the Axilla in Breast Cancer
Hiram S. Cody, III, MD
Memorial Sloan Kettering Cancer Center
Room 107

HIPEC: Who, What, When, Where, Why and How (in 60 minutes!)
David L. Bartlett, MD
University of Pittsburgh Cancer Institute
Room 105

Nonoperative Management of Rectal Cancer: Ready for Prime Time in Selected Patients
Martin R. Weiser, MD
Memorial Sloan Kettering Cancer Center
Room 111

Technical Aspects of Liver Resection
Yuman Fong, MD
City of Hope Medical Center
Room 109

BREAKFAST IN THE POSTER HALL
7-8 am, Friday, March 4
Exhibit Hall C

POSTER GRAND ROUNDS
7-7:55 am, Friday, March 4
Exhibit Hall Theater, Exhibit Hall D – Enter through Exhibit Hall C

CLINICAL POSTER AWARD NOMINEES
7-7:25 am

RESEARCH POSTER AWARD NOMINEES
7:30-7:55 am
PLENARY I

(See page 36 for listing of ACGME Core Competencies)
8-8:45 am, Friday, March 4
Auditorium
Moderator: Jeffrey A. Drebin, MD, PhD

8 am
Combination Anti-Estrogen Therapy and Anti-HER2 Dendritic Cell Vaccination Improves Pathologic Complete Response in ER+/HER2+ DCIS Patients
Lea Lowenfeld, University of Pennsylvania, Philadelphia, PA

2016 HARVEY BAKER TRAVELING FELLOW AWARD
The Society congratulates Lea Lowenfeld, MD who is attending the 69th Annual Cancer Symposium as the recipient of the 2016 Harvey Baker Traveling Fellow Award for the above abstract. See page 26 for full details. Supported by an independent grant from The SSO Foundation.

8:11 am
Neoadjuvant Chemotherapy Increases Complete Cytoreduction Rate but Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer
Heriberto Medina-Franco, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico

8:22 am
Probing Compensatory Signaling to MEK Inhibition Uncovers the Vulnerability of Pancreatic Cancer to Dual Therapy with Trametinib Plus Foretinib
Alex Michaels, University of Virginia, Charlottesville, VA

8:33 am
The Effect of Event-Free Years on the Risk of 5-Year Local Recurrence in Different Subtypes of Breast Cancer
Martine Moossdorff, Maastricht University Medical Center, Maastricht, Netherlands
DISTINGUISHED SERVICE AWARD
8:45-8:55 am, Friday, March 4
Auditorium
Presented by: V. Suzanne Klimberg, MD

Honoring: Mark S. Roh, MD
President and Chairman,
Department of Surgery
UF Health Cancer Center -
Orlando Health
Orlando, FL

This Distinguished Service Award recognizes Dr. Roh’s major contributions to the Society and the Annals of Surgical Oncology during his 22 years of service as the Journal’s Executive Editor.

Mark Roh, MD, MMM, FACS, serves as the president of UF Health Cancer Center - Orlando Health. Dr. Roh received his medical degree from The Ohio State University College of Medicine and completed his surgical residency at the University of Pittsburgh Medical Center. He fulfilled a clinical and research fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center. Previously, he served as chief of liver tumor surgery at The University of Texas MD Anderson Cancer Center. He graduated from the University of Southern California Marshall School of Business with a master’s degree in Medical Management in 2007.

Since 1994, Dr. Roh has served as the executive editor of the Annals of Surgical Oncology. He has been recognized as one of the Top 1% of Physicians in the Nation by US News & World Report and by his peers as one of the Best Doctors in America every year since 1992. He has served in multiple leadership positions in international oncology organizations and published hundreds of articles in peer-reviewed journals.
Margaret Foti, PhD, MD (hc), is the chief executive officer of the American Association for Cancer Research (AACR), the first cancer research organization in the world. Under her visionary leadership, membership has grown from about 3,000 members to 35,000 in 101 countries, and the AACR’s portfolio of peer-reviewed scientific journals has increased from one to eight.

Foti has been one of the most influential voices in advancing the field of cancer research, both in the United States and abroad. She was elected president of three professional societies in scholarly publishing and in cancer research. She has also served as a board member, committee member and consultant to a number of other nonprofit organizations. Her mentorship and support have created a league of young female and minority scientists whose careers have been advanced as a result of her influence.

Under Foti’s leadership, the AACR has served with distinction as the scientific partner of Stand Up To Cancer (SU2C). In this capacity, Foti and the AACR have brought extraordinary expertise and energy to their work with SU2C, especially in the scientific peer review of projects, scientific project management and administration.

Foti’s leadership was also instrumental in the production of the landmark AACR Cancer Progress Report 2011 and the equally impactful reports in 2012, 2013, 2014, and 2015, all of which celebrate the many ways that AACR members have made research count for cancer patients, with a focus on advances in the field.

Foti’s contributions have been widely recognized by organizations around the world. Her lengthy list of awards and formal recognitions includes honorary degrees in medicine and surgery from three universities in Italy and Spain.

Supported by an independent grant from The SSO Foundation.
SSO PRESIDENTIAL ADDRESS
Translational Cancer Research: The Surgeon’s Role
9-9:45 am, Friday, March 4
Auditorium
Introduction by: Daniel G. Coit, MD

Jeffrey A. Drebin, MD, PhD
The John Rhea Barton Professor and Chair, Department of Surgery
University of Pennsylvania
Philadelphia, PA

Dr. Drebin is the John Rhea Barton Professor and Chair of the Department of Surgery at the Perelman School of Medicine of the University of Pennsylvania. He received his MD and PhD degrees from Harvard, where his PhD work involved the development of the first monoclonal antibodies targeting the Her2/neu oncogene. He subsequently performed his surgical training at the Johns Hopkins Hospital.
Dr. Drebin has continued to work to advance cancer research and improve the treatment of patients with cancer throughout his career. He is involved with multiple organizations focusing on cancer research and treatment, currently serving as president of the Society of Surgical Oncology. He has also served as president of the Philadelphia Academy of Surgery and president of the Society of Clinical Surgery, as a member of the Board of Scientific Advisors of the U.S. National Cancer Institute and on the Executive Committee of the American College of Surgeons Oncology Group. A recipient of multiple research grants from the U.S. National Institutes of Health and other organizations, Dr. Drebin also served as co-Principal Investigator on the Stand Up to Cancer grant supporting the Pancreas Cancer Dream Team. In 2013, he was elected to the National Academy of Medicine (formerly the Institute of Medicine of the National Academy of Sciences) (USA).
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 am</td>
<td>Preclinical Studies of Tumor-Reactive T-Cells Derived from Human Pancreatic Cancer Draining Lymph Nodes for Use in Adoptive T-Cell Therapy</td>
<td>Kevin Choong</td>
<td>University Hospitals Case Medical Center</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td>10:27 am</td>
<td>Th1-type Immune Response in Metastatic Lymph Nodes from Pancreatic Adenocarcinoma is Associated with Improved Prognosis</td>
<td>Eran Nizri</td>
<td>Tel-Aviv Sourasky Medical Center</td>
<td>Tel-Aviv, Israel</td>
</tr>
<tr>
<td>10:39 am</td>
<td>A Novel Nomogram Predicts Survival in Patients with Nonfunctional Pancreatic Neuroendocrine Tumors</td>
<td>Megan Beems</td>
<td>University of Wisconsin</td>
<td>Madison, WI</td>
</tr>
<tr>
<td>10:51 am</td>
<td>Multi-Institution Review of the Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy in Metastatic Gastric Adenocarcinoma in the U.S.</td>
<td>Laura Enomoto</td>
<td>Penn State Hershey Medical Center</td>
<td>Hummelstown, PA</td>
</tr>
<tr>
<td>11:03 am</td>
<td>Influence of Preoperative Radiation Dose on Pathological Features, Local Control and Overall Survival Following Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma</td>
<td>Jordan Cloyd</td>
<td>MD Anderson Cancer Center</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Treatment of Borderline Resectable (BR) and Locally Advanced (LA) Pancreatic Cancer in the Era of FOLFIRINOX and Gemcitabine + Nab-Paclitaxel: A Multi-Institutional Study</td>
<td>Kamran Idrees</td>
<td>Vanderbilt University</td>
<td>Nashville, TN</td>
</tr>
<tr>
<td>11:27 am</td>
<td>Liquid Biopsy Reveals High Prevalence of Circulating Mutant KRAS from Exosome-derived DNA in Patients with Early Stage Pancreatic Cancer</td>
<td>Kelvin Allenson</td>
<td>The University of Texas MD Anderson</td>
<td>Houston, TX</td>
</tr>
</tbody>
</table>
11:39 am ................................................................. 46
Precision Cancer Therapy through Nanoparticle Delivery of siRNA Against KRAS
Matthew Strand, Washington University in St. Louis, Saint Louis, MO

11:51 am ....................................................................... 47
Differential Expression of microRNA in Human Pancreatic Fibroblasts and Pancreatic Cancer-Associated Stellate Cells
Mio Kitano, The Ohio State University Wexner Medical Center, Columbus, OH

12:03 pm ...................................................................... 48
A Molecular Biomarker Targeted Approach to Adjuvant Therapy for Resected Pancreatic Adenocarcinoma: Results of a Phase II Prospective Trial
Lauren Postlewait, Winship Cancer Institute, Emory University, Decatur, GA

PARALLEL SESSION
Breast Parallel Session 2

(See page 36 for listing of ACGME Core Competencies)
10:15 am-12:15 pm, Friday, March 4
Ballroom B
Moderators: Andrea V. Barrio, MD and Nora M. Hansen, MD

10:15 am ................................................................. 49
Sphingosine-1-phosphate Signaling Targeted by FTY720 Suppress Obesity-related Breast Cancer Progression, Metastasis, and Improve Survival
Kazuaki Takabe, Virginia Commonwealth University, Richmond, VA

10:27 am ..................................................................... 50
Breast Density and Contralateral Breast Cancer Risk
Maureen O’Donnell, John Hopkins Hospital, Baltimore, MD

10:39 am .................................................................... 51
Association Between Mammographic Breast Density (BD) and the Development of a Second Contralateral Breast Cancer (CBC): A Nested Case-control Study
Akshara Singareeka Raghavendra, MD Anderson, Houston, TX

10:51 am .................................................................... 52
Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ (DCIS) Patient Population at Low-risk of Upgrade to Invasive Carcinoma?
Melissa Pilewskie, Memorial Sloan Kettering Cancer Center, New York, NY
11:03 am ................................................................. 53
Age and Recurrence Risk in 2,996 Women with DCIS Treated with Breast-Conserving Surgery (BCS)
Patricia Cronin, Memorial Sloan Kettering Cancer Center, New York, NY

11:15 am ................................................................. 54
Disparities in Tamoxifen Recommendation and Compliance for Young Women with Ductal Carcinoma In Situ
Amy Voci, John Wayne Cancer Institute, Santa Monica, CA

11:27 am ................................................................. 55
Omitting a Re-excision for a Focally Positive Surgical Margin After Primary Breast Conserving Surgery is Safe
Elvira Vos, Erasmus MC Cancer Institute, Rotterdam, Netherlands

11:39 am ................................................................. 56
The Specimen Margin Assessment Technique (SMART) Trial: A Novel 3-D Method of Identifying the Most Accurate Method of Breast Specimen Orientation
Angel Arnaout, Ottawa Hospital Research Institute, Ottawa, ON, Canada

11:51 am ................................................................. 57
Preoperative Axillary Ultrasound in Early Stage Breast Cancer is Associated with More Axillary Surgery
Brittany Splittgerber, University of Iowa Hospitals and Clinics, Iowa City, IA

12:03 am ................................................................. 58
Survival Benefit of Bilateral Mastectomy for Young Women with Early Stage Breast Cancer
Olga Kantor, University of Chicago, Chicago, IL

PARALLEL SESSION
Melanoma Parallel Session
2
(See page 36 for listing of ACGME Core Competencies)
10:15 am-12:15 pm, Friday, March 4
Room 302/304
Moderators: Giorgos Karakousis, MD and Mark C. Kelley, MD, MMHC

10:15 am ................................................................. 59
Long-term Prospective Assessment of Quality of Life and Lymphedema After Inguinal or Inguinal and Pelvic Lymphadenectomy for Recurrent Melanoma in the Groin
Michael Henderson, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia
10:27 am ................................................................. 60
Preoperative Risk Factors Associated with Secondary Lymphedema Following Limb Lymphadenectomy for Melanoma
Daniel Mercante, University of Michigan Medical School, Dexter, MI

10:39 am ................................................................. 61
Improvement, and Persistent Disparities, in Completion Lymph Node Dissection: Lessons from the National Cancer Data Base
Brian Chu, University of Cincinnati College of Medicine, Cincinnati, OH

10:51 am ................................................................. 62
Patterns and Timing of First Relapse in PathologicStage II Melanoma Patients
Nicolas Droppelmann, Memorial Sloan Kettering Cancer Center, New York, NY

11:03 am ................................................................. 63
Prospective Randomized Clinical Trial for the Evaluation of a Stage Adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients: Results After One Year
Samantha Damude, University Medical Center Groningen, Groningen, Netherlands

11:15 am ................................................................. 64
The Impact of Smoking on Melanoma Sentinel Node Metastases: Analysis of Two Multicenter Clinical Trials
Maris Jones, John Wayne Cancer Institute, Santa Monica, CA

11:27 am ................................................................. 65
A Novel Gene Signature that Predicts the Survival of Patients Undergoing Surgical Resection for Metastatic Melanoma
Jenny Hong, Cedars-Sinai Medical Center, Los Angeles, CA

11:39 am ................................................................. 66
A Novel Dendritic Cell Vaccine Targeting Mutated BRAF Overcomes Vemurafenib Resistance and Synergistically Improves Survival in BRAF-Mutant Murine Melanoma
Jashodeep Datta, University of Pennsylvania, Philadelphia, PA

11:51 am ................................................................. 67
Local Excision has Comparable Survival to Abdominoperineal Resection in Patients with Anal Melanoma: An Analysis of 760 Patients from the National Cancer Data Base
Linda Youngwirth, Duke University Medical Center, Durham, NC
Durable Complete Responses (CRs) in Patients (pts) with Stage IIIB-IV Melanoma Treated with Talimogene Laherparepvec (T-VEC) in OPTiM

Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

LUNCH IN THE EXHIBIT AND POSTER HALLS
12:15-1:15 pm, Friday, March 4
(See page 19 for details)
View Exhibits & Posters
Exhibit Halls C & D

POSTER GRAND ROUNDS
12:30-1 pm
(See page 21 for details)  
Exhibit Hall C
PLENARY II

(See page 36 for listing of ACGME Core Competencies)

1:15-2 pm, Friday, March 4

Auditorium

Moderator: Daniel G. Coit, MD

1:15 pm .......................................................................................... 5
Cancer Registries: Can We Improve the Quality of Thyroid Cancer Data?
Colleen Kiernan, Vanderbilt University, Nashville, TN

1:26 pm .......................................................................................... 6
The National Quality Forum Colon Cancer Metrics and Survival: Does Hospital Performance Matter?
Meredith Mason, Baylor College of Medicine, Houston, TX

1:37 pm .......................................................................................... 7
Outcomes of Re-hepatectomy for Colorectal Liver Metastases: A Multi-Institutional Analysis
Julie Hallet, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada

1:48 pm .......................................................................................... 8
Comparative Analysis of Breast Cancer Phenotypes in African American, White American and West Versus East African Patients: Correlation Between African Ancestry and Triple Negative Breast Cancer
Lisa Newman, Henry Ford Health System Breast Oncology Program and University of Michigan, Ann Arbor, MI
THE GREAT DEBATES I
1, 2, 3, 4, 5, 6
(See page 36 for listing of ACGME Core Competencies)
2-3 pm, Friday, March 4
Auditorium
Moderators: Richard D. Schulick, MD, MBA and David C. Linehan, MD

Resectable Pancreatic Head Adenocarcinoma: Resect First

Pro: Keith D. Lillemoe, MD
Chief, Department of Surgery and Surgeon-in-Chief
Massachusetts General Hospital
Boston, MA

Con: Douglas B. Evans, MD
Ausman Foundation Professor of Surgery and Chair
Medical College of Wisconsin
Milwaukee, WI

Public Reporting of Hospital and Provider Level Outcomes

Pro: Daniel P. McKellar, MD
Chair, Commission on Cancer; American
College of Surgeons
Wayne HealthCare
Greenville, OH

Con: Karl Y. Bilimoria, MD, MS
Director, Surgical Outcomes and Quality Improvement Center (SOQIC)
Feinberg School of Medicine, Northwestern University
Chicago, IL

ICE CREAM BREAK IN EXHIBIT HALL
3-3:45 pm, Friday, March 4
View Exhibits & Posters
Exhibit Halls C & D
SYMPOSIUM
Making Treatment Choices in Colorectal Cancer Patients with Synchronous Hepatic Metastases (MOC)
2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
3:45-5:45 pm, Friday, March 4
Ballroom A
Moderators: George J. Chang, MD and Martin R. Weiser, MD

Introduction and Welcome
3:45 pm The Role of Liver Surgery: Synchronous or Metachronous Resection?
William R. Jarnagin, MD
Chief, Hepatopancreatobiliary Service
Memorial Sloan Kettering Cancer Center
New York, NY

4:10 pm Optimizing Chemotherapy in Primary Colorectal Cancer with Synchronous Liver Metastases
David P. Ryan, MD
Chief, Hematology-Oncology
Massachusetts General Hospital
Boston, MA

4:35 pm Liver Ablation: When, Why and How?
Steven A. Curley, MD
Professor of Surgery
Baylor College of Medicine
Houston, TX

5 pm Rectal Cancer with Synchronous Resectable Liver Metastases: What to Do?
Martin R. Weiser, MD
Stuart H.Q. Quan Chair in Colorectal Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

5:25 pm Case Presentation
George J. Chang, MD, MS
Associate Professor of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX
SYMPOSIUM

Joint SSO/ESSO Symposium: Cytoreductive Surgery for Malignancy: When Does It Make Sense? (MOC)

1, 2

(See page 36 for listing of ACGME Core Competencies)

3:45-5:45 pm, Friday, March 4

Ballroom B

Moderators: Santiago Gonzalez-Moreno, MD, PhD and James R. Howe, MD

Introduction and Welcome

3:45 pm  Metastatic Ovarian Carcinoma
          Dennis S. Chi, MD
          Deputy Chief and Head, Section of Ovarian Cancer
          Memorial Sloan Kettering Cancer Center
          New York, NY

4:05 pm  Metastatic GIST
          Chandrajit P. Raut, MD, MSc
          Associate Professor of Surgery
          Brigham and Women’s Hospital/
          Dana-Farber Cancer Institute
          Boston, MA

4:25 pm  Metastatic Colorectal/Pseudomyxoma
          Santiago González-Moreno, MD, PhD
          Medical Director and Head of Surgical Oncology
          MD Anderson Cancer Center
          Madrid, Spain

4:45 pm  Metastatic Carcinoid
          James R. Howe, MD
          Professor of Surgery
          University of Iowa Roy J. and Lucille A. Carver College of Medicine
          Iowa City, IA

5:05 pm  Panel Discussion with Q&A
SYMPOSIUM
Melanoma Multidisciplinary Tumor Board
1, 2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
3:45-5:45 pm, Friday, March 4
Room 302/304
Moderator: Jonathan S. Zager, MD

Tumor Board Panel:

Keith T. Flaherty, MD
Director, Henri & Belinda Termeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Boston, MA

Helen A. Shih, MD
Associate Professor of Radiation Oncology
Massachusetts General Hospital
Boston, MA

Vernon K. Sondak, MD
Chair, Department of Cutaneous Oncology
Moffitt Cancer Center
Tampa, FL

John F. Thompson, AO, MD
Professor; Executive Director
Melanoma Institute Australia
North Sydney, NSW, Australia

Introductions and Welcome

3:45 pm  Multiple Recurrent Demoplastic Melanoma
Edmund K. Bartlett, MD
General Surgery Resident
University of Pennsylvania
Philadelphia, PA

4 pm  Timing of Surgery, Targeted Therapy, Follow Up, and Prognosis in Metastatic Melanoma of Unknown Primary
Ismael Dominguez-Rosado, MD
HPB Fellow
Barnes & Jewish Hospital, Washington University School of Medicine
St. Louis, MO

4:15 pm  Regional Therapy for Regional Disease?
David Gyorki, MBBS, MD
Consultant Surgical Oncologist
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia
4:30 pm  A Challenging Case of Melanoma in Later Pregnancy  
Marc Moncrieff, MD  
Consultant Plastic & Reconstructive Surgeon  
Norfolk & Norwich University Hospital  
Norwich, Norfolk, United Kingdom

4:45 pm  Durable Pathologic Complete Response to Combined Targeted Therapy and Immune Checkpoint Blockade  
Peter A. Prieto, MD, MPH  
Fellow, Complex General Surgical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX

5 pm  A Challenging Pediatric Melanocytic Neoplasm  
Christopher A. Puleo, PA-C  
Physician Assistant - Certified  
H. Lee Moffitt Cancer Center  
Tampa, FL

5:15 pm  Management of Stage IIIC Melanoma  
Ashley N. Hardy, MD  
Surgical Oncology Fellow  
Fox Chase Cancer Center  
Philadelphia, PA

5:30 pm  Panel Discussion with Q&A
MEET THE PROFESSOR BREAKFASTS

6:45-7:45 am, Saturday, March 5
Separate registration and fee required. Limit 30 per session. Breakfast is included.

How Immunotherapy has Changed Surgical Therapy for Patients with Melanoma
Vernon K. Sondak, MD
H. Lee Moffitt Cancer Center
Room 111

IPMN: Who Should Undergo Resection?
Matthew H.G. Katz, MD
The University of Texas MD Anderson Cancer Center
Room 109

Local Excision of Rectal Cancer: Where are We Now?
Julio Garcia-Aguilar, MD, PhD
Memorial Sloan Kettering Cancer Center
Room 108

Management of Breast Cancer in the Elderly Patient
Riccardo A. Audisio, MD
University of Liverpool; St. Helens Teaching Hospital
Room 105

Minimally Invasive Inguinal Lymph Node Dissection
Keith A. Delman, MD
Emory University School of Medicine
Room 107

Surgery, Chemotherapy and Radiation in the Management Gastric Cancer: One, Two or All Three?
Mitchell C. Posner, MD
University of Chicago Medicine
Room 110
SYMPOSIUM

Update on Regional Therapy Options for Primary and Metastatic Liver Tumors (MOC) 1, 2, 6
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Saturday, March 5
Ballroom A

Moderators: Kenneth Cardona, MD and Robert E. Roses, MD

Introduction and Welcome
8 am  Introduction & Case Presentation

8:05 am  Is there an Ideal Embolic Therapy Option for Unresectable Primary or Metastatic Liver Tumors? An Update on the Role of Chemoembolization and Radioembolization
Robert C.G. Martin, II, MD, PhD
Sam and Lolita Weakley Endowed Chair in Surgical Oncology
University of Louisville School of Medicine
Louisville, KY

8:25 am  The Role of SBRT in Primary and Metastatic Liver Tumors
Theodore S. Hong, MD
Associate Professor, Department of Radiation Oncology
Harvard Medical School
Boston, MA

8:45 am  Isolated Hepatic Perfusion: Where are We At?
David L. Bartlett, MD
Bernard Fisher Professor of Surgery and Chief
University of Pittsburgh Cancer Institute
Pittsburgh, PA

9:05 am  Panel Discussion & Case Presentations

Refreshment Break
9:30-10 am, Saturday, March 5
Ballroom Foyer
SYMPOSIUM
Managing BRCA Mutation Carriers (MOC)
1, 2, 5, 6
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Saturday, March 5
Ballroom B
Moderators: Anees B. Chagpar, MD, MSc, MBA and Brian J. Czerniecki, MD, PhD

Introduction and Welcome
8 am  Managing the Breast Cancer Diagnosis in a Patient with Suspected BRCA Mutation
Hiram S. Cody, III, MD
Professor of Clinical Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

8:20 am  Medical Management of BRCA Mutation Carriers
Judy E. Garber, MD, MPH
Director, Center for Cancer Genetics and Prevention
Dana-Farber Cancer Institute
Boston, MA

8:40 am  The Role of Surgical Management in Both Prevention and Treatment in BRCA Mutation Carriers
Barbara Lynn Smith, MD, PhD
Director, Breast Program
Massachusetts General Hospital
Boston, MA

9 am  The Timing and Indications for Screening and Surveillance BRCA Mutation Carriers
Isabelle Bedrosian, MD
Associate Professor, Breast Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

9:20 am  Panel Discussion with Q&A

Refreshment Break
9:30-10 am, Saturday, March 5
Ballroom Foyer
SYMPOSIUM

Gene Expression Profiling of Cancer: Implications for Clinical Management (MOC) 1, 2
(See page 36 for listing of ACGME Core Competencies)
8-9:30 am, Saturday, March 5
Room 302/304
Moderators: Karl Y. Bilimoria, MD, MS and Randall P. Scheri, MD

Introduction and Welcome
8 am Setting the Stage for Gene Expression Profiling in Clinical Cancer Management: The Breast Cancer Experience
Fund a Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, TX

8:15 am Is there a Role for Gene Expression Profiling of Early Stage Primary Melanoma?
Keith A. Delman, MD
Associate Professor of Surgery; Carlos Professor of Surgery
Emory University School of Medicine
Atlanta, GA

8:30 am Can Genomic Profiling of GI Cancers Enhance Therapy?
Adam Bass, MD
Assistant Professor of Medicine, Division of Cellular and Molecular Oncology
Dana-Farber/Harvard Cancer Center
Boston, MA

8:45 am Integrative Risk Modeling and Clinical Tool Development: AJCC and Other Initiatives Relevant to the Surgical Oncology Community
Jeffrey E. Gershenwald, MD
Professor, Surgical Oncology and Cancer Biology
The University of Texas MD Anderson Cancer Center
Houston, TX

9 am Panel Discussion with Q&A

Refreshment Break
9:30-10 am, Saturday, March 5
Ballroom Foyer
David A. Tuveson, MD, PhD
Professor and Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Dr. Tuveson, Professor and Director of the Cancer Therapeutics Initiative (CTI) and Deputy Director of the Cancer Center at Cold Spring Harbor Laboratory, is an authority in the generation and characterization of mouse models of ductal pancreatic cancer and other malignancies. He is an affiliate oncologist at MSKCC and a thought leader on the clinical approach to pancreatic cancer. Dr. Tuveson is the Director of Research for the Lustgarten Foundation for Pancreatic Cancer Research, and has served on many national and international committees and organizations to bring scientific findings into clinical evaluation for pancreatic cancer patients. His laboratory established a methodology for drug development using mouse pancreatic cancer, and thereby identified several therapeutic opportunities regarding stromal targeting that are now undergoing clinical evaluation. Furthermore, his group discovered several fundamental aspects in tumor progression, including redox regulation by Nrf2 following oncogene expression. Most recently, his lab has developed murine and human organoid models of pancreatic cancer to accelerated basic and applied research applications.

Supported by an independent educational grant from the American Cancer Society.
CLINICAL INVESTIGATOR AWARD PRESENTATIONS
10:45-11:30 am, Saturday, March 5
Ballroom B
Moderator: Carol J. Swallow, MD, PhD

The CIA, established in 2007 by the SSO, helps to promote post-fellowship, patient-oriented research through the training of surgical oncologists in clinical and translational science. Each award consists of $100,000, disbursed in two yearly installments of $50,000. To date, 28 Clinical Investigator Awards totaling more than $2.8 million dollars have been granted to researchers. Beginning with the 2013-2016 awards cycle, the administration and management of the CIA program has moved under the auspices of The SSO Foundation.

The SSO Foundation Young Investigator Awards in Surgical Oncology were established from the 75 for 75 Campaign funds to promote and recognize clinical/translational research that advances innovative ideas and concepts designed to improve health outcomes through advances in the delivery of cancer-related care. Two awards of $25,000 each will be given at the conclusion of the CIA session.

Supported by independent grants from The SSO Foundation.

Introductions and Welcome
10:50 am The Microbiome and Human Breast Cancer
Stephen R. Grobmyer, MD
Section Head, Surgical Oncology
Cleveland Clinic
Cleveland, OH

11:02 am Identifying Novel Mechanisms of Metastases in Colorectal Cancer
Ryan C. Fields, MD
Assistant Professor of Surgery
Washington University School of Medicine
St. Louis, MO

11:14 am Final Remarks and Announcement of the 2016 CIA Award Recipient & SSOF Young Investigator Award Recipients
Mitchell C. Posner, MD
President, The SSO Foundation
Resection of Primary Colorectal Cancer with Unresectable Metastatic Disease

Pro: Jurgen Weitz, MD, MSc
Chair and Professor of Surgery
Technische Universität Dresden
Dresden, Germany

Con: Julio Garcia-Aguilar, MD, PhD
Chief, Colorectal Service; Benno C. Schmidt Chair in Surgical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Surgeons Should Discourage Women from Undergoing Contralateral Prophylactic Mastectomy

Pro: Todd M. Tuttle, MD, MS
Chief, Surgical Oncology
University of Minnesota
Minneapolis, MN

Con: V. Suzanne Klimberg, MD
Muriel Balsam Kohn Chair in Breast Surgical Oncology
Winthrop P. Rockefeller Cancer Institute
Little Rock, AR
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm</td>
<td>Survival Impact of Lymph Node Dissection in Patients with Microscopic Medullary Thyroid Cancer</td>
<td>Tricia Moo-Young, NorthShore University HealthSystems, Glenview, IL</td>
<td></td>
</tr>
<tr>
<td>1:41 pm</td>
<td>Loss of PTEN and Expression of p-S6rp in Pancreatic Neuroendocrine Tumors Predicts Survival</td>
<td>Mary Dillhoff, The Ohio State University, Columbus, OH</td>
<td></td>
</tr>
<tr>
<td>1:52 pm</td>
<td>The Role of Preoperative Imaging and Double Balloon Enteroscopy in the Surgical Management of Small Bowel Neuroendocrine Tumors: Is it Necessary?</td>
<td>Nicholas Manguso, Cedars-Sinai Medical Center, Los Angeles, CA</td>
<td></td>
</tr>
<tr>
<td>2:03 pm</td>
<td>Hashimoto’s Disease Increases Risk of Cancer in Indeterminate Thyroid Nodules with Suspicious Molecular Testing</td>
<td>Julia Terhune, University of Maryland Medical Center, Baltimore, MD</td>
<td></td>
</tr>
<tr>
<td>2:25 pm</td>
<td>Understanding a Rare Disease's Impact on Health Systems: A Population-Based Economic Analysis of Neuroendocrine Tumors Costs</td>
<td>Julie Hallet, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>2:36 pm</td>
<td>Epigenetic Alterations and Canonical Pathway Disruption in Papillary Thyroid Cancer: A Genome Wide Methylation Analysis</td>
<td>Michael White, University of Chicago, Pritzker School of Medicine, Chicago, IL</td>
<td></td>
</tr>
<tr>
<td>2:47 pm</td>
<td>Higher Tumor Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival</td>
<td>Kendall Keck, University of Iowa Carver College of Medicine, Iowa City, IA</td>
<td></td>
</tr>
</tbody>
</table>
PARALLEL SESSION
Quality Improvement/Clinical Outcomes
Parallel Session

(See page 36 for listing of ACGME Core Competencies)
1:30-3 pm, Saturday, March 5
Ballroom B
Moderators: Marcovalerio Melis, MD and Sandra L. Wong, MD, MS

1:30 pm ...............................................................................77
Association of Survival, Postoperative Morbidity and Mortality Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Using Quality of Life Assessments
Rebecca Dodson, Wake Forest Baptist Health, Winston-Salem, NC

1:41 pm ...............................................................................78
A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection
Brittany Murphy, Mayo Clinic, Rochester, MN

1:52 pm ...............................................................................79
Improving Hospital Level Quality Assessment in Rectal Cancer Surgery
Sameer Patel, MD Anderson Cancer Center, Houston, TX

2:03 pm .............................................................................80
Cancer Specialists’ Attitudes and Practices Regarding Disclosure, Feedback and Reporting of Pre-Referral Medical Errors
Lesly Dossett, Moffitt Cancer Center, Tampa, FL

2:14 pm ...............................................................................81
Postoperative Complications and Long-term Survival After Complex Cancer Resection
Hari Nathan, University of Michigan, Ann Arbor, MI

2:25 pm ..............................................................................82
Hypophosphatemia as a Novel Early Predictor of Intra-Abdominal Infections in 7,423 Patients Undergoing Colorectal Surgery
Eran Sadot, Memorial Sloan Kettering Cancer Center, New York, NY

2:36 pm ..............................................................................83
Race-Based Socioeconomic and Treatment Disparities in Adolescent and Young Adults with Stage II-III Rectal Cancer
David Lee, John Wayne Cancer Institute, Los Angeles, CA

PRESENTATION OF THE COLORECTAL CANCER RESEARCH SCHOLAR AWARD

See page 28 for more information
Modified Frailty Index (mFI) to Predict Morbidity and Mortality After Pancreatectomy
Rupen Shah, Roswell Park Cancer Institute, Buffalo, NY

PARALLEL SESSION
Sarcoma and Thoracic/Esophageal Parallel Session

1:30 pm
Aberrant Expression of Epigenetic Modifiers in Dedifferentiated Liposarcoma (DDLS) and the Effects of Dual Inhibition of DNA and Histone Methylation in DDLS Cell Lines
Ana Velez, Memorial Sloan Kettering Cancer Center, New York, NY

1:41 pm
Impact of Radiation Therapy on Retroperitoneal Sarcoma
Kelly Huynh, John Wayne Cancer Institute, Los Angeles, CA

1:52 pm
Radiation Therapy is Associated with Improved Survival for Retroperitoneal Sarcoma: A Contemporary Analysis of 9,068 Patients
Daniel Nussbaum, Duke University School of Medicine, Durham, NC

2:03 pm
Is there a Volume-Outcome Relationship for Short and Long-term Outcomes in Soft Tissue Sarcoma? Results from Analysis of the U.S. National Cancer Data Base
Sanjay Bagaria, Mayo Clinic, Jacksonville, FL

2:14 pm
Novel Calculators for Esophageal Adenocarcinoma Accurately Predict which Patients Benefit from Neoadjuvant Chemoradiation and Estimate Overall Survival
Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY

2:25 pm
Patterns and Predictors of Locoregional Recurrence Following Neoadjuvant Chemoradiation for Esophageal Cancer
Aaron Blackham, Moffitt Cancer Center, Lutz, FL
2:36 pm .............................................................................. 91
The Prognostic Significance of Programmed Death-Ligand 1 and its Relationship to Pathological Subtypes of Lung Adenocarcinoma in Patients with Resected Lung Adenocarcinoma
Jung-Jyh Hung, Taipei Veterans General Hospital, Taipei, Taiwan

2:47 pm ............................................................................... 92
Enhancing CAR T-Cell Efficacy and Functional Persistence in Solid Tumors
Leonid Cherkassky, Memorial Sloan Kettering Cancer Center, New York, NY

Refreshment Break
3-3:15 pm, Saturday, March 5
Ballroom Foyer
SYMPOSIUM

Neuroendocrine Tumors: Current Controversies (MOC)
1, 2, 5
(See page 36 for listing of ACGME Core Competencies)
3:15-4:45 pm, Saturday, March 5
Ballroom A
Moderators: Glenda G. Callender, MD and Carmen C. Solórzano, MD

Introduction and Welcome
3:15 pm  Resect or Observe the 1-2 cm PNET? Resect
Steven K. Libutti, MD
Vice-Chairman and Professor,
Department of Surgery
Montefiore Medical Center
Bronx, NY

3:30 pm  Resect or Observe the 1-2 cm
PNET? Observe
Douglas B. Evans, MD
Ausman Foundation Professor of Surgery
and Chair
Medical College of Wisconsin
Milwaukee, WI

3:45 pm  Resect or Observe the Primary SBNET in
the Presence of Liver Metastases? Resect
James R. Howe, MD
Professor of Surgery
University of Iowa Roy J. and Lucille A. Carver
College of Medicine
Iowa City, IA

4 pm  Resect or Observe the Primary SBNET in
the Presence of Liver Metastases? Observe
Matthew H. Kulke, MD
Director, Program in Neuroendocrine and
Carcinoid Tumors
Dana-Farber Cancer Institute
Boston, MA

4:15 pm  Hepatic Debulking of SBNETs: The 90%
Threshold is Necessary. Pro
Timothy M. Pawlik, MD, MPH, PhD
Chief, Division of Surgical Oncology
The Johns Hopkins Hospital
Baltimore, MD
4:30 pm  Hepatic Debulking of SBNETs: The 90% Threshold is Necessary. Con
Rodney F. Pommier, MD
Professor of Surgery
Oregon Health & Science University
Portland, OR

Break
4:45-5 pm, Saturday, March 5
Introduction and Welcome

3:15 pm  Prostate Cancer: Setting the Bar for Active Surveillance
Adam S. Kibel, MD
Chief of Urology
Brigham and Women’s Hospital/Dana-Farber Cancer Institute
Boston, MA

3:35 pm  Observation of Ductal Carcinoma In Situ of the Breast
Laura J. Esserman, MD, MBA
Director, Carol Franc Buck Breast Care Center
UCSF Medical Center
San Francisco, CA

3:55 pm Observation of Papillary Thyroid Carcinoma
Electron Kebebew, MD
Chief, Endocrine Oncology Branch
National Cancer Institute, National Institutes of Health
Bethesda, MD

4:15 pm  Observation of IPMN of the Pancreas
Peter J. Allen, MD
Murray F. Brennan Professor of Surgery, Hepatopancreaticobiliary Service
Memorial Sloan Kettering Cancer Center
New York, NY

4:35 pm  Panel Discussion with Q&A

Break
4:45-5 pm, Saturday, March 5
3:15 pm ................................................................. V1
Posterior Retroperitoneoscopic Approach for Extra-Adrenal Tumors
Jamii St. Julien, MD Anderson Cancer Center, Houston, TX

3:26 pm ................................................................. V2
Novel Use of Tumor Bed Sizers for Intraoperative Radiation Therapy
Brittany Splittgerber, University of Iowa Hospitals & Clinics, Iowa City, IA

3:37 pm ................................................................. V3
Colostomy Prolapse Treated with Total Prolapsed Bowel Resection with Manual Anastomosis
Claudio Quadros, Aristides Maltez Cancer Hospital, Salvador, Bahia, Brazil

3:48 pm ................................................................. V4
Laparoscopic Intra-Gastric Resection for Proximal Sub-Mucosal Gastric Tumors
Cindy Boulanger-Gobeil, University of Toronto, Toronto, ON, Canada

3:59 pm ................................................................. V5
Robotic Liver Resection of Left Lateral Section in a Cirrhotic Patient with Hepatocellular Carcinoma
Patricio Polanco, University of Texas Southwestern, Dallas, TX

4:10 pm ................................................................. V6
Laparoscopic Total Pancreatectomy for a Main Duct IPMN
Brandon Chapman, University of Colorado Denver, Denver, CO

4:21 pm ................................................................. V7
Evolving Trends Towards Minimally Invasive Surgery for Solid Pseudopapillary Neoplasms
Camille Stewart, University of Colorado School of Medicine, Aurora, CO

4:32 pm ................................................................. V8
Laparoscopic-Assisted Central Pancreatectomy for Solid Pseudopapillary Epithelial Neoplasm
Julie Hallet, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada

Break
4:45-5 pm, Saturday, March 5
TOWN HALL & ANNUAL SSO BUSINESS MEETING
5-5:30 pm, Saturday, March 5
Room 102

Annual SSO Business Meeting Agenda

I. Call to Order
   Jeffrey A. Drebin, MD, PhD, Presiding

II. Announcement of Annual Resident/Fellow Essay Award Winners

III. President’s Report
    • Recognition of Program Chair

IV. Secretary’s Report
    Armando Giuliano, MD
    • In Memoriam
    • Introduction of New Members

V. Treasurer’s Report
    David L. Bartlett, MD

VI. The SSO Foundation Report
    Mitchell C. Posner, MD

VII. Annals of Surgical Oncology Report
    Charles M. Balch, MD

VIII. Membership Open Forum
    Jeffrey A. Drebin, MD, PhD
    Daniel G. Coit, MD

IX. Recognition of Outgoing Councilors

X. Nominating Committee Report
    Monica Morrow, MD

XI. Introduction of New President

XII. New Business
    Daniel G. Coit, MD
    • SSO 2017 March 15-18, Seattle, WA

XIII. Adjourn

PRESIDENT’S RECEPTION
6-7:30 pm, Saturday, March 5
(Ticket required)

Grand Ballroom, Sheraton Boston Hotel (Level 2)
SSO President Dr. Jeffrey Drebin invites you to join him Saturday evening for cocktails and hors d’oeuvres. This event will provide an excellent opportunity for you to connect with friends and colleagues to discuss news from the meeting and make plans to reconnect next year in Seattle.
GLOBAL PARTNER POSTERS

As a result of SSO's international program, SSO 2016 will feature the debut of the Global Partner Posters section in the hall, where top abstracts from four worldwide events over the past year will be highlighted. These posters are located in the front section of Exhibit Hall C with separate signage. See page 93 for full poster information and hours.

Highlighted Posters from the Brazilian Society of Surgical Oncology

GP1 ypT Status and the Chance of ypNO in Patients with cT3 Rectal Adenocarcinoma Submitted to Neoadjuvant Chemoradiation and Total Mesorectum Excision
Ranyell M.S.S. Batista, Colorectal Cancer Department, A.C. Camargo Cancer Center, São Paulo, Brazil

GP2 Pathological Analyses of Patients with Colorectal Liver Metastases Resected After Preoperative Chemotherapy and its Correlation with Survival
Marcio C. Marques, Department of Abdominal Surgery, A.C. Camargo Cancer Center, São Paulo, Brazil

GP3 Predicting Lymph Node Metastasis Before Lymphadenectomy in Endometrial Cancer: A Pre- and Intraoperative Scoring System
Andressa M.S. Teixeira, Federal University of Sao Paulo-SP, São Paulo, Brazil

GP4 Predictive Factors of Complications in Pelvic Exenteration in the Treatment of Colorectal Cancer Locally Advanced or Relapsed
Tiago S. Bezerra, A.C. Camargo Cancer Center, São Paulo, Brazil

GP5 PET-CT Fails to Predict Complete Pathologic Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer
Wesley P. Andrade, Instituto de OncoMastologia, São Paulo, Brazil
Highlighted Poster from the Chinese Society of Clinical Oncology

GP10 Surgical Treatment for 310 Elderly Patients with Non-Small Cell Lung Cancer
Chunyi Jia, Jilin Province Cancer Hospital, Changchun City, Jilin Province, China

Highlighted Posters from the European Society of Surgical Oncology

GP20 Percutaneous Transesophageal Gastrostomy for Patients with Malignant Gastrointestinal Obstruction
Shinya Ueda, Nara Hospital, Kindai University School of Medicine, Ikoma, Nara, Japan

Walid Salamoun, Middle East Institution of Health, Bsalim, Lebanon

GP22 Accuracy of Preoperative Examination in Patients Undergoing Surgery, Using Trans-Anal, Endoscopic Microsurgery
Martin Ondrák, Masaryk Memorial Cancer Institute, Brno, Czech Republic

Highlighted Posters from the Indian Association of Surgical Oncology

GP30 Axillary Reverse Mapping in Patients Undergoing Axillary Lymph Node Dissection for Breast Cancer: A Feasibility Study in Indian Scenario
Sanghamitra Jena, Saroj Gupta Cancer Centre and Research Institute, Kolkata, West Bengal, India

GP31 Epidemiological Study of Gallbladder Cancer Patients from North Indian Gangetic Planes: A High Volume Centre’s Experience
Sameer Gupta, King George’s Medical University, Lucknow, Uttar Pradesh, India

GP32 Surgical Options for Reconstruction of Defects in Post Wide Excision of Scalp Tumors
Harish K. Hanumappa, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India

GP33 Primary Tumours and Tumorous Lesions of the Clavicle
Kiran Shankar, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
GP34 Chestwall Tumors: Review of 107 Cases Managed at a Tertiary Care Center
Vinaya Kumar, All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, India

GP35 Lymph Node Ratio as a Risk Factor for Loco-Regional Recurrence After Surgical Resection in Squamous Cell Carcinomas of Oral Cavity
Ghanish N. Panjwani, Mahavir Cancer Sansthan, Patna, India

GP36 Immediate Outcome Analysis After Completion Radical Surgery for Incidentally Diagnosed Carcinoma Gall Bladder: Experience of a New Surgical Unit
Amit Choraria, Tata Medical Centre, Kolkata, West Bengal, India

GP37 Total Robotic Three Stage Esophagectomy for Carcinoma Esophagus: Experience of a Single Institute
Prasanna Govindarajan, Manipal Comprehensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India
All Scientific Posters will be displayed from 11:45 am Thursday to 3:45 pm Friday. Presenters are requested to be available during the times below, as their schedules permit, to answer questions about their posters. Any posters withdrawn as of January 28, 2016 are not included in the following listing.

**THURSDAY, MARCH 3**
- 11:45 am-1 pm
- 2:45-3:45 pm
- 6-8 pm

**FRIDAY, MARCH 4**
- 7-8 am
- 9:45-10:15 am
- 12:15-1:15 pm
- 3-3:45 pm

Poster signage is color-coded by track.
- **Pink** Breast Track
- **Dark Blue** Colorectal Track
- **Light Blue** Gastrointestinal Track (Hepatobiliary; Upper Gastrointestinal)
- **Green** General Education Track (Quality Improvement/Clinical Outcomes)
- **Yellow** Melanoma and Sarcoma Track
- **Orange** Other Surgical Oncology Track (Endocrine; Head & Neck; Thoracic/Esophageal)
- **Purple** Global Partner Posters

*Poster Grand Rounds participants will all be marked with a star in the Program Guide and in the Poster Hall. Please see page 21 or the SSO 2016 Mobile App for Poster Grand Round details.*

**BREAST CANCER POSTERS**

**P1**
Hospital Level Adjusted Sentinel Lymph Node Positivity Rates in Breast Cancer
Elizabeth Berger, Division of Research and Optimal Patient Care, American College of Surgeons, Chicago, IL
P2 Risk of Prolonged Postoperative Opioid Use Among Patients Undergoing Breast Reconstruction
Alexandra Rzepecki, University of Michigan Medical School, Ann Arbor, MI

P4 Assessing Re-excision Rates Following Implementation of the Society of Surgical Oncology (SSO)/American Society of Radiation Oncology (ASTRO) Consensus Guideline
Kate Pawloski, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

P5 Translating a 2-D Mammogram into a 3-D Breast in the Operating Room
Ko Un Park, Henry Ford Health System, Detroit, MI

P7 A Matched Pair Cohort Study of the Effect of Neoadjuvant Chemotherapy in Stage I-III Breast Cancer
Julie Sprunt, USC Norris Cancer Center, Los Angeles, CA

P8 Down Regulation of the c2orf40 Gene Encoding the ECRG4 Chemokine in Human Breast Cancer Correlates with Disease Progression
Erin Ward, UCSD, San Diego, CA

P9 Contralateral Prophylactic Mastectomy: Becoming the New Norm Despite a Paucity of Evidence Indicating Survival Benefit?
Stephanie Wong, Harvard School of Public Health, Boston, MA

P10 Changes in Margin Re-excision Rates: A Single Institution’s Experience Incorporating the “No Ink on Tumor” Guideline into Practice
Caitlin Patten, Carolinas Medical Center, Charlotte, NC

P11 Omission of Sentinel Node Biopsy in Older Patients with Clinically Node-Negative Invasive Breast Cancer
Jean Bao, Cedars-Sinai Medical Center, Los Angeles, CA

P12 Bracketed Radioactive Seed Localization Reduces Re-excision Rates in Comparison to Bracketed Wire Localization
Monica Da Silva, University of Texas Southwestern Medical Center, Dallas, TX

P13 Defining the Incidence of Imaging and Biopsy After Mastectomy: It’s Not Zero
Soojin Ahn, Mount Sinai Medical Center/Dubin Breast Center, New York, NY
P14  Physician Preference and Patient Satisfaction with Radioactive Seed Versus Wire Localization
Anya Romanoff, Mount Sinai Medical Center/Dubin Breast Center, New York, NY

P15  The Use of One Step Nucleic Acid Amplification and Tumor-Related Risk Factors in the Treatment of Axillary Breast Cancer: A Predictive Model
Shramana Banerjee, Royal Free London NHS Trust, London, United Kingdom

P16  Impact of the 70-Gene Signature on Adjuvant Systemic Therapy Decisions in Early Breast Cancer Patients: Preliminary Results of a Prospective Multicenter Observational Study
Anne Kuijer, Diakonessenhuis Utrecht, Utrecht, Netherlands

P17  Preoperative MRI Exhibits Limited Utility in Axillary Staging for Breast Cancer
John Kuckelman, Madigan Army Medical Center, Tacoma, WA

P18  Prospective Evaluation of Skin and Nipple-Areola Sensation After Nipple-Sparing Mastectomy
Lesly Dossett, Moffitt Cancer Center, Tampa, FL

P19  Evaluating the Risk of Underlying Malignancy in Patients with Pathologic Nipple Discharge
George Li, Brigham and Women’s Hospital, Boston, MA

P20  The Effect of Radiation Therapy on Immediate Autologous Flap Reconstruction for Breast Cancer Patients
Princess Thomas, Yale, New Haven, CT

P21  Nativity Status Negatively Impacts Quality of Breast Cancer Care for Latinos in the U.S.
Daniella Acosta, Codman Center for Clinical Effectiveness in Surgery, Massachusetts General Hospital, Boston, MA

P22  Oncofertility Program Implementation Increases Access to Fertility Preservation Options and Assisted Reproductive Procedures in Breast Cancer Patients
Joceline Vu, University of Michigan Health System, Ann Arbor, MI

P23  Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients Meeting ACOSOG Z0011 Criteria
Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, NY
P24  Resection of the Primary Tumor Significantly Improves Median Overall Survival in Patients with Stage IV De Novo Inflammatory Breast Cancer
Rhiana Menen, MD Anderson Cancer Center, Houston, TX

P25  Breast Cancer Populations at Risk for Not Receiving Chemotherapy
Emily Marcinkowski, City of Hope, Duarte, CA

P26  Surgical Treatment of Paget Disease of the Breast: A Report from the National Cancer Data Base
Andrew Hanna, University of Maryland School of Medicine, Baltimore, MD

P27  Nearly Invisible Lumpectomy (NIL): Feasible and Safe
Amanda Nijhuis, VieCuri, Utrecht, Netherlands

P28  Differential Phosphoproteomics Between Chemosensitive and Resistant Triple Negative Breast Cancer Cells
Minna Lee, UCLA, Los Angeles, CA

P29  New Strategy to Tailor Axillary Treatment After Neoadjuvant Chemotherapy in Breast Cancer Patients
Mariëke Straver, NKI-AvL, Utrecht, Netherlands

P30  MRI for Axillary Breast Cancer Metastasis in the Neoadjuvant Setting: A Prospective Study
Anne Mattingly, Moffitt Cancer Center, Tampa, FL

P31  Neoadjuvant Chemotherapy Combined with Oncoplastic Reduction for High Stage Breast Cancer Patients
Justine Broecker, Emory University School of Medicine, Atlanta, GA

P32  Impact of Comorbidities on Surgical Outcomes Following Mastectomy in Elderly Breast Cancer Patients: An Analysis of the NSQIP Database
Simone Mays, Weill Cornell Medical College, New York, NY

P33  An Evaluation of HER2 Positivity in Invasive Breast Cancers with Associated Ductal Carcinoma In Situ
Liza Thalheimer, The Bryn Mawr Hospital, Bryn Mawr, PA

P34  Outcome Disparities in African American Compared to European American Women with Luminal A Tumors Treated within an Equal Access Health Care System
Rachel Ellsworth, Murtha Cancer Center, Windber, PA
P35  Pathologic Concordance of Preoperative Magnetic Resonance Imaging in Breast Cancer Patients Undergoing Contralateral Prophylactic Mastectomy for Symmetry
Stefania Nolano, The Bryn Mawr Hospital, Bryn Mawr, PA

P36  Tamoxifen Compliance in Duct Carcinoma In Situ (DCIS)
Lindsey Karavites, UIC/Mt. Sinai Hospital, Chicago, IL

P37  Concomitant Partial Mastectomy and Reduction Mammaplasty is Associated with Increased Postoperative Complications
Ann-Kristin Friedrich, University of Massachusetts, Southborough, MA

P38  A Contemporary Analysis of Axillary Lymph Node Dissection
Ameer Gomberawalla, Columbia University Medical Center, New York, NY

P39  Do Nurse-Navigated Treatment Summary-Survivorship Care Plans (TSSCPs) Improve Treatment and Follow-up Compliance in Underserved Populations?
Camille Manoukian, City of Hope, Boston, MA

P40  National Trends of the Impact of Rurality on Breast Cancer Surgery
Erin Canopy, Southern Illinois University School of Medicine, Springfield, IL

P41  Outcomes After Mastectomy and Lumpectomy in Elderly Patients with Early Stage Breast Cancer
Harveshp Mogal, Wake Forest University School of Medicine, Winston-Salem, NC

P42  Longer Time Intervals from Diagnosis to Surgical Treatment in Breast Cancer: Associated Factors and Survival Impact
Margaret Mariella, University of Louisville, Louisville, KY

P43  Interobserver Agreement for Assessment of Tumor Infiltrating Lymphocytes (TIL) in Breast Cancer
Elizabeth Mittendorf, MD Anderson Cancer Center, Houston, TX

P44  Postoperative Complications in Breast Cancer Patients are Independent of Age
Britt Ten Wolde, Canisius Wilhelmina Hospital, Nijmegen, Netherlands

Alexandra Gangi, Moffitt Cancer Center, Tampa, FL
P49 Screening Mammography in Women Ages 40-49: More Risks than Benefits? Rachelle Leong, Mount Sinai Beth Israel, New York, NY

P50 Can Risk Factors be Used to Select Women Aged 40-49 for Breast Cancer Screening? Aaron Sabbota, University of Rochester Medical Center, Rochester, NY

P51 Clinical Breast Examination Improves Breast Health Awareness and Stage at Diagnosis Among Peruvian Breast Cancer Patients Anya Romanoff, University of Washington, New York, NY

P52 The Impact of Axillary Ultrasound Results on a Sentinel Lymph Node Metastasis Prediction Nomogram Tiffany Chichester, Anne Arundel Medical Center, Annapolis, MD

P53 Income and Health Care Utilization May Influence Surgical Choice in Early Stage Breast Cancer Raeshell Sweeting, Vanderbilt University, Nashville, TN

P54 TOX3 as an Adjunct Novel Biomarker in Luminal B Breast Cancer Jenny Hong, Cedars-Sinai Medical Center, Los Angeles, CA

P55 The Role of Social Support in Surgical Decision Making for Black Women with Breast Cancer Raeshell Sweeting, Vanderbilt University, Nashville, TN

P56 Safety of Immediate Breast Reconstruction Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer Essa Aleassa, General Surgery, University of Manitoba, Winnipeg, MB, Canada

P57 Oncoplastic Breast Conserving Surgery is Associated with a Lower Risk of Surgical Site Complications Compared to Standard Breast Conserving Surgery Angelena Crown, Virginia Mason Medical Center, Seattle, WA

P58 Axillary Surgery in Patients with Ductal Carcinoma In Situ (DCIS): Analysis of the U.S. National Cancer Data Base (NCDB) from 1998-2012 John Bell, University of Tennessee Medical Center, Knoxville, TN
P59  Prospective, Single-Arm, Multi-Site Evaluation of a Non-Radioactive Surgical Guidance Technology for the Location of Non-Palpable Breast Lesions During Excision
Charles Cox, University of South Florida, Tampa, FL

P60  Accuracy of Sentinel Lymph Node Dissection (SLND) in Patients with Multicentric Breast Cancer
Min Yi, University of Texas MD Anderson Cancer Center, Houston, TX

P61  Does a Lower Tumour Stage Give a Higher Pathological Complete Response Rate in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Marissa Vane, Maastricht University Medical Centre, Maastricht, Netherlands

P62  Prognosis of Micrometastases Compared to Complete Nodal Response and Macrometastases in cN+ Breast Cancer Patients After Neoadjuvant Chemotherapy: A Population-Based Study
Martine Moossdorff, Maastricht University Medical Centre, Maastricht, Netherlands

P63  Long-term Satisfaction and Breast Cancer Outcomes After Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Judy Boughey, Mayo Clinic, Rochester, MN

P64  Postmastectomy Breast Reconstruction Disparities Across an Academic, Private, and Public Institution in the Same Metropolitan Area
Lauren Perry, Emory University School of Medicine, Atlanta, GA

P65  Observation Versus Excision of Lobular Neoplasia on Core Needle Biopsy
Brittany Arditi, Mount Sinai, New York, NY

P66  Are Triple Negative Breast Cancer Patients Screened for BRCA Mutations According to NCCN Guidelines?
Lindsay Petersen, University of Michigan, Ann Arbor, MI

P67  The Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype
Zahraa Al-Hilli, Mayo Clinic, Rochester, MN

P68  Adjuvant Endocrine Therapy Does Not Decrease Breast Cancer Mortality in the Elderly
Jeffrey Johnson, Cedars Sinai Medical Center, Los Angeles, CA
P69 DCIS is a Noninvasive Cancer, Not a Risk Factor for Breast Cancer
Amber Guth, NYU Langone Medical Center, New York, NY

P70 A Comparison of the Pathologic Response Rate After Neoadjuvant Chemoradiation in Patients with Locally Advanced Breast Cancer in an Underserved Population
Ajaratu Keshinro, Bellevue Medical Center, NYU Langone Medical Center, New York, NY

P71 Preoperative Axillary Imaging Compared to Sentinel Lymph Node Biopsy Results
Benjamin Scott, Thomas Jefferson University Hospitals, Philadelphia, PA

P72 Single Institution Experience of Local Recurrence and Toxicity Following a 2-Day Course of Accelerated Partial Breast Irradiation
Rebecca Fishman, Robert Wood Johnson University Hospital/Cancer Institute of New Jersey, New Brunswick, NJ

P73 Relationship Between BMI and Breast Cancer Subtype
Victoria Gershuni, University of Pennsylvania, Philadelphia, PA

P74 Survival Risk in Breast Cancer Related to Delays in Surgical Care
Christopher Oxner, Naval Medical Center Portsmouth, Portsmouth, VA

P75 Local Recurrence After Mastectomy for Breast Cancer in the Current Era: Which Subgroups are Still at Risk?
Martine Moosdorff, Maastricht University Medical Center, Maastricht, Netherlands

P76 Implementation of the Distress Thermometer Among Surgical Breast Cancer Patients at a Comprehensive Breast Center
Samilia Obeng-Gyasi, Duke University, Durham, NC

P77 The Utility of Screening MRI for Women Diagnosed with Atypical Breast Lesions
Jennifer Plichta, Massachusetts General Hospital, Boston, MA

P78 Trends in Sexual Function After Breast Cancer (BrCa) Surgery
Lauren Cornell, Mayo Clinic, Jacksonville, FL

P79 Does the Addition of Pertuzumab to Neoadjuvant Treatment for HER2 Positive Patients Result in Increased Nodal Downstaging or Eligibility for Breast Conservation?
Lindsay Petersen, University of Michigan, Ann Arbor, MI
P80  Oncoplastic Breast Surgery: Three Years Experience at National Cancer Institute Mexico City
Rafael Vazquez Romo, Instituto Nacional de Cancerología, Mexico City, Distrito Federal, Mexico

P81  Patient Experience with Breast Reconstruction Following Bilateral Mastectomy in BRCA Mutation Carriers
Suliat Nurudeen, Brigham and Women’s Hospital, Brighton, MA

P82  Body Mass Index, Pathologic Complete Response, and Circulating Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer
Oluwadamilola Fayanju, The University of Texas MD Anderson Cancer Center, Houston, TX

P83  National Practice Patterns Among Women with Stage IV Breast Cancer Undergoing Surgery at the Primary Site
Whitney Lane, Duke University School of Medicine, Durham, NC

P84  Clinical, Radiologic and Pathologic Findings After Use of Spiral 3-Dimensional Bioabsorbable Lumpectomy Marker
Cary Kaufman, University of Washington, Bellingham, WA

P85  How Fast Can the Immune Response Eliminate Murine Cancer Cells from a Different Background?
Eriko Katsuta, Virginia Commonwealth University, Richmond, VA

Colorectal Cancer Posters

P86  Early Results of Phase II Trial of Neoadjuvant Chemotherapy with S-1 and Oxaliplatin Plus Bevacizumab for Colorectal Liver Metastasis
Keisuke Uehara, Nagoya University Hospital, Nagoya, Aichi, Japan

P87  Innovation or Disparity? National Trends in Non-operative Management of Rectal Adenocarcinoma
Clayton Ellis, University of North Carolina, Chapel Hill, NC

P88  Comprehensive Genomic Analysis of Colon Tumors Reveals Differences in Molecular Patterns Between Early- and Late-onset Tumors
Jana Jandova, University of Arizona, Tucson, AZ

P89  The Incidence of Secondary Pelvic Tumors After Previous (Chemo)Radiation for Rectal Cancer
Anouk Rombouts, RadboudUMC, Nijmegen, Netherlands
P90 Oncologic Outcomes Following Laparoscopic Versus Open Resection of pT4 Colon Cancer: A Systematic Review and Meta-analysis
Adina Feinberg, University of Toronto, Toronto, ON, Canada

P91 Mesorectal Pathologic Assessment in Two Grades Predicts Accurately Recurrence, Positive Circumferential Margin and Correlates with Survival
Rosa Salcedo Hernandez, Instituto Nacional de Cancerologia, Mexico City, Mexico

P92 Factors Affecting Quality of Life Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer: A Prospective Study
Claramae Chia, National Cancer Centre Singapore, Singapore, Singapore

P93 Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Cost-effective for Metastatic Colorectal Cancer?
Zhen Jin Lee, Singhealth, Singapore, Singapore

P94 C6-Ceramide Restores Cetuximab Chemo-Enhancement in KRAS Mutant Colorectal Cancer Cells
Alvaro Menendez, Roger Williams Medical Center, Providence, RI

P95 Outcomes of Primary Colorectal Sarcomas: A National Cancer Data Base (NCDB) Review
Cornelius Thiels, Mayo Clinic, Rochester, MN

P96 Endoscopic Resection and Laparoscopic Surgery for Early Colorectal Cancer: A Case-Matched Study
Jeong Heum Baek, Gachon University Gil Medical Center, Incheon, The Republic of Korea

P97 Derivation of Stringent Transcriptomic Signatures from Multisampling of Colorectal Tumours
Kay Nguan, Kelvin Koh, National Cancer Centre Singapore, Singapore, Singapore

P98 Inhibition of Colon Cancer Growth and Migration by Polyamine Synthesis Inhibition and AMP Kinase Activation
Eddy Hsueh, Saint Louis University, St. Louis, MO

P99 Full Length LGR5-Positive Cells have Chemoresistant Characteristics in Colorectal Cancer
Hidekazu Takahashi, Osaka University Faculty of Medicine, Suita, Osaka, Japan
P100 Epigenetic Alterations by MicroRNAs in Carcinogenesis of Colorectal Cancer
Tsuyoshi Hata, Osaka University, Suita, Japan

P101 Predictors of Severe Morbidity After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis
Geert Simkens, Catharina Hospital Eindhoven, Eindhoven, Noord-Brabant, Netherlands

P102 Molecular Targeting B-RAF Mutant Colorectal Cancer: Novel AMPK-induced Autophagy Mechanism
Toshinori Sueda, Osaka University, Suita, Japan

P103 Histopathological Features of Patients with Synchronous Colorectal Peritoneal Metastases Strongly Influence Treatment and Survival
Geert Simkens, Catharina Hospital Eindhoven, Eindhoven, Noord-Brabant, Netherlands

P104 Mixed Adeno-Neuroendocrine Carcinoma: An Aggressive Clinical Entity
Shayna Brathwaite, The Ohio State University Wexner Medical Center, Columbus, OH

P105 Timing of Systemic Treatment in Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Metastases of Colorectal Origin
Geert Simkens, Catharina Hospital Eindhoven, Noord-Brabant, Netherlands

P106 Super Carbonate Apatite Nanoparticles Can Adjunctively Reduce Tumor Interstitial Fluid Pressure and Enhance the Uptake of Chemicals into Tumor
Xin Wu, CancerStem Tech Inc., Ibaraki, Osaka, Japan

P107 Exploring the Clinical Utility of MULE as a Biomarker in Colorectal Cancer
Weining Wang, National Cancer Centre Singapore, Singapore, Singapore

P108 Patients with Squamous Cell Cancers of the Anal Canal are at Risk for Second Cancers
Lily Lai, City of Hope, Duarte, CA

P109 Pelvic Exenterations Can be Performed Safely: A Morbidity and Mortality Analysis of the First 90 Days After Surgery
Nicholas Borja, UT Southwestern, Dallas, TX

P110 First In-Human Intraoperative Optical Imaging of Peritoneal Carcinomatosis of Colorectal Origin Using a VEGF Targeted Near-Infrared Fluorescent Tracer: A Feasibility Study
Steven de Jongh, University Medical Centre Groningen, Groningen, Groningen, Netherlands
P111 Validation of Verwaal’s Prognostic Score in an Asian population
Deanna Ng, National Cancer Centre Singapore, Singapore, Singapore

P112 Robotic Versus Laparoscopic Surgery for Rectal Cancer: An Analysis of the Nationwide Inpatient Sample (NIS) Database
Michelle Julien, Geisinger Medical Center, Danville, PA

P113 The Relationship of Socioeconomic Disparities with Age-Related Rates of Colorectal Cancer in the United States
Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY

P114 Can Mapping Procedures Prior to Definitive Wide Local Excision for Perianal Paget’s Disease Decrease Local Recurrence Rates?
Aaron Blackham, Moffitt Cancer Center, Lutz, FL

P115 To Screen or Not to Screen: Colonoscopy, a Story of Successful Population-Based Screening
Catalina Mosquera, Brody School of Medicine, Greenville, NC

P116 The Role of Glutaminase C and Glutamine Metabolism in Epithelial-Mesenchymal Transition in Colorectal Cancer
Hugh Colvin, Osaka University, Osaka, Japan

P117 Liposomal Indocyanine Green for Intraoperative Imaging of the Ureters and Prevention of Iatrogenic Damage
Eran Nizri, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

P118 The Role of Positron-Emission Tomography/Computed Tomography in Patients with Colorectal Liver Metastases Who are Candidates for Liver Resection: Is It Useful?
Takanori Hiraide, Hamamatsu University School of Medicine, Hamamatsu, Japan

P119 Evolution of Lymph Nodes Detected by Pathologist in Colorectal Cancer: A Comparison of National Cancer Data Base and Surveillance, Epidemiology and End Results Program (SEER) Between 1998-2010
Sukamal Saha, McLaren Flint, Flint, MI

P120 Emergency Room Utilization by Patients with Colorectal Cancer: Predictors of Use and Subsequent Admission
Nabil Wasif, Mayo Clinic in Arizona, Phoenix, AZ
P121 **Extended Pelvic and Sacral Resection in the Surgical Management of Recurrent Low Rectal Cancer**  
Wael Gawad, National Cancer Institute - NCI, Cairo, Egypt

P122 **Extent of Adjuvant Chemotherapy Use in Stage II and Stage III Colon Cancer through Examination of a National Cancer Data Base (NCDB)**  
Kei Nagatomo, Main Line Health, Philadelphia, PA

P123 **The Interaction of Primary Histology and Extent of Surgery on Overall Survival in Appendiceal Cancer**  
Kate Peng, Mayo Clinic, Phoenix, AZ

P124 **Inhibition of the AIM (Adhesion, Invasion, Migration) Pathway Limits Tumor Cell Metastatic Properties**  
Melinda Stack, University of Chicago, Chicago, IL

P125 **Predictors of Tumor Response and Survival After Preoperative Chemoradiotherapy for Locally Advanced Rectal Adenocarcinoma**  
Rodrigo Silva-Martínez, Hospital de Oncología IMSS CMN SXXI, Mexico City, Mexico

P126 **ACA Solutions for Colorectal Cancer Workup: Affordable Care?**  
Jennifer Perone, UTMB- Galveston, Galveston, TX

P127 **Detecting Peritoneal Surface Malignancies with Cathepsin-Based Fluorescent Imaging System**  
Carlos Chan, Massachusetts General Hospital, Boston, MA

P128 **Perioperative Outcomes for Robotic Total Mesorectal Excision After Preoperative Chemoradiation for Rectal Cancer**  
Ibrahim Nassour, University of Texas Southwestern, Dallas, TX

P129 **Utility of Positron Emission Tomography (PET) Scans in the Management of Patients with Peritoneal Disease**  
Jolene Wong, Singapore General Hospital, Singapore, Singapore

P130 **Exploring the Trend in Referrals for Consideration of CRS and HIPEC to Understand the Attitudes of Clinicians in the Development of a National Cancer Centre Program in Peritoneal Disease**  
Zachary Zihui Yong, Singapore General Hospital, Singapore, Singapore

P131 **Prognostic Significance of Nodal Count and Lymph Node Ratio in Irradiated Rectal Cancer**  
Wim Ceelen, Ghent University, Ghent, Belgium
P132 Platinum Distribution of Platinum After Clinical (H)IPEC Using Laser Ablation Inductively Coupled Plasma Mass Spectrometry
Charlotte Carlier, Ghent University, Ghent, Belgium

P133 The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Xenograft Model
Elodie Melsens, Ghent University, Ghent, Belgium

P134 Genipin-Crosslinked Gelatin Microspheres as a Strategy to Prevent Postsurgical Peritoneal Adhesions
Kaat De Clercq, Ghent University, Ghent, Belgium

P135 Propensity Score Matched Analysis of Postoperative Outcome After Hyperthermic or Normothermic Intraperitoneal Chemoperfusion
Felix Gremonprez, Ghent University, Ghent, Belgium

P136 Changes in Apparent Diffusion Coefficient Evaluated with Diffusion Weighted MRI May Predict Complete Pathologic Response After Neoadjuvant Therapy for Rectal Cancer: A Meta-analysis
Vincenzo Desiato, NYU School of Medicine, New York, NY

P137 Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Can We Improve Survival with Less Postoperative Complications?
Mecker Möller, University of Miami Miller School of Medicine, Miami, FL

P138 Mixed Adeno-Neuroendocrine Carcinoma (MANEC): A Population-Based Study of the Surveillance, Epidemiology and End Results (SEER) Registry
Shayna Brathwaite, The Ohio State University Wexner Medical Center, Columbus, OH

P142 Readmission Rates of Patients Undergoing Resection of a Colorectal Primary: An Analysis of SEER-Medicare
Patrick Lorimer, Levine Cancer Institute, Charlotte, NC

P143 Degree of Intraperitoneal Hyperthermia During HIPEC Predicts Overall Survival
Victor Phuoc, University of Texas MD Anderson Cancer Center, Houston, TX
P144 Molecular Profiling: Prognostic Biomarkers in Patients Presenting with Peritoneal Carcinomatosis of the Appendix and Colon Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Chukwuemeka Ihemelandu, Washington Hospital Center, Washington, DC

P145 Mutant-Allele Tumor Heterogeneity (MATH) Scores Correlate with Stage of Colon Cancer Ashwani Rajput, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM

P146 Frequent BRAF Mutations in Colonic High-Grade Neuroendocrine Carcinoma Chandrasekhar Padmanabhan, Vanderbilt University, Nashville, TN

P147 Resection of Non-regional Lymph Node Metastasis in Patients with Colorectal Cancer Christina Bailey, Vanderbilt University Medical Center, Nashville, TN

P148 Impact of KRAS/BRAF Mutations in Patients with Colorectal Peritoneal Metastases G. Paul Wright, University of Pittsburgh Medical Center, Pittsburgh, PA

P149 CEA Level Predicts Oncologic Outcomes Following Surgical Resection of Colorectal Peritoneal Metastases G. Paul Wright, University of Pittsburgh Medical Center, Pittsburgh, PA

P150 Establishing the Proper Timing of Surgical Decision-making in Rectal Cancer: Before or After Neoadjuvant Therapy? A Prospective Study for T3 Cancers of the Distal 1/3 of the Rectum Elizabeth Myers, Lankenau Institute for Medical Research, Wynnewood, PA

P151 Hospital Treatment Intensity and Guideline-Concordant Care for Resected Stage II/III Colorectal Cancer Robert Krell, University of Michigan, Ann Arbor, MI

P153 Care Coordination in Elderly Colon Cancer Patients Rebecca Hoffman, University of Pennsylvania, Philadelphia, PA

P154 Radical Surgery for Advanced Right Colic Cancer: Lymph Node Dissection in the Era of Complete Mesocolic Excision Shunsuke Tsukamoto, National Cancer Center Hospital, Tokyo, Japan
P155  Benefit of Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer with Unresectable Metastasis
Sean Maroney, Loma Linda University Hospital, Loma Linda, CA

Endocrine Cancer Posters

P156  Racial Disparities in Thyroid Cancer Surgery
Herbert Castillo Valladares, Yale School of Medicine, New Haven, CT

P158  Resection of Primary Gastrointestinal Neuroendocrine Tumor Improves Overall Survival with or without Treatment of Liver Metastases
Aaron Lewis, City of Hope, Duarte, CA

P159  Prognostic Significance of Diagnosed Hereditary Syndrome in Patients with Malignant Pheochromocytoma and Paraganglioma
Wei Li, University of Pittsburgh, Pittsburgh, PA

P161  Outcomes of Cytoreductive Surgery for Well-Differentiated Metastatic Neuroendocrine Tumors in the Setting of Extrahepatic Metastases
Julie Hallet, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada

P162  Functional Polymorphisms in Antioxidant Genes and Occurrence of Recurrent Disease in Patients with Hurthle Cell Carcinoma
Gasper Pilko, Institute of Oncology, Ljubljana, Slovenia

P163  Small Bowel Neuroendocrine Tumors: A Critical Analysis of Diagnostic Work-up and Operative Approach
Cecilia Ethun, Emory University, Atlanta, GA

P164  Demographic and Economic Disparities in the Presentation and Management of Carcinoid Tumor: A National Perspective
Zaid Al-Qurayshi, Tulane University School of Medicine, New Orleans, LA

P165  Access to Care and Outcomes for Neuroendocrine Tumors: Does Socioeconomic Status Matter? A Population-Based Analysis
Julie Hallet, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, ON, Canada

P166  Novel Nomogram Combining Depth of Invasion and Size Can Accurately Predict the Benefit of Regional Lymphadenectomy for Appendiceal Neuroendocrine Tumors (A-NET)
Catalina Mosquera, Brody School of Medicine, Greenville, NC
P167  Focused Parathyroidectomy without Intraoperative Parathormone Testing is Safe After Preoperative Localization with 18F-Fluorocholine PET/CT
Marko Hocevar, Institute of Oncology, Ljubljana, Slovenia

P168  Reevaluating the Significance of Multifocality in Sporadic Medullary Thyroid Carcinoma (MTC)
Elizabeth Grubbs, MD Anderson Cancer Center, Houston, TX

P169  Thyroglobulin Measurement in Fine-Needle Aspiration Improves the Diagnosis of Cervical Lymph Node Metastases in Papillary Thyroid Carcinoma
Zahraa Al-Hilli, Mayo Clinic, Rochester, MN

P170  Adjuvant Radiation Therapy in Patients Undergoing Curative Intent Resection for Adrenocortical Carcinoma: A Multi-Institutional Experience
Ioannis Hatzaras, NYU Langone Medical Center, New York, NY

P171  Number of Lymph Nodes Examined Predicts Survival in Node Negative Appendiceal Carcinoids
Mustafa Raoof, City of Hope Medical Center, Duarte, CA

P172  Lymphadenectomy for Adrenocortical Carcinoma: Is there a Therapeutic Benefit?
George Poultsides, Stanford University School of Medicine, Stanford, CA

P173  Double Balloon Enteroscopy in the Diagnosis of Multifocal Small Bowel Neuroendocrine Tumors: Clinical Utility or Over Utilization?
Jeffrey Johnson, Cedars Sinai Medical Center, Los Angeles, CA

P174  Significance of Intravenous Thrombus in the Management of Adrenocortical Carcinoma: Prognosis and Surgical Implications
Shuja Ahmed, Wake Forest Baptist Medical Center, Winston Salem, NC

P175  External Radiotherapy in Patients with Iodine Refractory Differentiated Thyroid Cancer
Andries Groen, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

P176  Socioeconomic and Insurance Status are Not Associated with Liver Directed Therapy Utilization or Survival in Neuroendocrine Tumors Metastatic to the Liver
Michael White, City of Hope, Arcadia, CA
P177 Small Change for Big Gains: Process Optimization for Sample Processing Provides Substantial Savings  
Kirk Caddell, UNC, Chapel Hill, NC

P178 Relative Recurrence of Differentiated Thyroid Cancer Following Radioactive Iodine Ablation After Lobectomy Versus Total Thyroidectomy: A Systematic Analysis  
Erin Dawson, Tulane University School of Medicine, New Orleans, LA

Hepatobiliary Cancer Posters

P180 With Modern Chemotherapy Prognostic Models Underestimate Which Patients May Benefit from Hepatic Resection for Colorectal Liver Metastases  
Robert Smalley, Harvard Medical School, Boston, MA

P181 Liver Resection Following Selective Internal Radiation Treatment with Yttrium-90: A Bi-Institutional Analysis  
G. Paul Wright, University of Pittsburgh, Pittsburgh, PA

P182 Racial Disparity or Different Biology? Variations in the Outcomes and Survival in Hepatocellular Carcinoma  
Eyas Alkhalili, University of New Mexico, Albuquerque, NM

P183 Development of Laparoscopic and Open Models for Training and Assessing Image-guided Liver Tumor Ablation  
Kaled Diab, University of Texas Medical Branch, Galveston, TX

P184 The Optimal Time-Interval to Re-resection for Incidentally Discovered Gallbladder Cancer: A Multi-Institution Analysis from the U.S. Extrahepatic Biliary Malignancy Consortium  
Cecilia Ethun, Emory University, Atlanta, GA

P185 Management Strategies for Patients with Solitary Hepatocellular Carcinoma ≤3 cm  
Allison Martin, University of Virginia, Charlottesville, VA

P186 The Treatment Outcomes After Hepatectomy for Advanced Hepatocellular Carcinoma  
Yukiyasu Okamura, Shizuoka Cancer Center Hospital, Sunto-Nagaizumi, Japan

P187 Use of Loco-regional Treatment for HCC: Trans-arterial Chemoembolization and Ablation Work Better Together  
Arthur Winer, NYU Langone Medical Center, New York, NY
P188  The Mechanism of Upregulating c-Met Expression During Preoperative Chemo-radiation Therapy in Pancreatic Ductal Adenocarcinoma
Hideo Tomihara, Osaka University, Osaka, Japan

P189  Hepatic Microenvironment: What Tips the Balance Towards Metastasis?
Fiona Hand, Trinity Biomedical Sciences Institute, Dublin, Ireland

P190  Morphomic Analysis and Frailty Assessment Improves Prediction of NSQIP Serious Complications Following Pancreaticoduodenectomy in Older Adults
Andrew Benjamin, University of Chicago, Chicago, IL

P191  Gemcitabine/Capecitabine for Advanced Biliary Cancer: Less Toxicity with Favorable Outcomes
Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY

P192  Conditional Survival Probability of Long-term Survival After Resection of Hilar Cholangiocarcinoma
Stefan Buettner, Johns Hopkins School of Medicine, Baltimore, MD

P193  Assessing Tools for the Management of Non-Colorectal Non-Neuroendocrine Liver Metastases: External Validation of a Prognostic Model
Melanie Tsang, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

P194  Rates and Patterns of Recurrence Following Complete Resection of Hilar Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Consortium
Harveshp Mogal, Wake Forest University School of Medicine, Winston-Salem, NC

P195  Transfused Blood from Older Donors is Associated with Improved Survival in Patients Undergoing Hepatic Surgery for Non-Hepatocellular Malignancies
Ryan Thomas, University of Florida, Gainesville, FL

P196  High Frequency Irreversible Electroporation (HFIRE): A Novel Method of Targeted Cell Death
Imran Siddiqui, Carolinas Medical Center, Charlotte, NC

P197  Management of Massive (>10cm) Hepatocellular Carcinoma at a Tertiary Referral Public Hospital
Yohei Rosen, NYU Langone Medical Center, New York, NY
P198 National Treatment Patterns of Hepatocellular Carcinoma Among Patients with Hepatitis B and C Infection: A Surveillance, Epidemiology, and End Results-Medicare Analysis
Christopher Scally, University of Michigan, Ann Arbor, MI

P199 Adjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma Does Not Improve Survival: National Cancer Data Base Analysis
Juan Santamaria-Barria, University of Texas Health Science Center at Houston, Houston, TX

P200 Coordinated Minimally Invasive Multi-Stage Surgery for Stage IV Colorectal Cancer
Claudius Conrad, University of Texas MD Anderson Cancer Center, Houston, TX

P201 Patient Ratings of Hospital Care Using the HCAHPS Survey Following Pancreatic Surgery are Influenced by Pain Management and Not Postoperative Complications
Trang Nguyen, Cleveland Clinic, Cleveland, OH

P202 Intrahepatic Cholangiocarcinoma: Ambitious Operations and Outcomes
Mustafa Raoof, City of Hope Medical Center, Duarte, CA

P203 PD-L1 Expression is an Unfavorable Prognostic Factor in Hepatocellular Carcinoma
Moo-Jun Baek, Soonchunhyang University Hospital, Cheonan, The Republic of Korea

P204 Extent of Lymph Node Burden Provides Enhanced Prognostic Value for Pancreatic Adenocarcinoma
Cinthya Yabar, Jefferson Pancreas, Biliary and Related Cancer Center, Thomas Jefferson University, Philadelphia, PA

P205 Towards an Absolute Bilirubin Threshold for Preoperative Biliary Decompression in Patients Undergoing Whipple
Catalina Mosquera, Brody School of Medicine, Greenville, NC

P206 Primary Malignancy is an Independent Determinant of Morbidity and Mortality Following Liver Resection
Marc Fromer, Cooper University Hospital, Camden, NJ

P208 The Utility of MELD Score in Predicting Mortality Following Liver Resection for Metastasis
Marc Fromer, Cooper University Hospital, Camden, NJ

P209 Lymph Node Yield Between Open and Laparoscopic Portal Lymphadenectomy
Cecilia Ong, Duke University Medical Center, Durham, NC
P210 Effect of Preoperative Bilirubin on Outcomes of Completely Resected Hilar Cholangiocarcinoma: A Multi-Institutional Analysis
Harveshp Mogal, Wake Forest University School of Medicine, Winston-Salem, NC

P211 Curative Resection for Hilar Cholangiocarcinoma: Does Adjuvant Therapy Impact Overall Survival? A Multi-Institution Analysis from the U.S. Extrahepatic Biliary Malignancy Consortium
Bradley Krasnick, Washington University School of Medicine, St. Louis, MO

P212 Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated with Better Outcome
Michael Cavnar, Memorial Sloan Kettering Cancer Center, New York, NY

P213 Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Trans-Arterial Chemoembolization Using Streptozotocin: A 10-Year Experience
Mashaal Dhir, University of Pittsburgh Medical Center, Pittsburgh, PA

P214 CA19-9 Level in Intrahepatic Cholangiocarcinoma is Independently Associated with Increased Mortality Hazard and Aggressive Tumor Biology: A NCDB Study
John Bergquist, Mayo Clinic, Rochester, MN

P215 A Risk Calculator for Oncological Outcomes in Patients Considering Hepatic Resection for Hepatocellular Carcinoma
Katherine Ostapoff, Roswell Park Cancer Institute, Buffalo, NY

P216 Are We Maximizing Liver Treatment for Metastases in Neuroendocrine Tumors?
Aaron Lewis, City of Hope, Duarte, CA

P217 Radiographic Predictors of Intrahepatic Recurrence After Resection of Colorectal Liver Metastases
Victor Phuoc, University of Texas MD Anderson Cancer Center, Houston, TX

P218 Interim Results of a Screening Protocol for Early Detection of Pancreatic Cancer in Asymptomatic High-risk Patients
Alexandra Gangi, Moffitt Cancer Center, Tampa, FL

P219 Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?
Thuy Tran, Stanford University, Stanford, CA

P220 30-Day Readmission After Liver Resection for Hepatocellular Carcinoma
Samer Tohme, University of Pittsburgh, Pittsburgh, PA
P221  The Effect of Postoperative Morbidity on Long-term Survival After Curative Resection for Extrahepatic Biliary Tumors: A Multi-Institution Analysis from the U.S. Extrahepatic Biliary Malignancy Consortium
Linda Jin, Washington University in St. Louis School of Medicine, St. Louis, MO

P222  Morbidity and Mortality of Surgical Palliation in Stage IV Pancreatic Cancer
Bradley Reames, University of Michigan, Ann Arbor, MI

P223  Conditional Probability of Survival in Gallbladder Carcinoma: An Apt Prognostic Tool for Long-term Survivors
Rahul Rajeev, Medical College of Wisconsin, Milwaukee, WI

P225  Radiotherapy for Intrahepatic Cholangiocarcinoma: An Analysis of the National Cancer Data Base
Nicholas Berger, Medical College of Wisconsin, Milwaukee, WI

Melanoma Cancer Posters

P226  Regression in Thin Melanoma is Associated with Nodal Recurrence After a Negative Sentinel Node Biopsy
Jill Rubinstein, Yale University, Guilford, CT

P227  Breslow Thickness Measurements of Melanomas Around AJCC Staging Cut-off Points: Imprecision and Terminal Digit Bias have Implications for Staging and Patient Management
John Thompson, Melanoma Institute Australia, Sydney, NSW, Australia

P228  Molecular Profiling and Clinical Outcomes in Malignant Melanoma: Experience at a NCI-Designated Cancer Center
Francis Zih, Fox Chase Cancer Center, Philadelphia, PA

P229  Prognostic Significance of Sentinel Node Status in Patients with Thick Melanoma
Danielle Bello, Yale-New Haven Hospital, New Haven, CT

P230  Treatment of Melanoma In Situ with Staged Contoured Marginal Excisions
Evan Glazer, Moffitt Cancer Center, Tampa, FL

P231  Videoscopic Ilioinguinal Lymphadenectomy for Lymph Node Metastases from Melanoma
Antonio Sommariva, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy
P232 Lymph Node Ratio is Less Prognostic in Melanoma When Minimum Node Retrieval Thresholds are Not Met
Mark Healy, *University of Michigan*, Ann Arbor, MI

P233 Tissue Harvesting for Adoptive T-Cell Therapy with “Young” Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
Douglas Zippel, *Chaim Sheba Medical Center*, Ramat Gan, Israel

P234 Identifying the Low-risk Subgroups Among Intermediate Thickness Melanoma Patients
James Chang, *Mayo Clinic*, Phoenix, AZ

P235 Preliminary Feasibility Data from the Melanoma Margins Trial (MelMarT) Pilot Study: Australian and New Zealand Melanoma Trials Group (ANZMTG) Study 03.12
Marc Moncrieff, *Norfolk & Norwich University Hospital*, Norwich, Norfolk, United Kingdom

P236 BRAF Inhibitors for Neoadjuvant Treatment in Irresectable or Marginally Resectable Stage III Melanoma
Douglas Zippel, *Chaim Sheba Medical Center*, Ramat Gan, Israel

P237 Isolated Limb Perfusion in Merkel Cell Carcinoma Offers High Complete Response and Durable Local-Regional Control: Systematic Review and Institutional Experience
Cornelius Thiels, *Mayo Clinic*, Rochester, MN

P238 Sentinel Node Biopsy for T1 Melanoma in Patients 75 Years of Age or Older Does Not Change Clinical Outcomes
Darryl Schuitevoerder, *Oregon Health & Science University*, Portland, OR

P239 Predicting Response to BRAF-Targeted Therapy Using an Immune Signature
Jessica Cintolo-Gonzalez, *Massachusetts General Hospital*, Boston, MA

P240 Predictors of Early Recurrence in Patients with Melanoma Nodal Micrometastases
Madalyn Peters, *Hospital of the University of Pennsylvania*, Philadelphia, PA

P241 MITF in Primary Melanoma Increases the Accuracy of Melanoma Nomogram in Predicting the Lymph Node Status
Samer Naffouje, *University of Illinois at Chicago Medical Center*, Chicago, IL

P242 Suppression of Renalase in TAMs Enhances Melanoma Invasion and Metastasis
Lindsay Hollander, *Yale University*, West Hartford, CT
P243 Fluorescent Nanodiamonds Engage Innate Immune Effector Cells: Potential Anti-Tumor Efficacy
Lorena Suarez-Kelly, The Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, OH

P244 Characteristics, Treatment and Outcomes of Invasive Malignant Melanoma in Giant Pigmented Nevi in Adults: 976 Cases from the National Cancer Data Base
Asley Turkeltaub, Baylor College of Medicine, Houston, TX

P245 Completion Lymphadenectomy Does Not Confer a Survival Advantage in Intermediate Thickness Melanoma
Catalina Mosquera, Brody School of Medicine, Greenville, NC

P246 Patterns of Failure Following Excision of In-Transit Lesions in Melanoma and Influence of Excision Margins
Alexandra Gonzalez, Mayo Clinic, Guaynabo, PR

P247 microRNA Profiling of Distant Metastatic Melanoma
Nicholas Latchana, The Ohio State University, Columbus, OH

P248 Cell-Free DNA V600E Measurements During Therapy with Vemurafenib in Metastatic Melanoma Patients
Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

P249 Intraoperative Frozen Section (FS) Analysis of Sentinel Lymph Nodes (SLNs) in Melanoma has a High False Negative Rate but Allows Patients with Larger Volume Disease to be Spared a Second Operation
Aodhnait Fahy, Mayo Clinic, Rochester, MN

P250 Sentinel Lymph Node Drainage to Multiple Basins in Head and Neck Melanoma
Camille Stewart, University of Colorado School of Medicine, Aurora, CO

P251 Sentinel Node Status in Patients 75 Years of Age or Older with Melanoma >1mm Thick is an Important Predictor of Disease Recurrence
Darryl Schuitevoerder, Oregon Health & Science University, Portland, OR

P252 Withanolides Inhibit Glycolysis, Growth, Migration, and Invasion in Melanomas through Induction of Reactive Oxygen Species
Peter White, University of Michigan, Ann Arbor, MI
P253 Effects of Time Interval Between Primary Melanoma Excision and Sentinel Node Biopsy on Positivity Rate and Survival
Charlotte Oude Ophuis, Erasmus MC Cancer Institute, Rotterdam, Netherlands

P254 The Additional Value of S-100B in a Risk Stratifying Model for the Prediction of Non-Sentinel Node Positivity in Melanoma Patients
Samantha Damude, University Medical Center Groningen, Groningen, Netherlands

P255 Factors Associated with Non-Performance of Sentinel Node Biopsy for Intermediate Thickness Melanoma: A National Study of 5,133 Patients
Linda Youngwirth, Duke University Medical Center, Durham, NC

P256 A Novel, Endovascular Approach to Hyperthermic Isolated Limb Infusion (HILI) for Advanced Locoregional Melanoma of the Lower Extremity
Alex Kim, University of Michigan Health Systems, Ann Arbor, MI

P257 Copy Number Alterations Determined by Array CGH Influence Prognosis in Stage III Metastatic Melanomas
Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

P258 Disease Recurrence Patterns of Head and Neck Melanoma
Andrew Blakely, Brown University/Rhode Island Hospital, Providence, RI

P259 Sentinel Lymph Node Biopsy in Octogenarians with Very Thick Melanomas Does Not Impact Survival
Sinziana Dumitra, City of Hope, Pasadena, CA

P260 Treatment with Neoadjuvant Targeted Therapy Yields High Response Rates and Pathologic Complete Responses in Patients with Resectable Metastatic Melanoma
Peter Prieto, University of Texas MD Anderson Cancer Center, Houston, TX

P261 Head and Neck Melanoma: Differences at Presentation and Treatment Obstacles
William Hewgley, University of Tennessee Health Science Center, Memphis, TN

P262 Ipilimumab Treatment is Effective for Patients with Melanoma, Whether at Initial Diagnosis or at the Time of Recurrent Disease
Joyce Au, Fox Chase Cancer Center, Philadelphia, PA
P263 Plasma microRNA Dynamics Following Surgical Resection of Metastatic Melanoma
Nicholas Latchana, The Ohio State University, Columbus, OH

P264 Molecular Profiling and Clinical Outcomes in Patients with In-Transit Recurrence of Melanoma
Francis Zih, Fox Chase Cancer Center, Philadelphia, PA

P265 Are there Gender-Based Differences in Skin Protection Behaviors Post Cutaneous Melanoma Treatment?
Subhasis Misra, TTUHSC, Amarillo, TX

P266 The Incidence and Prognostic Significance of Acquired Genetic Mutations Among High-risk Primary Melanoma Patients Undergoing Surgery
Christina Del Guzzo, Columbia University Medical Center, New York, NY

Quality Improvement/Clinical Outcomes Posters

P267 Non Surgical Management and Interval Cholecystectomy is Preferred for Acute Cholecystitis in Cancer Patients
David Santos, MD Anderson, Houston, TX

P268 Surgical APGAR Score Predicts Major Complications of the Patients After Hepatectomy
Ivo Mitsiev, Greenville Health System, Greenville, SC

P269 Biphasic Learning Curve of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion: Technical Competence and Refinement of Patient Selection
Nicholas Shannon, National Cancer Centre Singapore, Singapore, Singapore

P270 Development of a Simulated Interprofessional Geriatric Surgery Curriculum: Challenges and Opportunities
Subhasis Misra, Texas Tech University Health Sciences Center, Grand Prairie, TX

P271 Isolated Chemotherapeutic Perfusion as Neoadjuvant Therapy for Advanced/Unresectable Pelvic Malignancy
Harold Wanebo, Roger Williams Medcenter; Brown University, Providence, RI

P272 Evolution of Minimally Invasive Surgery at a Tertiary Cancer Center: Analysis of 10,000 Intraabdominal Cases
Luke Selby, Memorial Sloan Kettering Cancer Center, New York, NY
P273 Prognostic Significance of Neutrophil/Lymphocyte Ratio (NLR) and Platelet/Lymphocyte ratio (PLR) in Predicting Outcomes for Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Wei-Liang Loh, Singhealth, Singapore, Singapore

P274 Rethinking Priorities: Incremental Cost of Complications for Elective Resection
Cheryl Zogg, Center for Surgery and Public Health, Harvard Medical School and Harvard T.H. Chan School of Public Health, Brigham and Women’s Hospital, Boston, MA

P275 Glove and Instrument Handling in Cancer Cases: A Survey of Surgeons’ Beliefs and Practices
David Berger-Richardson, University of Toronto, Toronto, ON, Canada

P276 Rural Residence Correlates with Low Volume Surgical Centers and Poorer Survival for Pancreatic Adenocarcinoma
Benjamin Flink, Atlanta VA Medical Center, Atlanta, GA

P277 Disseminated Cancer Further Increases the Risk of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery for Malignancy
Annabelle Teng, Mt. Sinai St. Luke’s Roosevelt, New York, NY

P278 The Ergonomic Hazards of Operating: Symptoms and Injuries in Oncologic Surgeons
Rachel Voss, MD Anderson Cancer Center, Houston, TX

P279 Readmissions and Complications After Robotic Surgery: Experience of 9,234 Operations at a Comprehensive Cancer Center
Bertram Yuh, City of Hope, Duarte, CA

P280 Melanoma Quality Assessment Program in a Community Hospital Setting
Barrett Kielhorn, Metro Health Hospital, Grand Rapids, MI

P281 Key Gaps in Pathologic Reporting for Appendiceal Mucinous Neoplasms: Time for Universal Synoptic Reporting?
Eisar Al-Sukhni, Roswell Park Cancer Institute, Buffalo, NY

P282 Differences in Psychosocial Distress Screening Scores Between Black and White Cancer Patients
Jennifer Keller, Saint Louis University School of Medicine, Saint Louis, MO
P283 Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the U.S.
Mohamed Abdelgadir Adam, Duke University Medical Center, Durham, NC

P284 Outcomes After Pelvic Exenteration: Do Positive Margins Matter? A Multidisciplinary Cohort of Patients at Two Institutions
Mio Kitano, The Ohio State University Wexner Medical Center, Columbus, OH

P285 Current Trends in Diagnosis and Treatment of Merkel Cell Carcinoma Based on T Stage
Jing Li, Main Line Health, Philadelphia, PA

P286 Has Regionalization of Cancer Surgery in the United States Influenced Access to Care?
Nabil Wasif, Mayo Clinic in Arizona, Phoenix, AZ

P287 Surgery for Gastric Cancer is Poorly Centralized
Michael McCall, University of Calgary, Calgary, AB, Canada

P288 A New Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement to Improve Local Control During Close R0 and R1 Resections
Erika Simmerman, Georgia Regents University Medical Center, Augusta, GA

P289 Extent and Impact of Colorectal Cancer Surgery Regionalization in Canada
Richard Liu, Dalhousie University, Halifax, NS, Canada

P290 Improved Survival in Patients with Hepatocellular Carcinoma at Higher Volume Hospitals
Ali Mokdad, University of Texas Southwestern, Dallas, TX

P291 Infectious Complications Following Colorectal Cancer Surgery are Associated with Worse Long-term Survival
Ali Mokdad, University of Texas Southwestern, Dallas, TX

P292 Increases in the Global Incidence of Young Adult Colorectal Cancer (YA CRC) Pose Critical Challenges for the International Surgical Oncology Community
Joie Singh, State University of New York Health Sciences Center, Brooklyn, NY

P293 Missed Opportunity: Atypical Hyperplasia and Low Rates of Chemoprevention in the Community Cancer Center Experience
Ashley Tameron, TriHealth-Good Samaritan Hospital, Cincinnati, OH
P294 Indications for Readmission Following Mastectomy for Breast Cancer: An Assessment of Patient and Operative Factors
Jennifer Yu, Washington University School of Medicine, St. Louis, MO

P295 Accuracy of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Predicting Node Positivity and Metastatic Disease in Patients with Gastrointestinal Malignancies
Kenneth Meredith, Florida State University, SMH Campus, Sarasota, FL

P296 Fall Risk as a Predictor of Failure to Rescue After Palliative Surgery for Advanced Cancer
Andrew Blakely, Brown University/Rhode Island Hospital, Providence, RI

P297 Surrogate Indicators of Surgical Quality are Associated with Survival Following Treatment for Hepatocellular Carcinoma
David Roife, UTHealth, Houston, TX

P298 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can be Used to Predict Recurrences for All Gastrointestinal Malignancies
Kenneth Meredith, Florida State University, SMH Campus, Sarasota, FL

P299 Shaping Future Surgical Oncologists: Robotic Exposure During Surgical Oncology Fellowship is the Most Significant Predictor of Robot Use in Practice
Federico Tozzi, City of Hope, Duarte, CA

P300 Underutilization of Palliative Care Consultations in Patients with Hepatobiliary Malignancies
Bridget Fahy, University of New Mexico, Albuquerque, NM

Sarcoma Cancer Posters

P301 Genomic Alterations in Cancer Stem Cell Marker CD44 Predict Oncologic Outcome in Soft Tissue Sarcoma
Timothy Henderson, University of Vermont College of Medicine, Burlington, VT

P302 Radiation Independently Improves Survival for Patients with Early Stage Adult-type Soft Tissue Sarcoma and Positive Margins
Briana Lau, John Wayne Cancer Institute, Santa Monica, CA

P303 Surgical Resection of Recurrent Leiomyosarcoma of the Retroperitoneum May be Beneficial
Naruhiko Ikoma, MD Anderson Cancer Center, Houston, TX
P304 Surgical Management of Patients with Recurrent or Intra-Abdominal Metastatic GIST Following Neoadjuvant Tyrosine Kinase Inhibitor Therapy: Who is Benefiting?
Christina Roland, University of Texas MD Anderson Cancer Center, Houston, TX

P305 Effect of Intraoperative Radiotherapy in the Treatment of Retroperitoneal Sarcoma
Liz Wang, Boston University School of Medicine, Boston, MA

P306 Inguinal Liposarcoma: Is Local Resection Alone Adequate?
Travis Grotz, MD Anderson Cancer Center, Houston, TX

P307 Adherence to Stage-Specific Treatment Guidelines for Stages IIA & IIB/III Extremity and Trunk Soft Tissue Sarcoma is Associated with Superior Survival
Rachel Voss, MD Anderson Cancer Center, Houston, TX

P308 Differential miRNA Expressions Between Gastric and Metastatic Liver Gastrointestinal Stromal Tumors
Hirotoshi Kikuchi, Hamamatsu University School of Medicine, Hamamatsu, Japan

P309 Programmed Death Ligand-1 (PD-L1) Expression and Prognostic Value in Synovial Sarcoma
Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

P310 CT Scan as Single Modality, Cost-effective Surveillance Imaging for High-risk Extremity Soft Tissue Sarcomas
Allison Maciver, Roswell Park Cancer Institute, Buffalo, NY

P311 Pathologic Fracture in Childhood and Adolescent Osteosarcoma: A Single Institution Experience
Lindsay Haynes, St. Jude Children’s Research Hospital, Memphis, TN

P313 When Combined with Resection, Radiation Does Improve Survival in Retroperitoneal Sarcoma
Sinziana Dumitra, City of Hope, Pasadena, CA

P314 Disparities in Amputation Rates for Non-Metastatic Extremity Soft Tissue Sarcomas and the Impact on Survival
Trevan Fischer, John Wayne Cancer Institute, Santa Monica, CA
Thoracic/Eosophageal Cancer Posters

P316 Nuclear Notch1 Expression is Associated with Treatment Failure and Predicts Prognosis in Patients with Esophageal Squamous Cell Carcinoma
Yoshiaki Kita, Kagoshima University, Kagoshima, Japan

P317 Timing of Esophagectomy After Neoadjuvant Chemoradiation Therapy Affects Clinically Significant Anastomotic Leak Rates
Simon Roh, University of Iowa Hospitals and Clinics, Iowa City, IA

P318 Transthoracic Anastomotic Leak After Esophagectomy: No Longer a Catastrophe
Carrie Ryan, University of South Florida Morsani College of Medicine, Tampa, FL

P319 Does Minimally Invasive Esophagectomy Provide a Benefit Over Open Esophagectomy? A Study of the National Inpatient Sample
Ryan Erwin, Geisinger Medical Center, Danville, PA

P320 Effectiveness of Repeat Positron Emission Tomography Scan in Accurately Detecting Disease Progression After Neoadjuvant Chemoradiation for Esophageal Cancer
Emmanuel Gabriel, Roswell Park Cancer Institute, Buffalo, NY

P321 Pre-Neoadjuvant Therapy Clinical Staging Predicts Overall Survival in Esophageal Cancer Patients with Pathologic Complete Response
Alexandra Gangi, Moffitt Cancer Center, Tampa, FL

P322 Is Chemical Pyloroplasty Necessary for Minimally Invasive Esophagectomy?
Camille Stewart, University of Colorado School of Medicine, Aurora, CO

P323 Accuracy of Clinical Staging with EUS for Early Stage Esophageal Cancer: Are We Denying Patients Beneficial Neoadjuvant Therapy?
Carrie Luu, Moffitt Cancer Center, Tampa, FL

P324 Anti-Inflammatory Effect of Alpha-Lypoic Acid Derivative on Acute Lung Injury
Yoshiaki Shoji, Keio University, School of Medicine, Tokyo, Japan

P325 Near-Infrared Intraoperative Molecular Imaging Identifies Mesothelioma During Pleurectomy
Jane Keating, University of Pennsylvania, Philadelphia, PA
P326 Small Caliber Covered Self Expanding Metal Stents in the Management of Malignant Dysphagia
Kenneth Meredith, Florida State University, Sarasota, FL

P327 Readmission After Robotic Ivor Lewis Esophagectomy: Earlier Discharge, Increased Readmissions?
Kenneth Meredith, Florida State University, SMH Campus, Sarasota, FL

P328 The Effect of Neoadjuvant Therapy on the 30-Day Morbidity and Mortality of Esophageal Cancer: A Multicenter Study
Michel Sabra, University of Florida, Jacksonville, FL

P329 The Concentration of PD-L1 in the Peripheral Blood is a Prognostic Biomarker for Esophageal Squamous Cell Carcinoma
Yasunori Akutsu, Chiba University, Chiba, Japan

P330 Survival Rates After Surgery for Stage-3A (N2) Non-Small Cell Lung Cancer with Induction Versus Adjuvant Chemotherapy +/- Radiation Therapy
Eric Toloza, Moffitt Cancer Center, Tampa, FL

Upper Gastrointestinal Cancer Posters

P331 Protein Arginine Methyltransferase 5 Promotes Peritoneal Metastasis of Gastric Cancer Cells
Kazuhiro Ezaka, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

P332 The Non-T Cell-Inflamed Tumor: A Model for Pancreatic Cancer
Kinga Skowron, University of Chicago Medicine, Chicago, IL

P333 Role of Myeloid Derived Suppressor Cells in the Inflammatory Response of Pancreatitis and Pancreatic Cancer
Napoleon Cieza Rubio, University of Arizona, Tucson, AZ

P334 γδ T-Cells Support Pancreatic Oncogenesis by Inducing αβ T Cell Exhaustion
Donnele Daley, New York University School of Medicine, New York, NY

P335 Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Diffuse-Type Gastric Adenocarcinoma
Kevin Chang, Memorial Sloan Kettering Cancer Center, New York, NY
P336  Symptomatic Presentation as a Predictor of Recurrence in Gastroenteropancreatic Neuroendocrine Tumors: A Single Institution Experience Over 15 Years
Gillian Baptiste, Winship Cancer Institute, Emory University, Atlanta, GA

P337  Noninvasive Markers Can Predict Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas
Sonia Orcutt, Moffitt Cancer Center, Tampa, FL

P338  Impact of Minimally Invasive Gastrectomy on Use and Time to Adjuvant Chemotherapy for Adenocarcinoma
Chad Gonczy, Duke University Hospital, Durham, NC

P339  C6 Ceramide Potentiate Chemotoxicity of Gemcitabine Against Chemo Resistant Pancreatic Cancer Cell Lines
Harold Wanebo, Roger Williams Medical Center, Providence, RI

P340  Survival Impact of Neoadjuvant Therapy in Resected Pancreatic Cancer
Katelin Mirkin, Penn State Medical Center, Hershey, PA

P341  Vaccination Enhances Anti-tumor immunity in Pancreatic Adenocarcinoma Following Repolarization of the Tumor Microenvironment with CCR2 Blockade
Darren Cullinan, Washington University in Saint Louis, Saint Louis, MO

P342  Auranofin Prevents Progression of Human Pancreatic Ductal Adenocarcinoma
Mayrim Rios Perez, MD Anderson Cancer Center, Houston, TX

P343  The Mechanisms Acquiring Drug Resistance through the Exosome-Mediated Cell-Cell Interaction in Pancreatic Ductal Adenocarcinoma
Manabu Mikamori, Osaka University, Suita-shi, Osaka, Japan

P344  Adjuvant (AD) Radiotherapy (RT) Does Not Improve Outcomes Following Pancreatectoduodenectomy (PD) for Pancreatic Adenocarcinoma (PDA): A Margin-Stratified Analysis
Lee Ocuin, University of Pittsburgh Medical Center, Pittsburgh, PA

P345  Noninvasive Monitoring of Patient-Derived Orthotopic Xenograft: An Optimal System for Rapid In Vivo Testing
Mayrim Rios Perez, MD Anderson Cancer Center, Houston, TX
P346  A Multicenter Study of 349 Pancreatic Mucinous Cystic Neoplasms: Preoperative Risk Factors for Adenocarcinoma
Lauren Postlewait, Winship Cancer Institute, Emory University, Decatur, GA

P347  Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer by Textural Features Derived from Pretreatment FDG-PET Scans
John Plukker, University Medical Center Groningen, Groningen, Netherlands

P348  Pancreaticoduodenectomies with Venous Reconstruction Do Worse than Standard Pancreaticoduodenectomies
Bryan Goldner, City of Hope National Medical Center, Duarte, CA

P349  The Role of mTOR Inhibitors in Targeting a Putative Cancer Stem Cell-like Population in Esophageal Cancer
Da Wang, University Medical Center Groningen, Groningen, Netherlands

P350  Functional Screens for Gene Drivers of Pancreatic Cancer
Nicole Villafane, Baylor College of Medicine, Houston, TX

P351  EUS Complements CT in Predicting SMV/ PV Resection in Patients with Borderline Resectable Pancreatic Carcinoma
Evan Glazer, Moffitt Cancer Center, Tampa, FL

P352  Pancreatic Neuroendocrine Tumors: Degree of Cystic Component Influences Prognosis
Jordan Cloyd, Stanford University, Houston, TX

P353  Diagnostic Potential of Mucins in Pancreatic Juice for Pancreatic Cancer
Asish Patel, University of Nebraska Medical Center, Omaha, NE

P354  Effect of Incorporation of Pretreatment Serum Carbohydrate Antigen 19-9 into AJCC Staging for Pancreatic Adenocarcinoma
Mark Healy, University of Michigan, Ann Arbor, MI

P355  Multivisceral Resection for Gastric Cancer is Associated with Increased Morbidity and Mortality
Ann-Kristin Friedrich, University of Massachusetts, Southborough, MA

P356  Resident Liver Macrophages Suppress Outgrowth of Occult Liver Metastases and Prolong Survival in a Preclinical Mouse Model of Pancreatic Cancer
Timothy Newhook, University of Virginia, Charlottesville, VA
P357 Targeting Granulocytic Myeloid Derived Suppressor Cells Promotes Anti-Tumor Immunity in Pancreas Adenocarcinoma
Timothy Nywening, Washington University, St Louis, MO

P358 Irreversible Electroporation for the Treatment of Locally Advanced and Unresectable Pancreatic Cancer: One Institution’s Experience
Katherine Poruk, Johns Hopkins School of Medicine, Baltimore, MD

P359 Disparities in the Utilization of Multimodal Therapy for Gastric Cancer: Exploring the National Cancer Data Base
Kathryn Jaap, Geisinger Medical Center, Danville, PA

P360 Trends and Predictors of Multimodal Therapy for Gastric Cancer Using the National Cancer Data Base
Ryan Erwin, Geisinger Medical Center, Danville, PA

P361 Is Preoperative Chemoradiation Necessary for Borderline Resectable Pancreatic Cancer (BRPC)?: Clinical and Surgical Outcomes Associated with Neoadjuvant FOLFIRINOX Alone in BRPC
Sunhee Kim, University of California, San Francisco, San Francisco, CA

P362 A Multi-Institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis
Georgios Antonios Margonis, The Johns Hopkins University School of Medicine, Baltimore, MD

P364 Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-Volume Centers
Michael Lidsky, Duke University, Durham, NC

P365 Early and Long-term Outcomes of Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy and D2-Lymphadenectomy: A Comparative Study
Felipe J.F. Coimbra, A. C. Camargo Cancer Center, Sao Paulo, Sao Paulo, Brazil

P366 Development of a Prognostic Gene Expression Profile (GEP) Signature in Patients with Localized Esophageal Cancer (EC) Receiving Preoperative Chemoradiation (CTRT)
Danica Giugliano, Thomas Jefferson University, Philadelphia, PA

P367 Pancreaticoduodenectomy for Metastatic Pancreatic Neuroendocrine Tumor
Richelle Williams, Dana-Farber/Partners Cancer Care, Boston, MA
P368 Oncologic Outcomes of Patients with Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Gemcitabine-Based Chemoradiation: A 10-Year Experience
Raphael Louie, Dartmouth-Hitchcock Medical Center, Lebanon, NH

P369 Distal Pancreatectomy for Benign and Low-grade Malignant Tumors: The Importance of Spleen Preservation on Short-term Postoperative Outcomes. A Systematic Review and Update Meta-analysis
Danny Yakoub, University of Miami, Miami, FL

P370 Palliative Pancreaticoduodenectomy for Metastatic Pancreatic Adenocarcinoma is Associated with Excessive Postoperative Mortality
Richelle Williams, Dana-Farber/Partners Cancer Care, Boston, MA

P371 Pancreatic Neck/Body Benign and Low Grade Malignant Tumors: Is Central Pancreatectomy Better than Distal Pancreatectomy? An Update Meta-analysis
Danny Yakoub, University of Miami, Miami, FL

P372 Lymph Node Status and Patterns of Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma
Roi Weiser, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P373 Peritoneal Carcinomatosis of Gastric Cancer: The Microenvironment as a Potential Target for Therapy
Guy Lahat, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

P374 Erasing Site-specific Variation in Pancreatic Cancer Survival
Gyulnara Kasumova, Beth Israel Deaconess Medical Center, Boston, MA

P375 Overall Survival After Surgical Resection of Diffuse Type Gastric Adenocarcinoma is Equivalent in Caucasians and Asians
Michael Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

P377 Indeterminate Nodules in Pancreatic Adenocarcinoma: Are CT Scans of the Chest Necessary?
Winta Mehtsun, Massachusetts General Hospital, Boston, MA

P378 Outcomes of Surgical Intervention in Gastric Carcinoid Disease
Ann Falor, City of Hope Medical Center, Duarte, CA
P379  Pancreatic Neuroendocrine Tumors (PNETs): Survival Analysis Comparing Surgical Resection Versus Non-Surgical Management
Paige Finkelstein, University of Miami, Miami, FL

P380  The Value of Endoscopic Ultrasonography in a PET/CT Upfront Model in Staging Esophageal Cancer with Respect to Treatment Decision
Jan Binne Hulshoff, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

P381  Smoking Results in Distinct Alterations in Gene Expression and Upregulation of Protein Sialylation in Pancreatic Cancers
Matthew Mullen, University of Virginia, Charlottesville, VA

P382  Regional Therapy for Isolated Peritoneal Metastases from Small Bowel and Upper Gastrointestinal Malignancies
Deepa Magge, University of Pittsburgh Medical Center, Pittsburgh, PA

P383  Does Age Matter in Morbidity Following Gastric Cancer Resection? An ACS-NSQIP Analysis
Trevor Hamilton, Vancouver General Hospital, Vancouver, BC, Canada

P384  The Role of Staging Laparoscopy in Patients with Pancreatic Adenocarcinoma: Withstanding the Test of Time?
Zhi Ven Fong, Massachusetts General Hospital, Natick, MA

P385  Lymphovascular Invasion: An Underappreciated Prognostic Factor in Pancreatic Cancer
Jeffrey Epstein, Sidney Kimmel Medical College at Thomas Jefferson University, Oakhurst, NJ

P386  Neoadjuvant Chemoradiotherapy Versus Surgery in Gastric and Gastroesophageal Junction Cancer: A Single Institutional Review
David Baltrusaitis, Medical College of Wisconsin, Milwaukee, WI

P387  Time to Initiation of Adjuvant Chemotherapy Does Not Impact Survival in Resected Pancreatic Cancer
Katelin Mirkin, Penn State Hershey Medical Center, Hershey, PA

P388  The Necrosome Promotes Pancreatic Oncogenesis via CXCL1 and Mincle-Induced Immune Suppression
Gregor Werba, NYU Langone Medical Center, New York, NY

P389  HER Family Receptor Expression in Esophagogastroduodenal Tumorigenesis
Brett Ecker, University of Pennsylvania, Philadelphia, PA
P390  Lymph Node Evaluation and Survival After Curative Resection of Small Bowel Adenocarcinoma
Brett Ecker, University of Pennsylvania, Philadelphia, PA

P391  Differences in Pancreatic Surgery Management and Techniques: A Nationwide Multi-Institutional Survey
Muhammad Butt, Methodist Dallas Medical Center, Dallas, TX

P394  The Effect of Treatment Facility Type on Overall Survival in Surgically Treated Pancreas Cancer
Alessandro Paniccia, University of Colorado, Aurora, CO

P395  Patient-derived Xenograft (PDX) Models are Indispensable for Newly Discovered Patient Subtypes of Pancreatic Adenocarcinoma (PDAC)
Chelsea Becker, UNC-Chapel Hill, Carrboro, NC

P396  FOLFIRINOX and Gemcitabine/nab-Paclitaxel Demonstrate Improved Survival in Locally Advanced Unresectable Pancreatic Adenocarcinoma
Filip Bednar, University of Pittsburgh, Pittsburgh, PA

P397  Factors Leading to Omission of Adjuvant Therapy After Pancreatoduodenectomy: An Argument Against a Surgery-First Approach
Brent Xia, University of Cincinnati, Cincinnati, OH

P398  Yield of Staging Laparoscopy in Gastric Cancer
Naruhiko Ikoma, MD Anderson Cancer Center, Houston, TX

P399  Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation Among Patients with Resected Pancreatic Head Adenocarcinoma
Jan Franko, Mercy Medical Center, Des Moines, IA

P400  Actual 5-Year Long-term Nutritional Outcomes After Curative Gastrectomy in Gastric Cancer Patients
Do Joong Park, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-go, The Republic of Korea

P401  Cojugated Bile Acid Promote the Proliferation of Pancreatic Cancer via Sphingosine 1-Phosphate Receptor
Kazuaki Takabe, Virginia Commonwealth University, Richmond, VA
P402 Diagnosed in the Emergency Department: The Impact of Presenting Location on Outcomes for Gastric Cancer Patients
Ian Solsky, Montefiore Medical Center, Bronx, NY

P403 Race is a Risk for Lymph Node Metastasis in Early T Stage Gastric Cancer
Naruhiko Ikoma, MD Anderson Cancer Center, Houston, TX

P404 Staging Laparoscopy is Essential to Accurately Stage Gastric Cancer in Hispanic and African American Patients
Ibrahim Nassour, University of Texas Southwestern, Dallas, TX

P405 Inflammation Induced by Sphingosine Kinase of the Host Aggravates Pancreatic Cancer Peritoneal Carcinomatosis
Kazuaki Takabe, Virginia Commonwealth University, Richmond, VA

Other: Urology/Head & Neck Cancer Posters

P406 Field Change in Synchronous and Metachronous Squamous Cell Carcinomas: The Two Face Janus of Susceptibility
Chin-Ann Ong, Singapore General Hospital, Singapore, Singapore

P407 Tumour Markers in CRS-HIPEC Patients: An Analysis of 157 Patients in a Single Institution
Marianne Chee, Singapore General Hospital, Singapore, Singapore

P408 Clinical Profile, Treatment Patterns and Outcomes in Locally Advanced and Recurrent Orbital Tumors from a Tertiary Care Cancer Centre
Vinaya Kumar, All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, India

P409 Multimodality Therapy for Peritoneal Metastases from Epithelial Ovarian Cancer
Deepa Magge, University of Pittsburgh Medical Center, Pittsburgh, PA
DISCLOSURE POLICY AND DISCLOSURES

In accordance with the ACCME’s Accreditation Criteria and the Society of Surgical Oncology (SSO) policy, all educational planners, presenters, instructors, moderators, authors, reviewers and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily effect the opinions of the SSO.

All identified conflicts of interest have been resolved.

The following faculty, moderators, planners, reviewers and staff have disclosed financial relationships with commercial interests:

Adam Bass, MD
Advisory Board: Strand Life Science; Research: Onkaido, Sanofi

Murray F. Brennan, MD
Consultant: HemoShear, LLC; Research: Tau Therapeutics, LLC; Stocks - iTi Health, Inc.
George Chang, MD, MS
Consultant: Johnson & Johnson; Research: Agendia

Steven L. Chen, MD
Consultant: WL Gore; Employee: Avelas Biosciences (Spouse - Philips Electronics); Other: Genomic Health training compensation; Stocks: Avelas Biosciences

Luis A. Diaz, Jr., MD
Consultant; Merck; Employee: Johns Hopkins, Personal Genome Diagnostics; Stocks: Personal Genome Diagnostics and Pappgene, Inc.

Keith T. Flaherty, MD
Consultant: Novartis, GSK, Roche, Merck; Research: Novartis

Yuman Fong, MD
Consultant: Medtronic, Johnson and Johnson, Amgen, Baxter, Genelux, Perfint

Judy E. Garber, MD, MPH
Consultant: Pfizer, Sequenom (Spouse - Pfizer, Novartis, SV Life Sciences); Research: Myriad Genetics (Spouse - Novartis)

Jeffrey E. Gershenwald, MD
Advisory Board: Merck; Other: License - Mercator Therapeutics

Ricardo Gonzalez, MD
Speaker Honorarium: Novartis Pharmaceuticals

David Gyorki, MBBS, MD
Advisory Board: Amgen; Research: Amgen

Francis J. Hornicek, Jr., MD, PhD
Advisory Board: Desmoid Tumor Research Foundation; FDA; ISOLS; AATB; Consultant: Stryker Corporation; Research: NIH (U01); Grant: NIH; SARC SPORE

Kevin S. Hughes, MD
Other: Kevin S. Hughes, MD is a founder of and has a financial interest in Hughes Risk Apps, LLC. Dr. Hughes’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies; Speaker Honorarium: Myriad Genetics Speaker’s Bureau; Stocks; 5 AM Solutions (Health Care IT Company)

Adam S. Kibel, MD
Advisory Board: Dendreon, Sanofi Aventis, MTG, Profound, Medivation

* = Planners and Reviewers  § = Moderators
Henry M.  Kuerer, MD, PhD  
Advisory Board: Lightpoint Medical, Inc.; Grant: National Cancer Institute; Genomic Health, Inc.; Other: Royalties - McGraw-Hill Professional; UpToDate, Inc.; Speaker Honorarium: Physicians’ Education Resource, LLC

Matthew H. Kulke, MD  
Consultant: Ipsen, Novartis

§ David C. Linehan, MD  
Research: Pfizer Oncology

§ Kelly M. McMasters, MD, PhD  
Advisory Board: Provectus, Board of Directors: Board Compensation

Funda Meric-Bernstam, MD  
Advisory Board: Inflection Biosciences, Genentech; Consultant: Genentech, Novartis, Roche, Celgene; Grant: Novartis, AstraZeneca, Taiho, Genentech, Calithera, Debiopharma, Bayer; Honoraria: Genentech, Roche Diagnostics

Rodney F. Pommier, MD  
Advisory Board: Novartis Oncology; Consultant: Novartis Oncology; Speaker Honorarium: Novartis Oncology

Chandrajit P. Raut, MD  
Other: UpToDate/Wolter Kleuwers – Spouse is a gastroenterologist/editor

Mitsuru Sasako, MD  
Advisory Board: Ohtsuka Pharmaceutical; Research Taiho Pharmaceutical; Yakult Pharmaceutical; Speaker Honorarium: Taiho Pharmaceutical, Chugai Pharmaceutical, Lilly, Sanofi, Covidien Japan

*§ Richard D. Schulick, MD, MBA  
Other: Co-Inventor of patient licensed to Aduro Biotech and managed by Johns Hopkins University

Helen A. Shih, MD  
Other: Editor - International Journal of Radiation Oncology*Biology*Physics

Vernon K. Sondak, MD  
Consultant: Merck, OncoSec, Polynoma, Genentech/Roche, Navidea, Amgen, Provectus, Bristol-Myers Squibb, Glaxo Smith-Kline, Novartis; Other: DSMB: Bristol-Myers Squibb Glaxo Smith-Kline, Novartis

Sano Takeshi, MD  
Speaker Honorarium: Taiho Pharma; Chugai Roche; Yakult; Eli Lilly; Ethicon; Covidien; Olympus

* = Planners and Reviewers  § = Moderators
John F. Thompson, MD
Advisory Board: GSK; Proventus, BMS; Grant: Melanoma Foundation of University of Sydney; National Health and Medical Research Council of Australia

M. Eileen Widmer, CAE, CFRM (Staff)
Stocks: Amgen, Medtronic

Shawna C. Willey, MD
Advisory Board: BioPharmXi; Speaker Honorarium: Genomic Health; Medtronic; Genentech; Invuity; Stocks: Options-Invuity

Linwah Yip, MD
Consultant: Emmi Solutions; Other: Contributor for UptoDate

* § Jonathan S. Zager, MD
Advisory Board: Amgen, Delcath Medical, Castle Biosciences; Consultant: Amgen, Castle Biosciences; Grant: Delcath Medical; Research Funding: Proventus

The following faculty, moderators, planners, reviewers and staff have no relevant financial relationships to disclose:

H. Richard Alexander, Jr., MD
* Peter J. Allen, MD
Benjamin O. Anderson, MD
Cletus A. Arciero, MD
Riccardo A. Audisio, MD
* § Brian D. Badgwell, MD, MS
* § Andrea Barrio, MD
David L. Bartlett, MD
Edmund K. Bartlett, MD
Georgia Beasley, MD
Isabelle Bedrosian, MD
* § Adam C. Berger, MD
* § Karl Y. Billimoria, MD, MS
* Dan Blazer, MD
* Cherif Boutros, MD, MSc
Beth Boyd, RN
* § Glenda G. Callender, MD
* § Robert J. Canter, MD
* § Kenneth Cardona, MD
Ned Z. Carp, MD
§ Anees B. Chappar, MD
Dennis S. Chi, MD
Jessica A. Cinto

* § Io-Gonzalez, MD
Thomas Clancy, MD
Natalie G. Coburn, MD, MPH
Hiram S. Cody, III, MD
* § Daniel G. Coit, MD
* § Aimee M. Crago, MD, PhD
Charmaine Cummings, PhD, RN, CHCP
(Staff)
Steven A. Curley, MD
* § Brian J. Czerniecki, MD, PhD
Michael I. D’Angelica, MD
Giovanni De Manzoni, MD
Conor P. Delaney, MD, PhD
Keith A. Delman, MD
Rebecca M. Dodson, MD
Ismael Dominguez-Rosado, MD
* Laura Dominici, MD
* § Jeffrey A. Drebin, MD, PhD
Laura J. Esserman, MD, MBA
Douglas B. Evans, MD

* = Planners and Reviewers
§ = Moderators
Mark B. Faries, MD
* § Ryan C. Fields, MD
* § Richard E. Fine, MD
* Declan Fleming, MD
Julio García-Aguilar, MD, PhD
William E. Gillanders, MD
Mark Gittleman, MD
* Melanie Goldfarb, MD
* Santiago Gonzalez-Moreno, MD, PhD
Stephen R. Grobmyer, MD
Alessandro Gronchi, MD
* Dale Han, MD
* § Nora M. Hansen, MD
Ashley Hardy, MD
Ronda S. Henry-Tillman, MD
Theodore S. Hong, MD
* Susan Hoover, MD
* Marissa Howard-McNatt, MD
* James R. Howe, MD
Karen Hurley, MA (Staff)
David P. Jaques, MD
William R. Jarnagin, MD
* Brian Kaplan, MD
Matthew H.G. Katz, MD
* Electron Kebebew, MD
* § Mark Kelley, MD
* Sajid Khan, MD
* Lawrence Kim, MD
Hyung-Ho Kim, MD, PhD
Troy F. Kimsey, MD
V. Suzanne Klimberg, MD
Kazuyuki Kojima, PhD
Russell C. Langan, MD
Jeffrey E. Lee, MD
Augusto Leon, MD
Steven K. Libutti, MD
Keith D. Lillemoe, MD
Shishir Maithel, MD
* § Ajay Maker, MD
* Gary Mann, MD
* John Mansour, MD
Robert C.G. Martin, II, MD, PhD
Anne Mattingly, MD
* Dave McFadden, MD
* Kandace McGuire, MD
* Daniel P. McKellar, MD
* § Sarah McLaughlin, MD
* Marcovalerio Melis, MD
* Jane Mendez, MD
* § Nipun B. Merchant, MD
* § Jeffrey Moley, MD
* Marc Moncrieff, MD
* Monica Morrow, MD
* Ana Olivares, BS (Staff)
T. Salewa Oseni, MD
Ann Partridge, MD
* Kepal N. Patel, MD
* Timothy M. Pawlik, MD, MPH, PhD
Christopher Pezzi, MD
Raphael E. Pollock, MD, PhD
* § Mitchell C. Posner, MD
* Peter A. Prieto, MD, MPH
* Christopher Puleo, PA-C
* Jenny Ramion, BS (Staff)
* Abram Recht, MD
* Sanjay Reddy, MD
* Christina Roland, MD
* Sean Ronnekleiv-Kelly, MD
* Steven A. Rosenberg, MD, PhD
* § Robert E. Roses, MD
* Julie Rossberger (Staff)
* David P. Ryan, MD
* Rabih Salloum, MD
* § Randall P. Scheri, MD
* § Charles B. Scoggins, MD
* Surupa Sen Gupta, MD
* § David Shibata, MD
* Allan E. Siperstein, MD
* Rebecca S. Sippel, MD
* Barbara L. Smith, MD, PhD
* § Carmen C. Solorzano, MD
* Francis R. Spitz, MD
* Patti Stella, CHCP (Staff)

* = Planners and Reviewers  § = Moderators
All identified conflicts of interest have been resolved.

The following oral abstract and video abstract main authors, presenters and moderators have disclosed relevant financial relationships with commercial interests:

**Robert Andtbacka, MD**
Advisory Board: Amgen, Merck

**§ Giorgos Karakousis, MD**
Consultant: Amgen, Castle Biosciences

**§ David C. Linehan, MD**
Research: Pfizer Oncology

**Anthony Lucci, MD**
Consultant: Genomic Health

**§ Julie A. Margenthaler, MD**
Speaker Honorarium: Myriad, Genentech

The following oral and video presenters and moderators have reported that they have no relevant financial relationships with commercial interests to disclose:

- Kelvin Allenson, MD
- Neda Amini, MD
- Angel Arnaout, MD
- Sanjay Bagaria, MD
- **§ Andrea Barrio, MD**
- Megan Beems, MD
- Nicholas Berger, MD
- Aaron Blackham, MD
- Cindy Boulanger-Gobeil, MD
- Brandon
- Chapman, MD
- Leonid
- Cherkassky, MD

-Akiko Chiba, MD
-Kevin Choong, MD
-Oliver Chow, MD
-Ioannis Christakis, MD
-Brian Chu, MD
-Callisia Clarke, MD
-Jordan Cloyd, MD
-Claudius Conrad, MD
-Carlo Contreras, MD
-Patricia Cronin, MD
-Samantha
-Damude, MD
-Jashodeep Datta, MD
-Jesse Davidson, MD

* = Planners and Reviewers  § = Moderators
Lucy De La Cruz, MD
Mashaal Dhir, MBBS
Mary Dillhoff, MD
Rebecca Dodson, MD
Lesly Dossett, MD
Nicolas Droppelmann, MD
Laura Enomoto, MD
Cecilia Ethun, MD
Mark Fairweather, MD
Emmanuel Gabriel, MD
Julie Hallet, MD
§ Ho-Seong Han, MD, PhD
*§ Nora M. Hansen, MD
Mark Hardin, MD
Michael Henderson, MD
Jenny Hong, MD
Jung-Jyh Hung, MD
Kelly Huynh, MD
Kamran Idrees, MD
Doreen Jackson, MD
§ James W. Jakub, MD
Maris Jones, MD
Stephen Jones, MD
§ John M. Kane, MD
Olga Kantor, MD
Kendall Keck, MD
*§ Mark Kelley, MD
Colleen Kiernan, MD
Yuhree Kim, MD
§ T. Peter Kingham, MD
Mio Kitano, MD
§ David Kooby, MD
David Lee, MD
Andrew Loehr, MD
Lea Lowenfeld, MD
*§ Ajay V. Maker, MD
Anita Mamtani, MD
Nicholas Manguso, MD
Meredith Mason, MD
*§ Sarah A. McLaughlin, MD
Herniberto Medina-Franco, MD
*§ Marcovalerio Melis, MD
Daniel Mercante, BS
*§ Nipun B. Merchant, MD
Alex Michaels, MD
Vladimir Milovanov, MD
Subhasis Misra, MBBS
Elizabeth Mittendorf, MD, PhD
*§ Jeffrey Moley, MD
Martine Mooserdorff, MD
Tricia Moo-Young, MD
Brittany Murphy, MD
§ Garrett Nash, MD
Hari Nathan, MD
Lisa Newman, MD
Eran Nizri, MD
Daniel Nussbaum, MD
Maureen O'Donnell, MD
Kerris Ohman, MD
Go Oshima, PhD
Sameer Patel, MD
Melissa Pilewskie, MD
Patricio Polanco, MD
§ Mitchell C. Posner, MD
Lauren Postlewalt, MD
Carlos Puig, MD
Claudio Quadros, MD
Akshara Singareeka Raghavendra, MD
Rahul Rajeev, MBBS
Ulysses Ribeiro, MD, PhD
J. Bart Rose, MD
Eran Sadot, MD
Sukamal Saha, MD
Pablo Serrano Aybar, MD
Rupen Shah, MD
*§ David Shibata, MD
Geert Simkens, MD
Brittany Splittgerber, MD
Jamii St. Julien, MD
Camille Stewart, MD
Matthew Strand, MD
*§ Sonia Sugg, MD
Kazuki Takabe, MD
Julia Terhune, MD
Federico Tozzi, MD
Melanie Tsang, MD
*§ Jennifer Tseng, MD
Ana Velez, MD
Amy Voci, DO
Elvira Vos, MD
Timothy Vreeland, MD
*§ Sharon M. Weber, MD
Michael White, MD
§ Sandra L. Wong, MD, MS
* Heather Yeo, MD
Linda Youngwright, MD

* = Planners and Reviewers  § = Moderators
INDUSTRY FORUM
Genentech
Preoperative Multidisciplinary Considerations for HER2+ Breast Cancer
6:45–7:45 am, Thursday, March 3
Room 206
Breakfast Provided

Presenter: Helen Pass, MD, Women’s Breast Center, Stamford Hospital

Executive Summary:
Multidisciplinary presentation on identification and treatment of HER2+ Breast Cancer in the neoadjuvant setting; includes 2 patient case examples.
Effective Acute Postsurgical Pain Control: The Importance of a Multimodal and Opioid-Reducing Regimen
3-3:45 pm, Thursday, March 3
Exhibit Hall Theater, Exhibit Hall D

Presenter: Pedro T. Ramirez, MD, The University of Texas MD Anderson Cancer Center

Acute postsurgical pain can be a large source of fear for patients undergoing oncologic surgical procedures. Typically, patients undergoing these procedures are treated with copious amounts of opioids to control the acute postsurgical pain that occurs. For many patients, the potential side effects from opioids can be both annoying as well as life-threatening depending upon existing comorbidities. Many surgeons, along with medical societies and even the CDC, have recognized the contribution that opioids make to the current and outrageously large opioid epidemic in this country. This discussion will focus on the management of acute postsurgical pain employing a multimodal pain and opioid reducing regimen as well as the application of this premise in ERAS scenarios.

Amgen
Oncolytic Viral Therapy and Intralesional Injection: A Surgeon’s Perspective
12:30-1:15 pm, Friday, March 4
Exhibit Hall Theater, Exhibit Hall D
Lunch Provided

Presenter: Merrick I. Ross, MD, The University of Texas MD Anderson Cancer Center

This session will include a didactic presentation on the first and only FDA-approved Oncolytic Viral Therapy. The session will also include a demonstration of the intralesional injection technique for surgical oncologists.
GOT DATA?
Yes, we do.

Contact your local AngioDynamics Representative.

[VISIT US AT BOOTH #1024]

www.angiodynamics.com

The NanoKnife System is cleared in the United States for surgical ablation of soft tissue. It has not been approved for the treatment or therapy of any specific disease state. Indications, contraindications, warnings, precautions and instructions for use can be found in the Instructions for Use supplied with each device. Observe all instructions prior to use. Failure to do so may result in patient complications.

AngioDynamics, the AngioDynamics logo, NanoKnife and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. © 2016 AngioDynamics, Inc. ANGAD 105 GE Rev 01 01/16
EXHIBITS
The Exhibit Hall is located in Exhibit Hall D

Hours:
Thursday, March 3 11:45 am-8 pm
Friday, March 4 9:45 am-3:45 pm

Exhibit Hall Passport to Prizes
Visit SSO exhibitors to earn a chance to win exciting prizes! As you make your way through the Exhibit Hall talking with the exhibitors and visiting their booths, collect signatures on your Passport game card and enter to win.

View full details on page 16.

As of January 28, 2016

Exhibitors

Ambry Genetics  Booth 1008
15 Argonaut
Aliso Viejo, CA 92656
Phone: 866-262-7943; Fax: 949-900-5501
www.ambrygenetics.com

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Orange County, California. Ambry is a leader in providing genetic services focused on clinical diagnostics and genomic services, and has established a reputation for unparalleled customer satisfaction. To learn more, visit www.ambrygen.com.

Amgen  Booth 1210
One Amgen Center Drive
Thousand Oaks, CA 91320
Phone: 805-447-1000
www.amgen.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
AngioDynamics Inc.  
14 Plaza Drive  
Latham, NY 12110  
Phone: 518-795-1400; Fax: 518-798-1360  
www.AngioDynamics.com

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.

Annals of Surgical Oncology  
9525 W. Bryn Mawr Avenue, Suite 870  
Rosemont, IL 60018  
Phone: 239-217-0704  
@AnnSurgOncol Twitter

The Annals of Surgical Oncology (ASO) promotes high-quality surgical oncology management by communicating advances in research and education that are relevant and valuable to the provision of contemporary multidisciplinary care for patients with cancer. The official monthly journal of the Society of Surgical Oncology, ASO is the journal of choice of surgical oncologists worldwide regarding surgical oncology research and education.

Belmont Instrument Corporation  
780 Boston Rd.  
Billerica, MA 01821  
Phone: 978-663-0212-124; Fax: 978-663-0214  
www.belmontinstrument.com

The Belmont® Hyperthermia Pump is making hyperthermic therapy available for all patients. The affordable system uses patented electromagnetic induction technology precisely warms fluids to target temperature in a single pass. It is a safe, simple, efficient portable system. Belmont also offers the Belmont® Rapid Infuser and the Belmont buddy series of blood warmers.
For 30 years, BK Ultrasound has played a leading role in the development of surgical ultrasound imaging systems. With award-winning systems & advanced transducer designs, BK directly addresses the specialized needs & clinical challenges of oncological surgeons worldwide, offering unsurpassed imaging capabilities & enabling real-time image guidance with easy-to-use, state-of-the-art platforms. Visit us for a demonstration of the new bk5000 imaging platform & new surgical transducers.

Boiron, world leader in homeopathic medicines, is an $852 million public company with 3,700 employees and distribution in 59 countries. It is best known for Oscillococcinum®, a top-selling flu medicine, and its Arnica® line of pain relievers. For more than 80 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. As a pharmaceutical company, Boiron maintains the highest standards in manufacturing.

Cancer Treatment Centers of America is a national network of cancer treatment hospitals that offer a unique, whole-person approach to cancer treatment. Patients are surrounded by a care team that creates personalized treatment plans to specifically meet the needs of each individual patient. CTCA continuously updates treatment protocols to utilize the latest, best technology and the most recent, relevant clinical research on behalf of cancer patients.

Captive Risk Planners/Perfect Tax
Carl Zeiss Meditec, Inc.  
5160 Hacienda Drive  
Dublin, CA 94568  
Phone: 925-557-4854  
www.meditec.zeiss.com  

Carl Zeiss Meditec AG’s extensive portfolio encompasses the unique ZEISS INTRABEAM® Radiotherapy System for intraoperative radiotherapy. The ZEISS INTRABEAM Radiotherapy system provides additional radiotherapy options for a wide range of tumors as for example Breast cancer, Spinal Metastases, Gastrointestinal Tumors, Skin Cancer or Brain tumors.

Castle Biosciences, Inc.  
2014 San Miguel Drive  
Friendswood, TX 77546  
Phone: 866-788-9007; Fax: 866-431-2924  
www.castlebiosciences.com  

Castle Biosciences is a leading cancer molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment based on the individual molecular signature of their tumor. We offer tests for rare and underserved cancers including cutaneous melanoma, uveal melanoma, esophageal and thymic cancers, and mesothelioma. Based in Friendswood TX with laboratory facilities in Phoenix AZ, find more information at www.castlebiosciences.com.

Checkpoint Surgical, Inc.  
22901 Millcreek Blvd., Ste. 110  
Beachwood, OH 44122  
Phone: 919-623-7974  

Cianna Medical  
6 Journey, Suite 125  
Aliso Viejo, CA 92656  
Phone: 949-360-0059; Fax: 949-297-4527  
www.ciannamedical.com  

CivaTech Oncology, Inc.  
104 T W Alexander Drive, #4  
Res Triangle Park, NC 27709  
Phone: 919-314-5515; Fax: 919-314-5516
Complex General Surgical Oncology is an official publication of SSO. It is a new educational program platform for surgeons in training and in practice for lifelong learning. From preparing for boards to satisfying CME to handling MOC, you will find CGSO provides one stop shopping to keep you on top of the latest information.

The MarginProbe® System is an FDA approved tissue assessment device that significantly improves the breast surgeon’s ability to intra-operatively identify cancer on the margin of excised tissue during lumpectomy, helping to reduce the positive margin rate following the initial lumpectomy procedure.

The Recirculator 8.0 and 8100 Lavage Procedure Kit. State-of-the-art technology. Elegant and simple in design and function. The Recirculator 8.0 is the latest and most straight forward device developed specifically for intraperitoneal and thoracic hyperthermia.

Ethicon US LLC, a Johnson & Johnson company, commercializes a broad range of innovative surgical products, solutions and technologies used to treat some of today’s most prevalent medical issues, such as: colorectal and thoracic conditions, women’s health conditions, hernias, cancer and obesity. Learn more at www.ethicon.com, or follow us on Twitter @Ethicon.
As the specialist in specimen radiography, Faxitron continues to be the world’s most trusted brand in dedicated digital radiography systems for breast biopsy and lumpectomy specimens. Our new industry leading 21 lp/mm detector, featured in Faxitron’s BioVision+, delivers 3X the resolution of standard mammography/tomosynthesis. Raising the standard-of-care to new heights for patients undergoing surgical excision or core biopsy procedures.

Focal Therapeutics, located in Aliso Viejo, CA, manufactures and distributes BioZorb, an implantable marker, placed by surgeons at the time of surgical tissue excision. BioZorb is a 3D, bioabsorbable implant that uniquely delineates the surgical site after tissue removal and helps visualize the area on clinical imaging. Clinicians using BioZorb have shown its clinical utility across many aspects of breast cancer care, including oncoplastic surgery, radiation therapy and long term follow-up.

For more than 30 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.
Genomic Health, Inc.
301 Penobscot Drive
Redwood City, CA 94063
Phone: 866-662-6897; Fax: 866-444-0640
www.oncotypedx.com

Genomic Health’s Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.

Hitachi Aloka Medical
10 Fairfield Boulevard
Wallingford, CT 06492
Phone: 800-872-5652; Fax: 203-269-6075
www.hitachi-aloka.com

Hitachi Aloka Medical’s commitment to ultrasound for surgeons allows us to offer a wide range of consoles and specifically designed transducers to meet the needs of every surgeon. Recognized for our superior image quality, outstanding system reliability and intuitive use of cutting edge technology, we remain the standard in the field of ultrasound for surgeons.

Hologic, Inc.
250 Campus Drive
Marlborough, MA 01752
Phone: 781-999-7300; Fax: 781-280-0667
www.hologic.com

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure.

ImpediMed, Inc.
5900 Pasteur Court, Suite 125
Carlsbad, CA 92008
Phone: 877-247-0111; Fax: 760-804-9245
www.impedimed.com

What if it were possible to prevent clinical lymphedema following cancer care? There are advancements in reimbursement and technology which allow for the early detection of subclinical lymphedema. L-Dex is an objective assessment tool which is quick, easy, painless, and could create significant savings in survivorship care. Imagine a day when lymphedema is just a memory.
**Integrated Oncology**
Booth 926
1904 Alexander Drive
Research Triangle Park, NC 27709
Phone: 800-345-4363
www.integratedoncology.com

Integrated Oncology, a member of LabCorp’s Specialty Testing Group, provides comprehensive pathology, molecular & genomic testing to aid clinicians in the treatment of cancer across the entire continuum of care. Our test menu is coupled with extensive managed care contracts and robust connectivity and logistics solutions to ensure the broad access for patients to impactful diagnostic information.

**IntraOp Medical Corporation**
Booth 1125
570 Del Rey Avenue
Sunnyvale, CA 94085
Phone: 408-636-1020-128; Fax: 408-636-0022
www.intraopmedical.com

IntraOp Medical provides innovative technology for the treatment and eradication of cancer through the safe and effective administration of intraoperative electron radiotherapy. Mobetron, the first fully portable, self-shielding intraoperative electron radiotherapy device is designed for use in any operating room. Founded in 1993, IntraOp continues to be encouraged by the positive clinical outcomes published in peer-reviewed journals by Mobetron users worldwide for all treated body sites.

**Intuitive Surgical**
Booth: 1219
1266 Kifer Rd., Bldg. 101
Sunnyvale, CA 94086-5304
Phone: 408-523-2100; Fax: 408-523-1390
www.intuitivesurgical.com

Intuitive Surgical is the global leader in minimally invasive, robotic-assisted surgery. Its da Vinci® Surgical System – with a 3D-HD vision system and EndoWrist® instrumentation – enables surgeons to offer a minimally invasive approach for a range of complex procedures. da Vinci is used in more than 2,500 hospitals around the world.
Invuity  
Booth 1112  
444 De Haro Street  
San Francisco, CA 94107  
Phone: 415-655-2178  
www.invuity.com  
Invuity’s patented Intelligent Photonics™ devices provide direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. Our technology is integrated into sophisticated retractor systems, handheld devices and intracavity drop-in illuminators; each utilizing our proprietary waveguide technology that directs and shapes light into broad, uniform illumination to provide enhanced direct visualization inside dark surgical cavities.

Ipsen  
Booth 1208  
65 Quai Georges Gorse  
Basking Ridge, NJ 07920  
Phone: 908-275-6300; Fax: 908-275-6301  
www.ipsenus.com  
Ipsen Biopharmaceuticals, Inc. is a specialty pharmaceutical company that is a North American U.S. subsidiary of the Ipsen Group. Our areas of therapeutic focus are in the fields of Neuroscience, Endocrinology, and Oncology.

Lightpoint Medical  
Booth 1113  
Cardinal Point Park Road  
Rickmansworth, WD3 1RE  
United Kingdom  
Phone: 855 842-6708  
www.lightpointmedical.com  
Lightpoint Medical introduces an innovative molecular imaging technology designed to improve the detection of cancer during surgery and the assessment of surgical margins. Based on Cerenkov Luminescence Imaging, Lightpoint Medical’s products combine the benefits of optical imaging with commonly used PET radiopharmaceuticals. New products include the LightPath Imaging System and the EnLight intraoperative scope (for investigational use only).

Lymphedivas  
Booth 928  
703 West Housatonic, Suite 101  
Pittsfield, MA 01201  
Phone: 413-998-0214  
www.lymphedivas.com  
Lymphedivas is the only fashionable and medically correct compression apparel line for lymphedema. Lymphedivas allows those living with lymphedema to feel beautiful, strong and confident.
Merck & Co., Inc.  
Booth 917
600 Corporate Drive, W415C
Lebanon, NJ 08883
Phone: 908-423-4492; Fax: 908-735-1685
www.merck.com

Today’s Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States & Canada. Through our prescription medicines, vaccines, biologic therapies & animal health products, we work with customers & operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com

Mercy Clinic  
Booth: 900
19655 South Fremont, Suite 200
Springfield, MO 65804
Phone: 417-820-3526; Fax: 417-820-7495
www.mercy.net

Meridian Health  
Booth 1217
1967 Highway 34, Building C, Suite 104
Wall, NJ 07719
Phone: 732-751-3561; Fax: 732-361-9122
www.MeridianHealth.com

Meridian Health is a leading not for profit health care organization in NJ comprised of Jersey Shore University Medical Center, K Hovnanian Children’s Hospital, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, Bayshore Community Hospital, Raritan Bay Medical Center, Old Bridge and Raritan Bay Medical Center, Perth Amboy. Meridian Cancer Care is investing $128 million over the next 3 years with 6 expansion projects underway

Mylan, Inc.  
Booth: 1317
1000 Mylan Boulevard
Canonsburg, PA 15317
Phone: 724-485-6160

Myriad Genetic Laboratories  
Booth: 1113
320 Wakara Way
Salt Lake City, UT 84108
Phone: 801-584-3600; Fax: 801-883-3260
www.myriad.com

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.
NeuWave Medical, Inc.  
3529 Anderson Street  
Madison, WI 53704  
Phone: 608-512-1500; Fax: 608-512-1509  
www.neuwave.com

The NeuWave Medical Intelligent Ablation System changes the game in the operating room - offering a complete solution for ablating lesions of all shapes & sizes with speed, consistency & control. The system goes beyond open or laparoscopic target ablation, acting as a powerful resection assistance tool. Build your ablation program with the only system that has it all.  
www.neuwave.com

Novartis Oncology  
One Health Plaza  
East Hanover, NJ 07936  
Phone: 862-778-7358  
www.novartisoncology.com

Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. For more information, visit www.novartisoncology.com.

Pacira Pharmaceuticals  
5 Sylvan Way  
Parsippany, NJ 07054  
Phone: 973-254-3560  
www.pacira.com

PathGroup  
5301 Virginia Way, Suite 300  
Brentwood, TN 37027  
Phone: 615-234-3910; Fax: 615-234-3785  
www.pathgroup.com

Sirtex Medical Inc.  
300 Unicorn Park Drive  
Woburn, MA 01801  
Phone: 888-474-7839; Fax: 781-721-3880  
www.sirtex.com

Sirtex develops oncology treatments using novel small particle technology to improve outcomes for patients with cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during Selective Internal Radiation Therapy (SIRT). Data shared at the 2015 ASCO Annual Meeting showed a 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable mCRC treated first line with SIR-Spheres microspheres plus standard chemotherapy.
The Society of Surgical Oncology (SSO) is the premier organization for surgeons and health care provider. Founded in 1940 as the James Ewing Foundation, the SSO focuses on all solid tumor disease sites including Breast, GI, Colorectal, HBP, Melanoma, Sarcoma, Endocrine, and Head & Neck. SSO offers a variety of programs and services to advance the science and practice of surgical oncology. The monthly journal, Annals of Surgical Oncology, is on the top 10 list of the best medical journals in the US. With over 500 pages per issue, it offers articles on solid tumors to improve multidisciplinary patient care. SSO offers a Surgical Oncology Self-Assessment Program (SOSAP), Maintenance of Certification - Part 2 credits, the Annual Cancer Symposium, a Career Center with job postings, and training programs for Fellows and Residents. The Society recently launched the “Best of SSO” for the sharing of educational content from the Annual Meeting with select societies from around the world. The Society welcomes all surgeons, scientists and health care providers dedicated to and interested in advancing the science and treatment of cancer patients worldwide. To join SSO stop by the booth or go to www.surgonc.org.

The SSO Foundation
9525 W. Bryn Mawr Avenue, Suite 870
Rosemont, IL 60018
Phone: 847-427-1400
www.surgonc.org

Supported by contributions from SSO members, patients, private individuals and organizations, The SSO Foundation is a not-for-profit 501(c)(3) organization that provides funding for translational and clinical cancer research and surgical oncology education programs and initiatives. Through its sponsorship of lectureships and awards, the Foundation recognizes excellence and innovation in, and contributions to, the advancement of multi-disciplinary surgical oncology patient care. Visit The SSO Foundation at the SSO Membership Booth and make your donation today!
Springer
233 Spring Street
New York, NY 10013
Phone: 212-460-1500; Fax: 212-460-1700
www.springer.com

Springer publishes Annals of Surgical Oncology, the official journal of the Society of Surgical Oncology. Come by to get your sample copy! Don’t forget to check out the website at www.annsurgoncol.org. Also browse some of our leading books, including the new AJCC Cancer Staging Atlas, 2nd Edition.

StoreMyTumor
200 Locust St., Suite. 25B
Philadelphia, PA 19106
Phone: 267-702-5501; Fax: 425-944-6445
www.StoreMyTumor.com

Storing the tumor specimen in the right format is one of the most important recommendations you can make to your cancer patients. Everyone knows that the standard of care treatments today are simply not enough. We help your patients seek the latest and best available treatments and diagnostics (all over the world), including cutting-edge vaccine and immunotherapy programs. Bottom line, we help keep your patients in remission longer.

Strategic Business Holdings “SBH”
9620 Research Dr.
Irvine, CA 92618
Phone: 949-305-3300; Fax: 949-600-8874
www.sbhsurgical.com

SBH is a medical device company focused on a streamlined supply chain and operational efficiency, offering a comprehensive line of premium surgical hand-held instruments for use in ENT, Micro, Neuro, Ophthalmic, Plastic, Reconstructive, Vascular and Thoracic Surgery, SBH offers also a wide range of surgical retractor systems such as abdominal, bariatric, liver and... At SBH, we pledge an uncompromising commitment to the excellence. For more information visit us online at www.sbhsurgical.com.
ThermaSolutions, Inc.  
Booth 1108
1889 Buerkle Road  
White Bear Lake, MN 55110  
Phone: 651-209-3900; Fax: 651-209-3903  
www.thermasolutions.com

ThermaSolutions Inc. is recognized as the global leader in Hyperthermic Medical Technology providing fully integrated systems specifically designed and manufactured for intraperitoneal hyperthermia (IPH). Currently utilized in more than 100 Oncology Centers throughout the USA, Europe, Middle East and Asia, ThermaSolutions Inc. has established leadership through extensive research, development and product innovation. The ThermoChem™ family includes: the recently FDA cleared HT-2000 and HT-1000.

Thompson Surgical Instruments, Inc.  
Booth 1224
10170 E Cherry Bend Rd.  
Traverse City, MI 49684  
Phone: 231-922-0177; Fax: 231-922-0174  
www.thompsonsurgical.com

Thompson Surgical is a leader in exposure and the original manufacturer of the table-mounted retractor. We understand the value of exposure in surgery and are dedicated to providing innovative, high quality systems that deliver safe, versatile, and low-profile retraction. From pediatric to obesity, simple to complex exposures, we offer unlimited customization and safe, independent, retraction. The Thompson Retractor allows surgeons in multiple specialties to achieve Uncompromised Exposure.

UM Products  
Booth: 901
1921 Carnegie Avenue, Suite C  
Santa Ana, CA 92705  
Phone: 714-540-5595

Vector Surgical, LLC  
Booth 920
20975 Swenson Drive, Suite 430  
Waukesha, WI 53186  
Phone: 262-798-7970; Fax: 262-798-7972  
www.vectorsurgical.com

Vector Surgical offers devices that improve outcomes in cancer surgery. The Vector Surgical Tissue Orientation System, comprised of MarginMarker sterile inks and CorrectClips radiographic clips, provides secure and accurate designation of specimen margins in cancer surgery. Use of the system can result in more accurate re-excisions, fewer unnecessary re-excisions and lower cancer recurrence. SilversteinWrap is a unique post-surgical compression dressing that improves outcomes in breast surgery.
Wolters Kluwer

Two Commerce Sq, 2001 Market Street
Philadelphia, PA 19103
Phone: 215-521-8300
www.lww.com

Lippincott Williams & Wilkins, a Wolters Kluwer Health company, is a leading international publisher of medical books, journals, and electronic media. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit booth 312 to browse our comprehensive product line or visit www.lww.com.

Xoft-a subsidiary of iCAD, Inc.

98 Spit Brook Rd., Ste. 100
Nashua, NH 03062
Phone: 603-882-5200; Fax: 603-880-3843
www.xoftinc.com

BREAST CANCER TREATMENT IN AS LITTLE AS ONE DAY. Breast Intraoperative Radiation Therapy (IORT) with the Xoft eBx® system delivers radiation therapy at the time of lumpectomy. Conformal targeting with Xoft’s stepping x-ray source attacks the cancer from directly within the lumpectomy cavity and minimizes dose to surrounding healthy tissue. The Xoft System is FDA cleared for treatment anywhere in the body including early stage breast cancer (APBI and IORT), skin cancer and gynecological cancers.
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander, Jr., H.R.</td>
<td>5, 87</td>
</tr>
<tr>
<td>Allen, P.J.</td>
<td>63</td>
</tr>
<tr>
<td>Allenson, K.</td>
<td>48</td>
</tr>
<tr>
<td>Amini, N.</td>
<td>59</td>
</tr>
<tr>
<td>Anderson, B.O.</td>
<td>39</td>
</tr>
<tr>
<td>Andtbacka, R.H.I.</td>
<td>67</td>
</tr>
<tr>
<td>Arciero, C.A.</td>
<td>39</td>
</tr>
<tr>
<td>Arnaout, A.</td>
<td>65</td>
</tr>
<tr>
<td>Audisio, R.A.</td>
<td>74</td>
</tr>
<tr>
<td>Badgwell, B.D.</td>
<td>5, 43</td>
</tr>
<tr>
<td>Bagaria, S.</td>
<td>83</td>
</tr>
<tr>
<td>Barrio, A.V.</td>
<td>17, 49, 64</td>
</tr>
<tr>
<td>Bartlett, D.L.</td>
<td>3, 42, 58, 75</td>
</tr>
<tr>
<td>Bartlett, E.K.</td>
<td>72</td>
</tr>
<tr>
<td>Baselga, J.</td>
<td>26, 54</td>
</tr>
<tr>
<td>Bass, A.</td>
<td>77</td>
</tr>
<tr>
<td>Beasley, G.</td>
<td>45</td>
</tr>
<tr>
<td>Bedrosian, I.</td>
<td>76</td>
</tr>
<tr>
<td>Beems, M.V.</td>
<td>63</td>
</tr>
<tr>
<td>Berger, A.C.</td>
<td>5, 56</td>
</tr>
<tr>
<td>Berger, N.G.</td>
<td>47</td>
</tr>
<tr>
<td>Bilimoria, KY.</td>
<td>5, 69, 77</td>
</tr>
<tr>
<td>Blackham, A.</td>
<td>83, 104</td>
</tr>
<tr>
<td>Boulanger-Gobeil, C.</td>
<td>88</td>
</tr>
<tr>
<td>Boyd, B.</td>
<td>40</td>
</tr>
<tr>
<td>Brennan, M.F.</td>
<td>45, 87</td>
</tr>
<tr>
<td>Callender, G.G.</td>
<td>5, 85</td>
</tr>
<tr>
<td>Canter, R.J.</td>
<td>5, 44, 57</td>
</tr>
<tr>
<td>Cardona, K.</td>
<td>5, 44, 75</td>
</tr>
<tr>
<td>Carp, N.Z.</td>
<td>41</td>
</tr>
<tr>
<td>Chapgar, A.B.</td>
<td>76</td>
</tr>
<tr>
<td>Chang, G.J.</td>
<td>70</td>
</tr>
<tr>
<td>Chapman, B.C.</td>
<td>88</td>
</tr>
<tr>
<td>Chen, S.L.</td>
<td>39</td>
</tr>
<tr>
<td>Cherkassky, L.</td>
<td>84</td>
</tr>
<tr>
<td>Chi, D.S.</td>
<td>71</td>
</tr>
<tr>
<td>Chiba, A.</td>
<td>48</td>
</tr>
<tr>
<td>Choong, K.</td>
<td>63</td>
</tr>
<tr>
<td>Chow, O.S.</td>
<td>50</td>
</tr>
<tr>
<td>Christakis, I.</td>
<td>81</td>
</tr>
<tr>
<td>Chu, B.</td>
<td>66</td>
</tr>
<tr>
<td>Cintolo-Gonzalez, J.A.</td>
<td>45, 115</td>
</tr>
<tr>
<td>Clarke, C.N.</td>
<td>50</td>
</tr>
<tr>
<td>Cloyd, J.</td>
<td>63, 126</td>
</tr>
<tr>
<td>Cody, III, H.S.</td>
<td>58, 76</td>
</tr>
<tr>
<td>Coit, D.G.</td>
<td>3, 43, 62</td>
</tr>
<tr>
<td></td>
<td>68, 80, 89, 164</td>
</tr>
<tr>
<td>Conrad, C.</td>
<td>52, 112</td>
</tr>
<tr>
<td>Contreras, C.</td>
<td>52</td>
</tr>
<tr>
<td>Cronin, P.A.</td>
<td>65</td>
</tr>
<tr>
<td>Curley, S.A.</td>
<td>70, 164</td>
</tr>
<tr>
<td>Czerniecki, B.J.</td>
<td>5, 26</td>
</tr>
<tr>
<td></td>
<td>57, 76</td>
</tr>
<tr>
<td>Damude, S.</td>
<td>66, 117</td>
</tr>
<tr>
<td>D’Angelica, M.I.</td>
<td>42</td>
</tr>
<tr>
<td>Datta, J.</td>
<td>26, 66</td>
</tr>
<tr>
<td>Davidson, J.T.</td>
<td>47</td>
</tr>
<tr>
<td>De La Cruz, L.M.</td>
<td>49</td>
</tr>
<tr>
<td>de Manzoni, G.</td>
<td>43</td>
</tr>
<tr>
<td>Delaney, C.P.</td>
<td>41</td>
</tr>
<tr>
<td>Delman, K.A.</td>
<td>39, 42, 74, 77</td>
</tr>
<tr>
<td>Dhir, M.</td>
<td>47, 113</td>
</tr>
<tr>
<td>Diaz, L.</td>
<td>57</td>
</tr>
<tr>
<td>Dillhoff, M.</td>
<td>81</td>
</tr>
<tr>
<td>Dodson, R.M.</td>
<td>46, 82</td>
</tr>
<tr>
<td>Dominguez-Rosado, I.</td>
<td>72</td>
</tr>
<tr>
<td>Dossett, L.</td>
<td>82, 95</td>
</tr>
<tr>
<td>Drebin, J.A.</td>
<td>3, 11, 23, 41</td>
</tr>
<tr>
<td></td>
<td>52, 59, 61, 62, 89, 164</td>
</tr>
<tr>
<td>Droppelmann, N.</td>
<td>66</td>
</tr>
<tr>
<td>Enomoto, L.M.</td>
<td>63</td>
</tr>
<tr>
<td>Esserman, L.J.</td>
<td>87</td>
</tr>
<tr>
<td>Ethun, C.G.</td>
<td>47, 108, 110</td>
</tr>
<tr>
<td>Evans, D.B.</td>
<td>58, 69, 85</td>
</tr>
<tr>
<td>Fairweather, M.</td>
<td>48</td>
</tr>
<tr>
<td>Faries, M.B.</td>
<td>57</td>
</tr>
<tr>
<td>Fields, R.C.</td>
<td>5, 27, 57, 79</td>
</tr>
<tr>
<td>Fine, R.E.</td>
<td>40</td>
</tr>
<tr>
<td>Flaherty, K.T.</td>
<td>72</td>
</tr>
<tr>
<td>Fong, Y.</td>
<td>58</td>
</tr>
<tr>
<td>Foti, M.</td>
<td>27, 61</td>
</tr>
<tr>
<td>Gabriel, E.</td>
<td>83, 104</td>
</tr>
<tr>
<td></td>
<td>111, 123</td>
</tr>
<tr>
<td>Garber, J.E.</td>
<td>76</td>
</tr>
<tr>
<td>Garcia-Aguilar, J.</td>
<td>74, 80</td>
</tr>
<tr>
<td>Gershenwald, J.E.</td>
<td>5, 77</td>
</tr>
<tr>
<td>Gillanders, W.E.</td>
<td>57</td>
</tr>
<tr>
<td>Gittleman, M.A.</td>
<td>40</td>
</tr>
<tr>
<td>Gonzalez, R.J.</td>
<td>44</td>
</tr>
<tr>
<td>González-Moreno, S.</td>
<td>71</td>
</tr>
<tr>
<td>Grobmyer, S.R.</td>
<td>27, 79</td>
</tr>
<tr>
<td>Gronchi, A.</td>
<td>44</td>
</tr>
<tr>
<td>Gyorki, D.</td>
<td>72</td>
</tr>
<tr>
<td>Hallet, J.</td>
<td>68, 81, 88, 108</td>
</tr>
<tr>
<td>Han, H.S.</td>
<td>47</td>
</tr>
<tr>
<td>Hansen, N.M.</td>
<td>64</td>
</tr>
<tr>
<td>Hardin, M.</td>
<td>49</td>
</tr>
<tr>
<td>Hardy, A.N.</td>
<td>73</td>
</tr>
<tr>
<td>Henderson, M.A.</td>
<td>65</td>
</tr>
<tr>
<td>Henry-Tillman, R.S.</td>
<td>41</td>
</tr>
<tr>
<td>Hong, J.J.</td>
<td>66, 98</td>
</tr>
<tr>
<td>Hong, T.S.</td>
<td>75</td>
</tr>
</tbody>
</table>
Shibata, D.........................50
Shih, H.A....................... 72
Simkens, G ................. 50, 103
Siperstein, A.E ............. 55
Sippel, R.S .................... 55
Smith, B.L..................... 76
Solórzano, C.C ............. 5, 40
...................................... 55, 85
Sondak, V.K............... 72, 74
Spitz, F.R...................... 39
Splittergerber, B.E........ 65, 88
St. Julien, J .................. 88
Stewart, C.L ................. 88, 116, 123
Stopfkuchen-Evans, M.F .............. 41
Strand, M....................... 64
Stuart, H ....................... 45
Sugg, S.L ..................... 81
Swallow, C.J .................. 79
Tafra, L ....................... 40
Takabe, K ................. 64, 130, 131
Terhune, J.H ............... 81
Thompson, J.F .......... 72, 114
Tozzi, F ....................... 52, 121
Tsai, S ......................... 58
Tsang, M ..................... 52, 111
Tseng, J.F ................... 5, 63
Tuttle, T.M................... 80
Tuveson, D.A .............. 27, 78
Velez, A.M ................. 83
Voci, A.E ...................... 65
Vos, E ......................... 65
Vreeland, T ................. 49
Weber, S.M .................. 3, 47
Weiser, M.R .................. 58, 70
Weitz, J ....................... 80
White, M.G .................. 81, 109
Willey, S.C .................... 40
Winchester, D.J ........... 5, 40, 87
Wong, S.L .................... 18, 42, 82
Yeo, H ......................... 50
Yip, L ......................... 41
Youngwirth, L ............. 66, 117
Zager, J.S ..................... 72
HYNES LEVEL 2

South Lobby

Veteran’s Memorial Auditorium

Exhibit Hall C

Exhibit Hall D

Room 200

Room 201-205

Boylston Street Hallway

Room 206

Room 207

Room 208

Room 209

Room 210

Room 207

Stairs up to Level 3

LEVEL TWO
HYNES LEVEL 3

South Lobby

Ballroom C
Ballroom B
Ballroom A

Exhibit Hall D (Below)

Audit orium Balcony

Exhibit Hall E

Exhibit Hall D

Veterans Memorial Auditorium (Below)

Boylston Street Hallway

South Lobby

Exhibit Hall F

Exhibit Hall G

Exhibit Hall H

Exhibit Hall I

Exhibit Hall J

Exhibit Hall K

Exhibit Hall L

Exhibit Hall M

Exhibit Hall N

Exhibit Hall O

Exhibit Hall P

Exhibit Hall Q

Exhibit Hall R

Exhibit Hall S

Exhibit Hall T

Exhibit Hall U

Exhibit Hall V

Exhibit Hall W

Exhibit Hall X

Exhibit Hall Y

Exhibit Hall Z

Exhibit Hall AA

Exhibit Hall BB

Exhibit Hall CC

Exhibit Hall DD

Exhibit Hall EE

Exhibit Hall FF

Exhibit Hall GG

Exhibit Hall HH

Exhibit Hall II

Exhibit Hall JJ

Exhibit Hall KK

Exhibit Hall LL

Exhibit Hall MM

Exhibit Hall NN

Exhibit Hall OO

Exhibit Hall PP

Exhibit Hall QQ

Exhibit Hall RR

Exhibit Hall SS

Exhibit Hall TT

Exhibit Hall UU

Exhibit Hall VV

Exhibit Hall WW

Exhibit Hall XX

Exhibit Hall YY

Exhibit Hall ZZ

Exhibit Hall AAA

Exhibit Hall BBB

Exhibit Hall CCC

Exhibit Hall DDD

Exhibit Hall EEE

Exhibit Hall FFF

Exhibit Hall GGG

Exhibit Hall HHH

Exhibit Hall III

Exhibit Hall JJJ

Exhibit Hall KKK

Exhibit Hall LLL

Exhibit Hall MBB

Exhibit Hall NNN

Exhibit Hall OOO

Exhibit Hall PPP

Exhibit Hall QQQ

Exhibit Hall RRR

Exhibit Hall SSS

Exhibit Hall TTT

Exhibit Hall UUU

Exhibit Hall VVV

Exhibit Hall WVV

Exhibit Hall XXX

Exhibit Hall YYY

Exhibit Hall ZZZ

Exhibit Hall AAAA

Exhibit Hall BBBB

Exhibit Hall CCBB

Exhibit Hall DDDD

Exhibit Hall EEEE

Exhibit Hall FFFF

Exhibit Hall GGGG

Exhibit Hall HHHH

Exhibit Hall IIII

Exhibit Hall JJJJ

Exhibit Hall KKKK

Exhibit Hall LLLL

Exhibit Hall MMMM

Exhibit Hall NNNN

Exhibit Hall OOOO

Exhibit Hall PPPP

Exhibit Hall QQQQ

Exhibit Hall RRRR

Exhibit Hall SSSS

Exhibit Hall TTTT

Exhibit Hall UUUU

Exhibit Hall VVVV

Exhibit Hall WWWW

Exhibit Hall XXXX

Exhibit Hall YYYY

Exhibit Hall ZZZZ

Exhibit Hall AAAA

Exhibit Hall BBBB

Exhibit Hall CCBB

Exhibit Hall DDDD

Exhibit Hall EEEE

Exhibit Hall FFFF

Exhibit Hall GGGG

Exhibit Hall HHHH

Exhibit Hall IIII

Exhibit Hall JJJJ

Exhibit Hall KKKK

Exhibit Hall LLLL

Exhibit Hall MMMM

Exhibit Hall NNNN

Exhibit Hall OOOO

Exhibit Hall PPPP

Exhibit Hall QQQQ

Exhibit Hall RRRR

Exhibit Hall SSSS

Exhibit Hall TTTT

Exhibit Hall UUUU

Exhibit Hall VVVV

Exhibit Hall WWWW

Exhibit Hall XXXX

Exhibit Hall YYYY

Exhibit Hall ZZZZ

Exhibit Hall AAAA

Exhibit Hall BBBB

Exhibit Hall CCBB

Exhibit Hall DDDD

Exhibit Hall EEEE

Exhibit Hall FFFF

Exhibit Hall GGGG

Exhibit Hall HHHH

Exhibit Hall IIII

Exhibit Hall JJJJ

Exhibit Hall KKKK

Exhibit Hall LLLL

Exhibit Hall MMMM

Exhibit Hall NNNN

Exhibit Hall OOOO

Exhibit Hall PPPP

Exhibit Hall QQQQ

Exhibit Hall RRRR

Exhibit Hall SSSS

Exhibit Hall TTTT

Exhibit Hall UUUU

Exhibit Hall VVVV

Exhibit Hall WWWW

Exhibit Hall XXXX

Exhibit Hall YYY
2015-2016
THE SSO FOUNDATION
BOARD OF DIRECTORS

OFFICERS
President Mitchell C. Posner, MD (2017)
Vice President Monica Morrow, MD (2017)
Treasurer Robert C.G. Martin, II, MD (2016)
Executive Vice President M. Eileen Widmer, CAE, CFRM

BOARD OF DIRECTORS
SSO President Jeffrey A. Drebin, MD, PhD (2017)
SSO Immediate Past President Ronald J. Weigel, MD, PhD (2016)
SSO President-Elect Daniel G. Coit, MD (2018)
H. Richard Alexander, Jr., MD (2018)
Charles M. Balch, MD (2017)
David L. Bartlett, MD (2017)
Peter D. Beitsch, MD (2016)
Steven A. Curley, MD (2018)
Armando E. Giuliano, MD (2018)
Mehra Golshan, MD (2017)
Charles A. Staley, MD (2018)
Mark S. Talamonti, MD (2017)

STAFF
Executive Vice President M. Eileen Widmer, CAE, CFRM
Manager, Board Governance Rochelle M. Jerry
Director, Corporate Relations Deborah A. Cohen
Senior Accountant William Rohe, MBA

HEADQUARTERS OFFICE
9525 W. Bryn Mawr Avenue, Suite 870
Rosemont, IL 60018
P: 847-427-1400 • F: 847-427-1411
ssofoundation@surgonc.org
CONTRIBUTE TO THE SSO FOUNDATION!

Your generous contribution will help support The SSO Foundation’s new research initiatives, including awards encompassing the spectrum of surgical oncology research to help foster the careers of promising young surgical oncology investigators.

Funds from the recent 75 for 75 Member Campaign have been earmarked for two surgical oncology research awards for young investigators. Contribute and help ensure future generations of surgical oncologists obtain the necessary skills and competencies to continue advancing cancer patient care for the next 75 years and beyond. We invite you to visit The SSO Foundation at the SSO’s membership booth 1019 in the Exhibit Hall to find out more about how to make a contribution to The SSO Foundation. To donate online, visit surgonc.org and click on “Donate to The SSO Foundation” in the footer.

For a full listing of The SSO Foundation Contributors, please see the SSO 2016 Mobile App or mobile.SSO2016.org.

FUTURE MEETINGS

MARCH 15-18, 2017
Seattle, WA

MARCH 21-24, 2018
Chicago, IL

MARCH 27-30, 2019
San Diego, CA